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Abstract 
The SOCS family of proteins are known negative feedback regulators of both 
cytokine and growth factor signaling, with mammalian studies showing that 
several of the SOCS family members play significant roles during development. 
However, detailed understanding of two family members, SOCS4 and SOCS5, 
has remained elusive. The studies described in this thesis have investigated 
the evolution and biology functional roles of SOCS4 and SOCS5 using the 
zebrafish developmental model.  
Bioinformatic analysis revealed new insights into the evolution of the SOCS 
family, including the identification of two paralogues for both SOCS4 and 
SOCS5. These data underpinned the subsequent detailed functional analysis 
of the three of the four members of the zebrafish SOCS4/5 sub-family, socs4a, 
socs4b and socs5a.  
Investigation of socs4a, the most divergent zebrafish paralogue, revealed a 
dynamic expression profile during embryogenesis, with initial ubiquitously 
expression becoming restricted to sensory ganglia within the developing 
nervous system. Knockdown of zebrafish Socs4a using anti-sense morpholino 
technology revealed an essential role during embryonic convergence and 
extension, as well as its participation in the formation of a functional 
mechanosensory system, with knockdown of Socs4a leading to a blunted touch 
response. In contrast, expression of socs4b was relatively consistent across 
embryonic development and in adult zebrafish tissues. However, restricted 
expression was evident in cells lining the third and fourth ventricles and in 
multiple cell layers of the retina in developing embryos. Zinc finger nuclease-
 xii 
mediated genome editing produced an allele socs4bΔ18, in which the start 
codon was deleted. Fish homozygous for the allele showed no overt 
developmental phenotype. 
In vitro studies revealed a likely role for Socs4b in the negative regulation of 
EGFR signaling, consistent with data on mammalian Socs4 data. This was 
corroborated by a statistically significant increase in transcript levels of egr1, a 
gene downstream of EGFR signaling. 
Finally, expression of zebrafish socs5a was observed in the retinal layers of 
the eye, as well as in the olfactory bulbs during embryogenesis. Functional 
analysis of a zebrafish socs5a knockout line revealed a contribution of Socs5a 
to T cell development that appeared to affect proliferation during the initial 
stages of lymphopoiesis. However, this did not overtly affect survival rates of 
socs5a knockout fish. 
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1.1 Signaling proteins 
Overview    
The ability of a cell to respond to external signals, especially those from other 
cells, represents a fundamental process for multi-cellular organisms. Growth 
factors and cytokines participate in the cell-to-cell signaling that underpins 
development and especially hematopoiesis [1]. These proteins are secreted by 
cells, often in response to environmental stimuli such as infection or hypoxia, 
and then act by binding to specific receptors on the surface of responsive cells. 
This initiates a cascade of intracellular signaling pathways, which impacts on 
the transcription of key target genes, encoding proteins that mediate 
differentiation, proliferation, apoptosis and survival [2]. A number of proteins 
serve to negatively regulate cell signaling.  
 
1.2 Cytokine and growth factor signaling 
Cytokines act via cytokine receptors, which lack tyrosine kinase activity. 
Extracellular binding of the ligand to its receptor promotes dimerization or 
oligomerization of receptor molecules that are intimately associated with 
intracellular tyrosine kinases such as Janus kinases (JAK), which 
phosphorylate receptor tyrosine residues [3, 4]. These phospho-tyrosine 
residues operate as docking sites for Src homology-2 (SH2) domain containing 
signaling proteins, thus leading to the initiation of several intracellular signaling 
pathways that transduce signals to the nucleus [3].  
Growth factors act via receptor tyrosine kinases (RTKs), which have intrinsic 
tyrosine kinase catalytic activity. Extracellular ligand binding to the receptor 
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also promotes dimerization or oligomerization of these receptors, but in this 
case facilitates auto-phosphorylation of the tyrosine residues in the cytoplasmic 
domain of the receptor [4].  
Three signaling pathways common to both receptor classes are the PI3K/Akt 
pathway, the Ras/Raf/ERK pathway and the JAK/STAT pathway. 
The PI3K/Akt pathway 
The phosphoinositide 3-kinase (PI3K)/Akt pathway is activated through binding 
of one or more SH2-containing adaptor proteins to receptor phosphotyrosines, 
such as the PI3K D-subunit or insulin-like receptor substrate 1. This recruits the 
PI3K catalytic subunits, that become activated by phosphorylation, dissociating 
from the receptor complex to phosphorylate phosphotidylinositol 4,5-
bisphosphate (PIP2) molecules, converting them to phosphatidylinositol 3,4,5-
trisphosphate (PIP3) molecules. These PIP3 molecules then stimulate the 
activity of the serine/threonine protein kinase Akt, which can then translocate 
to the nucleus, where it phosphorylates appropriate transcription factors, such 
as Forkhead [5], to induce transcription of target genes associated with cell 
survival [5, 6].  
The Ras/Raf/ERK pathway 
Initiation of the Ras/Raf/ERK pathway also occurs via various adaptor proteins 
that dock to the receptor, especially Grb2 and Shc [7]. However, in this case, 
the adaptor protein complex recruits guanidine exchange factors (GEFs) to 
which Ras and related molecules bind. These lead to Ras activation by 
promoting the release of guanosine 5'-diphosphate (GDP) and subsequent 
binding of guanosine 5'-triphosphate (GTP) to the protein. From this point, Ras 
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can activate multiple downstream mitogen-activated protein kinase (MAPK) 
cascades. Most commonly it activates the Raf protein, which phosphorylates 
the extracellular-regulated kinases (ERK) 1 and 2 that then move from the 
cytoplasm into the nucleus where they phosphorylate transcription factors 
controlling target genes [8].  
The JAK/STAT pathway 
The JAK/STAT pathway is commonly used by both cytokine and growth factor 
receptors [9, 10]. JAKs are activated by ligand binding and contribute to 
phosphorylation of the receptor complex. Signal transducer and activator of 
transcription (STAT) proteins can then bind directly via their SH2-domains to 
phosphotyrosine residues on the receptor or the associated Janus kinases 
(JAKs). The STATs are then phosphorylated by the activated JAKs and other 
kinases leading to STAT dimerization. The STAT protein dimers then migrate 
to the nucleus where they act as transcription factors for target genes [11].  
Signaling complexity 
The three pathways described above represent just a few of those that can be 
engaged downstream of cytokine and growth factor receptors, with each able 
to induce different transcriptional and biological outcomes. Moreover, signaling 
proteins utilized in these pathways are often not exclusive and can act as 
modular units within other pathways via cross-talk [12, 13]. It is these 
combinatorial variations in pathways and receptor expression that results in the 
huge variety of transcriptional changes and downstream biological responses 
that ultimately determines the signaling specificity essential for complex 
multicellular organisms. 
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Control of signaling 
Since growth factors and cytokines are involved in the regulation of important 
biological processes, it is essential that their signaling be regulated. Excessive 
signaling can have devastating effects such as uncontrolled cell proliferation 
and defective differentiation with concomitant disruption to key developmental 
or homeostatic processes. Therefore, there exist several families of negative 
regulators that maintain signaling and downstream cellular responses at an 
appropriate level/extent.  
Protein tyrosine phosphatases (PTPs) act to dephosphorylate phosphotyrosine 
residues, such as those on cell surface receptors or downstream signaling 
molecules [14]. There are four distinct groupings within the PTP family, 
encoded by a staggering total of 107 PTP genes, which are all characterized 
by a single catalytic PTP domain [15]. Several members have been identified 
as important in regulation of cytokine and growth factor signaling, including the 
SH2-containing protein-tyrosine phosphatases (SHP)-1 and 2, which are 
capable of directly binding to activated substrates via their SH2 domain [16, 
17]. Protein inhibitor of activated STAT (PIAS) proteins are another family of 
negative regulators that act to directly inhibit STATs. PIAS1 and PIAS3 have 
been found to inhibit the activity of STAT1 and STAT3, respectively, by blocking 
DNA binding of the STAT protein [18]. Other members of the family do not block 
DNA binding ability, but instead recruit co-repressor molecules to inhibit 
transcription [19]. Finally, the suppressor of cytokine signaling (SOCS) proteins 
act as negative feedback regulators, and have been shown to be of particular 
importance for normal cytokine and growth factor signaling.  
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1.3 SOCS proteins 
The genes encoding the SOCS proteins are amongst those induced by 
cytokine and growth factor signaling. The newly translated SOCS proteins then 
suppress further receptor signaling, thereby acting as classical negative 
feedback regulators. There are eight mammalian SOCS family members; 
SOCS1-7, and the alternatively named Cytokine-inducible SH2-containing 
protein (CISH) [20] (Fig 1.1). While SOCS proteins are able to regulate 
signaling downstream of a range of receptors, current evidence indicates that 
CISH and SOCS1-3 are most often associated with regulation of cytokine 
receptor signaling through the JAK-STAT pathway, while SOCS4-7 
predominantly regulate growth factor receptor signaling [21-23]. This difference 
reflects their evolutionary history, with the precursors to the SOCS4-7 sub-
family existing prior to the emergence of a functional cytokine receptor 
pathway, while the sub-family comprising of SOCS1-3 and CISH emerged 
later, co-incident with the cytokine receptor family [24, 25]. Within each sub-
family, pairs of SOCS proteins have similar structure and function: 
CISH/SOCS2, SOCS1/SOCS3, SOCS4/SOCS5 and SOCS6/SOCS7, again 
reflecting their evolutionary history [24]. 
Each SOCS protein contains three distinct domains; an N-terminal domain of 
low conservation, a conserved central Src-homology 2 (SH2) domain, and a 
more highly conserved C-terminal domain termed the SOCS box. The N-
terminal domain is variable in length between members, with SOCS1-3 and 
CISH having a shorter N-terminal domain in comparison to SOCS4-7 [26]. 
Within the N-terminal domains of SOCS1 and SOCS3 is a so-called kinase-
inhibitory region (KIR), which is responsible for inhibition of cytokine receptor-
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associated Janus kinases (JAKs) [27]. SOCS4 and SOCS5 also possess a 
highly conserved region within their N-terminal domain, termed the N-terminal 
conserved region (NTCR), although the role of this sequence has not been 
elucidated [28]. In contrast, the N-terminal domains of SOCS6 and SOCS7 
have been shown to be required for their respective nuclear translocation and, 
in the case of SOCS7, appears to be involved in transporting other proteins 
into the nucleus [29-31]. The SH2 domains of the SOCS proteins interact in a 
context-specific manner with phosphotyrosine residues present on their target 
proteins, including cell surface receptors, imparting target specificity on SOCS 
proteins [32]. These are longer than typical SH2 domains due to a so-called 
extended SH2 sequence (ESS) also found in STAT1 and STAT3, which 
contributes to their function [27]. Finally, the SOCS box is comprised of two 
functional sub-domains; a BC box that recruits Elongin B and C, and a Cul box 
that mediates Cullin5 binding. The resulting complex is able to bind RBX2, 
leading in turn to recruitment of the remaining components of an E3 ubiquitin 
ligase complex [33, 34]. 
 8
 9
Figure 1.1 Structural and functional relationships amongst SOCS 
proteins 
SOCS proteins can be grouped into pairs with similar structure and function, 
and these further grouped into those mainly acting on Cytokine receptor 
(CytoR) signaling and those mainly acting on Receptor tyrosine kinase (RTK) 
signaling, reflecting evolutionary relationships. All SOCS proteins consist of 
three conserved domains, the N-terminal, SH2 and SOCS box domains. The 
N-terminal domain is the least conserved and has a variety of roles, with 
specific sub-domains identified in certain SOCS pairs, including the kinase 
inhibitory region (KIR) in SOCS1 and SOCS3 and the N-terminal conserved 
region (NTCR) in SOCS4 and SOCS5. The SH2 domain is lengthened by the 
addition of an extended SH2 sequence (ESS) and is involved in substrate 
binding via interaction with specific phosphotyrosine residues on the target 
protein. The SOCS box consists of BC box and Cul box sub-domains that 
recruit Elongin B and C, Cullin5, RBX1 and other E3 ligase components to 
mediate ubiquitination of target proteins and their subsequent proteasomal 
degradation. 
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Control of signaling by SOCS proteins 
All SOCS proteins are able to regulate receptor signaling through the 
recruitment of proteasomal degradation components to their target proteins, be 
they specific receptors or associated molecules (Fig 1.2). This is achieved by 
binding to these targets through their SH2 domains and recruitment of the E3 
ubiquitination complex via their SOCS box [34, 35]. SOCS-associated 
molecules are then readily able to be ubiquitinated, which typically targets 
these proteins to the proteasome. SOCS members can also regulate signaling 
via alternate methods. This is particularly true of SOCS1 and SOCS3, which 
bind Cullin5 at a much lower affinity than other SOCS proteins and remain 
partially active even in the absence of their SOCS box [35, 36]. As an 
alternative mechanism, SOCS1 and SOCS3 are able to directly inhibit JAK 
kinases, binding via their KIR domain to the JAK activation loop to directly 
inhibit kinase activity [27, 37-39]. CISH, SOCS2 and SOCS3, SOCS4 and 
SOCS5 can also inhibit signaling via their ability to bind to phosphotyrosine 
residues typically on receptors, thereby blocking access of other SH2-
containing signaling molecules [26, 40-43]. SOCS7 has also been shown to 
directly bind signaling proteins to prevent their nuclear translocation, thereby 
inhibiting their ability to signal [44]. SOCS proteins can also participate in cross-
talk between receptors and also regulate other pathways, such as Toll-like 
receptors (TLRs). 
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Figure 1.2 Signaling by cytokines and growth factors and negative 
regulation by SOCS proteins 
Cytokines (A) or growth factors (B) bind to their respective cell surface 
receptors, Cytokine receptors (CytoRs) and Receptor tyrosine kinases (RTKs), 
leading to receptor dimerization. For CytoRs this leads to activation of 
associated intracellular JAKs, which phosphorylate tyrosine residues on the 
receptor complex, creating docking site for STATs. These are then 
phosphorylated, enabling dimerization with other STATs, followed by 
translocation to the nucleus, where they act as transcription factors to induce 
expression of target genes that mediate a range of biological processes. These 
targets include SOCS genes capable of regulating receptor signaling, creating 
a negative feedback loop. RTKs possess intrinsic tyrosine kinase activity and 
may by-pass JAK and/or STAT activation. Individual SOCS proteins negatively 
regulate signaling by several mechanisms: degradation of receptors or 
associated proteins via the proteasomal pathway; inhibition of JAK tyrosine 
activity; competition for receptor phosphotyrosine residues thereby blocking 
other signaling molecules; prevention of nuclear translocation of key signaling 
molecules.  
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Functional role of SOCS proteins 
The function of individual SOCS proteins has been investigated by a range of 
approaches, with mouse knockout (KO) and transgenic (Tg) models revealing 
important roles in development (Table 1.1). Moreover, the SOCS proteins are 
being increasingly implicated in disease (Table 1.2). 
1.3.1.1 CISH 
CISH, the founding member of the SOCS family, was identified as an 
immediate-early gene induced in hematopoietic cells in response to stimulation 
by a variety of cytokines which encoded a protein that was able to bind to 
activated cytokine receptors [2, 45]. It is known to be induced by erythropoietin 
(EPO), interleukin-2 (IL-2), IL-3, and granulocyte-macrophage colony-
stimulating factor (GM-CSF), growth hormone (GH), prolactin (PRL) [46-48], 
IL-9 [49], thrombopoietin (TPO) [50, 51] and granulocyte colony-stimulating 
factor (G-CSF) [52], each of which also activate STAT5. In mice, strong 
expression of Cish was observed in the kidney, lung and liver [2], with lower 
expression in heart, stomach, testis, spleen, and thymus [2, 50]. Stat5a/b KO 
mice showed no detectable Cish expression [53, 54], underpinning the key role 
of STAT5 in CISH gene regulation. Indeed, CISH has been shown to be a direct 
STAT5 target gene, with two sets of conserved tandem STAT5 binding sites 
present in its promoter [45, 55]. CISH is also induced by IL-6 [50], IL-10 [56], 
interferon (IFN)α [57], IFNγ [50], tumor necrosis factor (TNF)α [50], thymic 
stromal lymphopoietin (TSLP) [58], leptin [59], and ciliary neurotropic factor 
(CNTF) [60], and T cell receptor (TCR) stimulation [61], none of which activate 
STAT5, indicating alternate pathways are also involved. Recent studies 
suggest that CISH is regulated post-transcriptionally by microRNAs (miRs), 
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with miR-98 or let-7 shown to target the 3’ untranslated region (UTR) of the 
CISH mRNA, causing translational repression. Stimulation with bacterial 
lipopolysaccharide (LPS) or Cryptosporidium parvum infection in vitro was able 
to decrease expression of miR-98 and let-7, thereby relieving the their 
translational suppression of CISH [62]. The CISH 3’UTR also contains ATAA 
destabilization motifs, while the CISH protein possesses PEST sequences, 
which lead to rapid turnover of the mRNA and protein, respectively [2]. 
CISH is known to negatively regulate signaling induced by EPO [45], GH [41], 
IL-2 [63], IL-3 [2], and PRL [48, 64]. CISH binds via its SH2 domain to 
phosphorylated tyrosine residues of activated cytokine receptors, where it 
suppresses signaling via at least two mechanisms [40, 41]. Firstly, CISH can 
bind to the same receptor phosphotyrosine sites as STAT5, thereby physically 
blocking further STAT5 docking, which has been demonstrated for the EPO 
receptor (EPOR) and growth hormone receptor (GHR) [40, 41, 65]. CISH can 
also negatively regulate signaling at the receptor level by facilitating 
proteasomal degradation of activated receptor complexes via interactions 
between its SOCS box, Elongin B/C  and Cullin5 [66, 67]. Interestingly, CISH 
has been suggested to be a positive regulator of TCR-mediated MAPK 
activation in T cells, although the mechanism remains to be elucidated [61]. 
Transgenic mice expressing CISH under the control of the β-actin promoter 
exhibited growth retardation caused by reduced GHR signaling, defective 
mammary gland development due to disrupted PRL receptor (PRLR) signaling, 
and altered T and Natural killer (NK) cell responses as a result of blunted IL-
2R signaling in T cells [68]. These phenotypes were consistent with those 
observed in Stat5a/b-deficient mice [53, 54], suggesting a specific in vivo role 
in the regulation of STAT5. An alternate transgenic mouse expressing CISH in 
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CD4+ T cells showed inhibited TCR signaling, but in a STAT5-independent 
manner [61]. 
CISH has been implicated during the GM-CSF-mediated ex vivo development 
of mouse bone marrow-derived dendritic cells (BMDCs). CISH was found to be 
induced by GM-CSF treatment, and CISH knockdown caused a decline in MHC 
class I, pro-inflammatory cytokines, and co-stimulatory molecule expression, 
concurrent with a substantial increase in the production of BMDCs via 
increased proliferation and reduced apoptosis. This was associated with 
enhanced STAT5 activation. Therefore, CISH expression appears to regulate 
progenitor cell proliferation late in development via feedback inhibition of 
STAT5 activation to allow differentiation to proceed effectively [69]. A CISH KO 
mouse has been recently described and was found to spontaneously develop 
airway inflammation. Analysis of adult lymphopoiesis revealed CISH 
participates in Th cell differentiation mediated by IL-4 [70].  
Functional analysis of a zebrafish CISH homologue, cish.a, has revealed it to 
be a direct downstream target of the JAK2/STAT5 pathway in vivo, with specific 
ablation of cish.a leading to a significant enhancement of embryonic 
erythropoiesis, myelopoiesis and lymphopoiesis, consistent with a role for 
CISH in the negative regulation of the JAK2/STAT5 pathway in vivo [71].  
CISH has also been implicated in disease. An association has been found 
between single nucleotide polymorphisms (SNPs) in human CISH and 
susceptibility to infectious diseases, including bacteremia, malaria, and 
tuberculosis. A SNP at position -292 of the CISH promoter was the most highly 
associated, increasing the overall risk of infectious disease by at least 18% 
among persons carrying the variant allele. This allele blunted the induction of 
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CISH mRNA following IL-2 stimulation, suggesting enhanced IL-2R signaling 
might be responsible for the increased susceptibility [72]. The -292 SNP was 
also found to be associated with hepatitis B virus infection in a Vietnamese 
population [73]. Other studies have suggested that CISH contributes to 
expansion of regulatory T cells (Tregs) in response to microbial infection [74]. 
Levels of CISH mRNA were also found to be higher in peripheral blood 
mononuclear cells (PBMCs) from systemic lupus erythematous (SLE) patients 
in acute phase compared to either normal individuals or patients with inactive 
phase of disease, suggesting that CISH represents a marker of SLE and may 
be involved in disease pathogenesis [75]. Alterations in CISH levels have also 
recently been linked to osteoarthritis, although in this case CISH mRNA levels 
were found to be 10-fold lower in chondrocytes from osteoarthritic patients 
compared to control samples [76]. This suggests CISH plays a clinically 
relevant role that might provide new strategies for controlling infectious agents 
and inflammatory diseases. 
1.3.1.2 SOCS1  
SOCS1 has been demonstrated to be highly expressed in both mouse and 
human thymus and spleen [20, 50, 77]. It was also expressed in the lung, testis 
[50], colon and mesenteric lymph nodes [20]. SOCS1 has been shown to be 
induced by numerous cytokines in vitro and ex vivo, including IL-2 [78], IL-4 
[37, 79], IL-6 [37], IL-13 [80], IFNα/β [81, 82], IFN-γ [50, 83], EPO [38, 50], G-
CSF [37], LIF [37], PRL [48], GH [46], CNTF [60] and TNFα [84]. SOCS1 is 
also induced by Toll-like receptor (TLR) ligands, such as LPS [85, 86] and CpG 
DNA [87], as well as insulin [88] and thyroid stimulating hormone (TSH) [89]. 
Bioinformatic analysis has identified the 3'UTR region of SOCS1 as a potential 
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target of miR-155. This miR is normally induced by TNF-α through the JNK 
pathway with knockdown of miR-155 in mouse osteoblastic cells resulting in 
increased SOCS1 protein expression following TNFα stimulation. In contrast, 
transfection with miR-155 inhibited wild-type SOCS1 [90]. In T cells, FOXP3 
negatively regulates miR-155 thereby contributing to the maintenance of 
SOCS1 levels in these cells [91].  
SOCS1 has also been found to regulate signaling by a raft of receptors in vitro, 
including those for the cytokines IFNα [83], IFNγ [83], EPO [38], PRL [47, 48], 
GH [46, 65], LIF [37], TNF-α [84], IL-2 [38, 78], IL-3 [38], IL-4 [79], IL-6 [37], IL-
7 [92], IL-12 [93], IL-15 [94], EPO [38], TPO [50], TSLP [58], oncostatin M 
(OSM) [50], and leptin [95], as well as the receptors for insulin [96] and IGF-1 
[97], and the TLRs [98]. SOCS1 is known to regulate signaling via two 
mechanisms. Firstly, it can bind directly to cytokine receptor-associated JAK1, 
JAK2, and TYK2 to inhibit their tyrosine kinase activity via its ESS/KIR 
domains, and consequently suppress activation of downstream pathways [27, 
36-38]. However, like other SOCS family members, SOCS1 can also interact 
with Elongin B/C and Cullin5 via its SOCS box, facilitating ubiquitination and 
proteasomal degradation of target substrates [33, 99], including JAK1 [99], 
JAK2 [100], TEL-JAK2 [101, 102], GEF, VAV [103], insulin receptor substrate 
(IRS)-1 and IRS-2 [104], as well the TLR2/4 adaptor protein MAL [98]. 
Interestingly, the SOCS box has also been shown to protect SOCS1 against 
proteolytic degradation [105]. 
SOCS1 has been shown to have several essential roles in immunity. Socs1 
KO mice developed a fatal neonatal disease that resulted in death by three 
weeks of age [106, 107]. These animals exhibited severe lymphopenia and T 
cell-mediated autoimmune inflammatory disease, characterized by monocytic 
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infiltration of major organs along with fatty degeneration and necrosis of the 
liver [106]. These phenotypes were significantly reduced in Ifnγ/Socs1 double 
KO mice and in Socs1 KO mice treated with anti-IFNγ antibodies [108, 109], 
indicating that hyper-responsiveness to IFNγ was the chief cause of the 
inflammatory response, and confirming SOCS1 as a potent in vivo regulator of 
IFNγ. However, these Ifnγ/Socs1 double KO mice later developed additional 
phenotypes, including polycystic kidneys, chronic infections, and inflammatory 
lesions, which resulted in survival to only 6 months of age [109]. T cell 
development was also perturbed, including reduced T cells numbers [110], 
disrupted Th2 responses [111], a reduced CD4/CD8 ratio [110], as well as 
abnormal development of Th17 cells [112], resulting from hypersensitivity to 
cytokines acting via the γc receptor: IL-2, IL-4, IL-7, IL-15 [113] and IL-12 [93].  
T cell-specific Socs1 KO mice did not develop the lethal multi-organ 
inflammation, but rather specific lymphoid deficiencies, including increased 
differentiation toward CD8(+) T cells and phenotypes correlating with 
hypersensitivity to γc receptor utilizing cytokines [114]. These mice also 
showed a 10-fold increase in FOXP3(+) CD4(+) T regulatory (Treg) cells in the 
thymus, indicating SOCS1 potentially negatively regulates the generation 
and/or accumulation of these cells [115]. The increase in Treg cells was still 
apparent when these mice were crossed with those lacking IFNγ or IL-7 
indicating other cytokines mediate this effect [115]. Further supporting a Treg 
role, mice lacking SOCS1 expression in all but their T and B cells developed 
spontaneous dermatitis, splenomegaly, and lymphadenopathy. They showed 
an accumulation of DCs in their thymi and spleens, which were hyper-
responsive to both IFNγ and IL-4, resulting in increased levels of BAFF/BLyS 
and APRIL, facilitating the generation of autoantibodies. This resulted in the 
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development of systemic autoimmune-like diseases with 
hypergammaglobulinemia at an early age [66]. Whilst it has been demonstrated 
that SOCS1 is important in helper T cell (Th) differentiation, there is conflicting 
data regarding exactly which cell fate SOCS1 drives differentiation towards. 
Some studies have suggested that SOCS1 favors Th1 differentiation, while 
others suggest that IL-6 induced SOCS1 blocks Th1 development via the 
inhibition of IFNγR, leading to accelerated Th2 differentiation [116]. To add to 
the complexity, SOCS1 has been shown to be necessary for Th17 
differentiation via its suppressive effects on IFNγ [117]. 
SOCS1 has been demonstrated to have several other in vivo regulatory 
functions. Thus, Socs1 KO mice also showed impaired osteoblast 
differentiation [118], as well as enhanced insulin signaling [119]. In addition, 
cells from SOCS1 transgenic mice were unable to respond to LPS, suggesting 
that SOCS1 inhibited TLR/NF-κB signaling in vivo [85]. Socs1 deficiency also 
resulted in excessive macrophage and dendritic cell activation [66, 85], 
potentially caused by the combined effects of unrestrained signaling via 
IFNAR1 [120] and TLRs [98, 121]. Knockdown of zebrafish socs1 resulted in 
perturbation of specific myeloid populations during embryogenesis prior to the 
commencement of lymphopoiesis, along with reduced numbers of T cells. 
Zebrafish SOCS1 was shown to interact with the zebrafish JAK2/STAT5 
pathway both in vitro and in vivo. This demonstrated SOCS1 has a conserved 
role in T cell development, but exerts a T cell-independent function in 
embryonic myelopoiesis likely mediated via regulation of receptors that utilise 
the JAK2-STAT5 pathway [122]. 
Defective SOCS1 signaling has been associated with a range of inflammatory 
disorders. In a murine arthritis model, SOCS1 was expressed in multiple cell 
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types in the arthritic joint, with the extent of joint destruction and synovial 
inflammation exacerbated in Socs1 KO mice [123]. SOCS1 expression has 
been shown to correlate inversely with the severity of disease in idiopathic 
pulmonary fibrosis patients, with adenovirally-delivered SOCS1 decreasing 
fibrosis, inflammation and mortality in a murine model of pulmonary 
inflammation [124]. However, SOCS1 does not always confer protection 
against inflammatory/immune diseases. Thus, SOCS1 Tg mice spontaneously 
develop colitis, with severe intestinal inflammation [125]. Moreover, a SOCS1 
promoter SNP which increases SOCS1 expression was associated with adult-
onset asthma [126]. SOCS1 was also shown to protect E-cells from cytotoxic T 
cells in a murine type 1 diabetes model [127]. Moreover, increased expression 
of SOCS1 was observed in insulin-resistant mice, with down-modulation of 
SOCS1 leading to increased insulin-sensitivity in these animals [128]. 
SOCS1 has also been suggested to have a tumor suppressor role, particularly 
in hematological malignancies and proliferative disorders. Thus, the SOCS1 
gene has been found to be frequently mutated in both classical Hodgkin 
lymphoma [129, 130] and primary mediastinal B-cell lymphoma [131], leading 
to augmented signaling by STAT5 [129, 131] and STAT6 [130]. The SOCS1 
gene was shown to be commonly silenced by hypermethylation (and 
occasionally mutation) in acute myeloid leukemia [132, 133], with the 
reintroduction of SOCS1 causing growth suppression in affected cells [133]. 
Chronic myeloid leukemia patients also demonstrated hypermethylation of 
SOCS1 that reverted to an unmethylated state during remission [134]. Some 
Philadelphia chromosome (Ph)-negative myeloproliferative disorders (MPDs) 
also exhibited SOCS1 hypermethylation, which may complement other 
mutations, such as the hyperactive JAK2V617F mutation [135]. Others have 
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alternatively found that SOCS1 is overexpressed in Ph-negative MPDs, 
potentially acting as a compensatory feedback mechanism [136]. Indeed, 
constitutive expression of SOCS1 has been observed in chronic myeloid 
leukemia [137], in line with hypomethylation of this gene [138]. SOCS1 
expression in CML also correlated with a poor response to interferon D, 
treatment, likely due to a direct effect on receptor signaling [137]. 
Hypermethylation of the SOCS1 gene has also been commonly reported in 
solid tumors, including 61% of cervical cancer samples [139], and  45% of 
esophageal squamous cell carcinoma samples [140], as well as occasionally 
in Barrett’s adenocarcinoma [141], with combined hypermethylation/gene loss 
observed in hepatocellular carcinoma [142]. Hypermethylation-mediated 
silencing has also been seen in glioblastoma multiforme, with concomitant 
enhancement of radio-resistance, indicative of a pro-apoptotic function [143]. 
Hypermethylation silencing of SOCS1 has also been observed in breast and 
ovarian cancer, where SOCS1 reintroduction was again able to suppress cell 
growth [144]. Spontaneous colorectal cancer was also seen in Socs1 KO mice 
in an IFNJ-dependent manner [145]. SOCS1 has also been shown to suppress 
oncogenic forms of VAV [103], c-MET [146], ABL and c-KIT [147], as well as 
TEL-JAK2 and BCR-ABL fusions [147].  
Finally, SOCS1 plays additional roles in the response to infectious agents. For 
example, SOCS1 has been shown to protect against lethal inflammation 
induced by Chlamydia pneumoniae, although it hampered bacterial clearance 
due to its effects on IFND/E-induced STAT1 [148]. SOCS1 also inhibited the 
antiviral response to influenza [149], and increased SOCS1 levels were 
associated with enhanced disease severity in tuberculosis [150]. In fact, many 
infectious agents specifically target SOCS1 to augment the infection process. 
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Thus, Toxoplasma gondii induces SOCS1 expression leading to inhibition of 
cytokine signaling and suppression of immune responses [151]. Similarly, 
Mycobacterium bovis induces SOCS1 and SOCS3 to inhibit IFNJ-induced 
STAT1 [152]. Furthermore, bacterial flagellin was shown to act via TLR5 to 
induce SOCS1 thereby suppressing TCR-mediated T cell activation [153]. In 
contrast, hepatitis C core protein mediates down-regulation of SOCS1, 
resulting in enhanced STAT5 signaling in B cells [154].  
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1.3.1.3 SOCS2 
SOCS2 was shown to be highly expressed in the fetal kidney [155], as well as 
adult kidney, lung, testes, liver [50, 155, 156], pancreatic islets [157], peripheral 
blood mononuclear leukocytes [158], and to a lesser extent in adult heart, 
muscle and brain [155, 156]. SOCS2 is most closely related to CISH, and like 
CISH is induced by cytokines that activate STAT5, including GH [46, 159], EPO 
[50, 160], PRL [48], IL-2 [161], IL-3, GM-CSF and G-CSF [50]. However, it is 
also induced by factors that don’t act through STAT5: CNTF [60], IFNα [57], 
IFNγ [50, 158], leukaemia inhibitory factor (LIF) [50], IL-1β [158], IL-4 [50], IL-
6 [158], IL-15 [162] and insulin [88]. 
SOCS2 acts to regulate signaling induced by the cytokines GH [41], PRL [163], 
LIF [161], IL-2, IL-3 [164] and IL-6 [36], but also by growth factors, such as 
epidermal growth factor (EGF) [165] and insulin-like growth factor (IGF)1 [155]. 
SOCS2 differs from other SOCS family members in two important and 
interesting ways. Firstly, SOCS2 appears to play a dualistic regulatory role, 
both inhibiting and potentiating signaling dependent on its concentration and 
cellular context [36, 48, 166]. In vitro studies have demonstrated that low levels 
of SOCS2 led to a reduction in GH signaling, while higher levels actually 
increased GH signaling [166]. Secondly, SOCS2 has been shown to possess 
the ability to antagonize other SOCS family members [64]. Thus, SOCS1 
inhibition of GH signaling was reduced with increasing doses of co-transfected 
SOCS2 [166], while SOCS2 was shown to exert an antagonistic role in the 
negative regulation of IL-2 and IL-3 signaling by SOCS1 and SOCS3, 
respectively [164]. SOCS2 primarily exerts its effects by stimulating 
ubiquitination of target proteins, including receptors, such as GHR [167], and 
signaling proteins, such as SOCS3 [164].  
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Socs2 knockout mice were indistinguishable from their littermates until 3 weeks 
of age, at which point they began to demonstrate increased overall growth, 
being 40% heavier than wild-type (WT) littermates by adulthood [156]. The 
increase in weight was due to increased bone length and enlargement of 
internal organs [156]. Constitutive expression of SOCS2 produced a similar 
phenotype, with SOCS2 transgenic mice being significantly larger than WT 
animals [168], consistent with the dualistic nature of SOCS2. A naturally-
occurring mouse mutant, high growth (hg), which exhibited a 30-50% increase 
in postnatal growth, has been mapped to the Socs2 region, indicating that hg 
is most likely an allele of Socs2 – although whether it is hypomorphic or 
hypermorphic allele remains to be determined [169]. Socs2 KO mice 
demonstrated prolonged STAT5B activation in response to GH, and crossing 
with Stat5b KO mice partially relieved the growth enhancement [159]. This 
suggests that SOCS2 regulates the GH/IGF-1 axis through negative control of 
the downstream STAT5b [156, 159]. SOCS2 plays a similar role in the 
regulation of prolactin-induced mammary gland development, which appears 
to be through the control of STAT5A activation [163].  SOCS2 also exerts a 
dualistic role in the regulation of EGF signaling, with increased intestinal growth 
in Socs2 KO mice due to enhanced responsiveness to EGF [170], and 
increased neural outgrowth of cortical neurons derived from SOCS2 transgenic 
mice, apparently also due to enhanced EGF signaling [171]. Transgenic mice 
overexpressing SOCS2 specifically in pancreatic E-cells using the rat insulin 
promoter displayed hyperglycemia and glucose intolerance, but did not exhibit 
overt diabetes [172]. In contrast, the pancreatic E-cells of Socs2 KO mice 
showed unaltered insulin and glucose tolerance when compared to WT mice 
[173].  
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SOCS2 also functions in immune cells, with roles in both dendritic cells (DCs) 
and CD4+ T cells. When SOCS2 was silenced in DCs, maturation was 
disrupted and a reduction in LPS stimulated MAPK activation was observed 
[174], suggesting a requirement for SOCS2 in TLR-induced DC activation. 
However, others have argued that SOCS2 is a TLR-responsive gene with its 
delayed expression providing a mechanism for late-phase counter-regulation 
to limit inflammation-driven DC activity [175]. SOCS2 silencing in CD4+ T cells 
resulted in increased preference for helper T cell (Th)2 differentiation, which is 
consistent with elevated Th2 responses observed in Socs2 KO mice [176]. In 
human NK cells, SOCS2 was shown to be induced by IL-15 and targeted PYK2 
for degradation, with SOCS2 knockdown resulting in defective NK cell effector 
functions [162].  
Like its close homologue CISH, SOCS2 has been linked to osteoarthritis, with 
SOCS2 mRNA levels also found to be 10-fold lower in osteoarthritic samples 
when compared to control samples, with increased expression seen following 
cytokine treatment [76]. A SNP in the 5’ region of the SOCS2 gene was 
associated with type 2 diabetes (T2D) in a Japanese population. Adenovirus-
mediated expression of the SOCS2 gene in pancreatic islets significantly 
suppressed glucose-stimulated insulin secretion, suggesting a likely 
mechanism by which SOCS2 may influence susceptibility to T2D [77]. SOCS2 
also appears to be a cellular target of the HIV-1 transactivator protein (Tat) in 
primary human monocytes, leading to increased SOCS2 levels, which can 
suppress IFNγ-activated STAT1 phosphorylation, resulting in dysregulated 
cytokine production and immune evasion [177]. Finally, SOCS2 has been 
implicated in oncogenesis, where it also shows a dualistic nature. Patients with 
active acromegaly and colonic polyps showed a significantly increased SOCS2 
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expression, which mediated a reduction in SOCS1, leading to elevated 
STAT5B levels, potentially resulting in upregulation of GH-mediated 
proliferation of colonic epithelial cells [178]. In contrast, SOCS2 expression was 
shown to have a favorable prognostic value in breast cancer [179], and 
hypermethylation of SOCS2 was detected in ovarian but not breast cancer 
[144]. 
1.3.1.4 SOCS3 
SOCS3 has been shown to be expressed in a wide variety of murine and 
human tissues. In mice, SOCS3 was found to be expressed in the spleen, 
thymus, and lung [50], while in humans SOCS3 was expressed in the colon, 
spleen, bladder, peripheral blood leukocytes, trachea and placenta, with very 
high expression in the lung, adipose tissue, ovary and aorta [77]. SOCS3 has 
been demonstrated to be induced by the cytokines IL-1β [180], IL-2 [181], IL-3 
[182], IL-4 [79], IL-6 [183], IL-9 [49], IL-10 [56], IL-11 [184], IL-13 [50], IL-22 
[185], IFN-γ [83], IFNα [83], EPO [186], LIF [46], PRL [48], GH [46], leptin [187], 
G-CSF [50], GM-CSF [188], CNTF [60], TPO [82], TNFα [189], cardiotrophin 
(CT)1 [190] and OSM [191]. It is also induced by several growth factors, 
including EGF [192, 193], platelet-derived growth factor (PDGF) [192], thyroid 
stimulating hormone (TSH) [89], insulin [88], and basic fibroblast growth factor 
(BFGF) [194]. 
SOCS3 has been demonstrated to play a regulatory role in signaling 
downstream of a wide range of cytokine receptors, including those for IL-2 
[181], IL-4 [79], IL-6 [36], IL-9 [49], IL-11 [184], IL-23 [195], IL-27 [196], IFNα/β 
[83], IFNγ [83], G-CSF [197], EPO [186], PRL [47, 48], GH [46, 65], LIF [46], 
leptin [187], CNTF [60], IL-1β [198], OSM [191] and CT1 [190], as well as IGF-
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1 [97], insulin [199], CD28 [200] and calcineurin [201]. Like its closest 
homologue, SOCS1, the SOCS3 protein can directly inhibit receptor-bound 
JAKs, although it achieves this via a high-affinity interaction between its SH2 
domain and a phosphotyrosine residue on the receptor (e.g. GP130), rather 
than the JAK [186], binding simultaneously to both [202]. SOCS3 also regulates 
signaling via binding site competition. Thus, SOCS3 has been shown to bind 
to the same site as the SH2-domain hematopoietic phosphatase (SHP)-2 on 
several receptors [42] and with STAT4 on others [203]. Finally, like other 
members of the SOCS family, SOCS3 can also regulate signaling by targeting 
proteins for degradation, although this is not its primary mechanism of action, 
since it can still regulate signaling without its SOCS box [36]. It has been 
demonstrated that an IL-6 transcriptional response can be converted to one 
mimicking that of interferons when SOCS3 is absent [183, 204]. Moreover, IL-
7-induced viral clearance has been shown to occur via a mechanism that 
required both the induction of IL-6 and inhibition of SOCS3 expression [205]. 
Collectively, this suggests that SOCS3 primarily functions by dampening 
cytokine-induced STAT3 and STAT1 activation. Induction of SOCS3 is most 
pronounced by cytokines that strongly activate STAT3, with its regulatory 
specificity determined by the presence of high-affinity SOCS3-binding sites on 
target receptors. 
Socs3 KO embryos exhibited fatal placental defects during embryonic 
development and although anatomically sound, they did not survive past 13 
days of gestation. These embryos showed expanded numbers of giant 
trophoblast cells in the placenta, as well as abnormalities in the 
spongiotrophoblast and labyrinth placental layers [206]. Lifr deficiency was able 
to rescue the Socs3 KO placental defect and embryonic lethality, establishing 
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SOCS3 as an essential regulator of LIFR signaling during placental formation 
[207]. However, these double KO mice died by 190 days of age due to 
neutrophilia accompanied by inflammatory-cell tissue infiltration [208]. 
Hematopoietic-specific Socs3 KO mice developed a variety of inflammatory 
conditions, including prolonged and enhanced responses to G-CSF that 
facilitated neutrophilia and enhanced progenitor cell survival, suggesting 
SOCS3 is an important in vivo regulator of G-CSFR signaling [197]. 
Interestingly, differentiation of SOCS3-deficient progenitors was skewed 
toward a macrophage state in response to G-CSF and IL-6 stimulation, 
suggesting that SOCS3 is also important in maintaining the specificity of 
biological responses mediated by cytokine signaling [209]. SOCS3 was also 
shown to be a positive regulator of TLR4 responses in macrophages via 
inhibition of IL-6R-mediated STAT3 activation [210], as well as endogenous 
TGFE-mediated/SMAD3 [211]. Socs3 deficiency in either hepatocytes or 
macrophages resulted in prolonged IL-6-induced activation of STAT1 and 
STAT3, but normal IFNγ and IL-10 signaling [183, 204, 210]. These 
observations strongly suggest that SOCS3 targets GP130 dependent signal 
transduction pathways in vivo.  
SOCS3 has been shown to be selectively expressed in Th2 cells [212] and 
required for Th2 development. Mice heterozygous for Socs3 or expressing a 
dominant-negative SOCS3 showed reduced Th2 development, while those 
expressing a SOCS3 transgene exhibited enhanced Th2 polarity [213]. T cell-
specific Socs3 KO mice showed increased CD8(+) T cell proliferation via 
enhanced IL-6 and IL-27 signaling [196]. It has been suggested that the ability 
of SOCS3 to skew T cell differentiation to the Th2 phenotype may be due to an 
ability to compete for the STAT4 binding site on the IL-12Rβ2 chain, thus 
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inhibiting IL-12/STAT4-driven polarization to the alternative Th1 phenotype 
[203], or alternatively via its inhibition of interferon-induced STAT1 activation 
that is also associated with Th1 polarization [183]. 
SOCS3 has diverse roles outside of the immune and hematopoietic lineages. 
Mammary stem/progenitor cell-specific Socs3 KO mice exhibited impaired 
lactation resulting from reduced proliferation [214]. Loss of SOCS3 from 
differentiated luminal cells resulted in accelerated tissue remodeling upon 
weaning [214]. SOCS3 has also been shown to play a role in fine-tuning 
photoreceptor cell differentiation [215], while SOCS3 transgenic mice showed 
reduced pancreatic β-cell mass and proliferation [216]. SOCS3 was also shown 
to be required for normal wound healing, again via its action on GP130 
signaling [217]. Finally, elevated levels of SOCS3 in the arcuate nucleus of the 
hypothalamus have been associated with leptin resistance and obesity in mice 
[187].  
SOCS3 has also been associated with the progression of a number of 
inflammatory conditions. SOCS3 expression has been reported in synovial 
tissue from mice during experimental arthritis, and in peripheral blood 
mononuclear cells in patients with rheumatoid arthritis (RA) [218]. Mice with a 
GP130 receptor mutation that ablates SOCS3 binding develop a RA-like joint 
disease [219]. Similarly, hematopoietic and endothelial cell-specific Socs3 KO 
mice exhibited severe phenotypes in experimental arthritis models, most likely 
due to enhanced responsiveness of IL-6, G-CSF and possibly IL-1 [220]. 
Moreover, adenovirally delivered SOCS3 could eliminate joint inflammation in 
mice with experimental autoimmune arthritis, mediate via inhibition of IL-6 
signaling [221]. SOCS3 was found to be highly expressed in lamina propria and 
epithelial cells in the colon of mice with inflammatory bowel disease (IBD), as 
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well in human patients with both ulcerative colitis and Crohn’s disease (CD), 
suggested to be due to enhanced IL-6 signaling (via STAT3) [222]. In contrast, 
SOCS3 has been found to be upregulated in the peripheral T cells from patients 
with Th2 type diseases, such as atopic asthma and dermatitis, where its 
expression has been found to correlate tightly with disease severity [213]. 
Similarly, SOCS3 has been associated with allergic conjunctivitis (AC), with 
high expression at the site of disease, with reduction of SOCS3 leading to 
decreased clinical severity [223].  
SOCS3 appears to also play a tumor-suppressor/anti-proliferative role. For 
example, overcoming SOCS3 regulation seems to be a common theme in 
proliferative syndromes. Thus, the myeloproliferative disease-associated 
JAK2V617F mutant is no longer able to be negatively regulated by SOCS3 [224]. 
Similarly, G-CSFR truncations associated with severe congenital neutropenia 
leading to acute myeloid leukemia have lost the sequences required for 
SOCS3-mediated control of STAT5 activation [225]. Once again though the 
exact role for SOCS3 is complex. For example, overexpression of SOCS3 was 
associated with decreased survival in a cohort of patients with de novo follicular 
lymphoma [226], while SOCS3 was able to potentiate the JAK2V617F mutation 
[224]. However, hypermethylation of SOCS3 occurs frequently in both Barrett’s 
adenocarcinoma [141] and hepatocellular carcinoma [227], in the latter case 
leading to increased JAK2/STAT3 activation [227]. Hypermethylation-mediated 
reduction in SOCS3 expression has also been observed in malignant human 
melanoma [228], while constitutive SOCS3 expression was shown to confer a 
proliferative advantage to a human melanoma cell line [229]. SOCS3 was also 
found to be frequently silenced by hypermethylation in human lung cancer 
where it suppressed cell growth [230].  SOCS3 was able to limit inflammation-
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associated tumorigenesis in the colon, via regulation of STAT3 and NFκB [231], 
while in ulcerative colitis, loss of SOCS3 expression was observed in the areas 
of colon dysplasia [232]. SOCS3 was protective against hepatitis-induced 
hepatocellular carcinoma, with loss of SOCS3 leading to resistance to 
apoptosis and increased proliferation [233]. Similar epigenetic silencing of 
SOCS3 has been seen in cholangiocarcinoma cells, resulting in enhanced IL-
6/STAT3 signaling and reduced apoptosis [234]. SOCS3 hypermethylation was 
also seen in glioma [13], and prostate cancer tissues, although not in benign 
prostate hyperplasia [235]. Finally, reduced expression of SOCS3 was also 
specifically observed in breast cancer with lymph node metastasis, suggesting 
a role in tumor spread [236].  
Finally, SOCS3 has been associated with infectious diseases. For example, 
the severe inflammation mediated by SARS virus infection was found to 
correlate with lower expression of SOCS3 in infected cells [237]. In contrast, 
SOCS3 was able to inhibit the antiviral response to influenza [149]. Moreover, 
pathogenic strains of Salmonella sp. could increase SOCS3 expression in 
macrophages to mediate suppression of immune responses [151]. Similarly, 
M. bovis was able to induce SOCS3 to mediate inhibition of IFNJ-induced 
STAT1 [152]. High levels of SOCS3 have also been found to be associated 
with non-responsiveness to combined IFN antiviral therapy [238]. 
1.3.1.5 SOCS4 
SOCS4 remains the least studied member of the SOCS family. It has been 
shown to be particularly highly expressed in the intestine and thymus of adult 
pig [239]. Available mouse data suggests SOCS4 is widely expressed, with 
higher expression in the olfactory bulb 
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(http://biogps.org/#goto=genereport&id=122809). To date, SOCS4 has been 
shown to be induced only by EGF, at least in vitro [240]. Similar to CISH, the 
microRNAs miR-98 and let-7 are thought to post-transcriptionally regulate 
SOCS4, facilitating translational repression by targeting its 3’UTR region. 
Infection of biliary epithelial cells with C. parvum decreased miR-98 and let-7, 
leading to increased SOCS4 expression [62]. 
SOCS4 has been demonstrated to regulate EGFR signaling in vitro [21, 240]. 
This appears to be mediated through docking of SOCS4 to phosphotyrosine 
residues on the activated EGFR, subsequently targeting the receptor for 
proteasomal degradation by recruitment of E3 ubiquitin ligase activity [21, 26]. 
However, SOCS4 binds with high affinity to the same EGFR phosphotyrosine 
as STAT3, and therefore may also inhibit STAT3 activation directly by blocking 
its ability to dock to EGFR [26]. SOCS4 also has a low micromolar affinity for 
JAK2 and c-KIT, the biological consequences of which remain to be determined 
[26]. One report has suggested a role for SOCS4 in the regulation of primordial 
follicle activation, a process initiated by LIF activation of the JAK1/STAT3 
pathway. This occurred concurrently with SOCS4 induction, with SOCS4 
shown to interact with several proteins involved in ovarian follicular 
development [241].  
Mice carrying a Socs4 gene mutation encoding a highly truncated protein 
lacking part of the N-teminal and the entirety of the SH2 domain and SOCS 
box have been generated. These were shown to be fertile and without an overt 
phenotype. However, when inoculated with an H1N1 influenza virus, they 
succumbed more rapidly to the infection than control animals. This increased 
mortality was linked to an elevation of pro-inflammatory cytokines and 
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chemokines, including IL-6, and impaired trafficking of CD8 T cells to the 
infection site [242].  
Several studies have also suggested a tumor suppressor role for SOCS4. An 
inverse relationship between SOCS4 expression levels and tumor node 
metastasis stage has been reported in human breast cancer [243]. In addition, 
SOCS4 expression was found to be significantly lower in cancerous tissue 
compared to non-cancerous tissue in a patient with gastric cancer, mediated 
by hypermethylation-mediated silencing of the SOCS4 gene [244]. Mouse 
studies also suggest a tumor suppressor role in epithelial cells via RUNX1-
mediated repression of the Socs4 promoter, leading to decreased SOCS4 
levels and increased STAT3 activity, thereby contributing to tumor 
development [245]. 
1.3.1.6 SOCS5 
SOCS5 is most closely related to SOCS4, and also has not been fully 
characterized. SOCS5 has been shown to be expressed in a variety of adult 
tissues including heart, brain, retina, lung, colon, bladder, testis and skeletal 
muscle as well as the placenta [20, 240, 246, 247]. Expression was particularly 
high in lymphoid organs including the spleen, lymph nodes, thymus, and bone 
marrow, with specific expression in primary B and T cells [248], suggesting 
possible immune-related functions [246]. Like SOCS4, SOCS5 expression has 
been shown to be induced by EGF in vitro [240]. 
SOCS5 appears able to regulate both RTK and cytokine receptor signaling. 
Thus, SOCS5 has been shown to negatively regulate EGFR in vitro [21, 240], 
and more weakly IL-6R, LIFR [36] and IL-4R signaling [43]. This appears to be 
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a conserved function since overexpression of the Drosophila melanogaster 
SOCS5 homologue, SOCS36E, resulted in several phenotypes consistent with 
reduction in both cytokine receptor and EGFR signaling. SOCS5 is thought to 
regulate signaling by initiating the proteasomal degradation of its target 
proteins, as seen in the regulation of EGFR, where both its SH2 domain and 
SOCS box required for initiation of degradation [21, 240]. Interestingly, the 
SOCS5 protein has been found to associate with EGFR independent of ligand 
stimulation, binding via its N-terminal domain [240]. 
Consistent with its expression in lymphoid organs and in vitro effects on IL-4 
signaling, SOCS5 has been implicated in T helper cell differentiation, 
particularly in the balance between Th1 and Th2 cells, with SOCS5 protein 
preferentially expressed in Th1 cells. SOCS5 Tg mice showed a significant 
reduction in Th2 development, thought to be facilitated by the ability of SOCS5 
to inhibit IL-4R mediated STAT6 activation that normally stimulates 
differentiation of naïve T cells toward Th2 [43]. Interestingly, SOCS5 was found 
to associate with the IL-4R regardless of tyrosine phosphorylation [43, 240]. 
However, Socs5 KO mice showed no abnormalities in Th1/Th2 differentiation, 
indicating possible redundancy in its lymphoid role [248]. 
SOCS5 has been implicated in a variety of predominately immune-related 
disease states, such as allergic conjunctivitis [223], atopic dermatitis [249], 
asthma [250] and uveitis [251], although some of these associations have so 
far only been identified in rodent models. These studies also provide further 
support for a role for SOCS5 in regulating the balance between Th1 and Th2 
cells. For example, SOCS5 expression was decreased in patients with the Th2 
dominant disease atopic dermatitis (AD) compared to healthy controls, with 
patients demonstrating eosinophilia having even lower levels of SOCS5 [249]. 
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Moreover, constitutive SOCS5 expression has been found to reduce eosinophil 
infiltration in allergic conjunctivitis [223], further implicating SOCS5 in the 
balance of Th1/Th2 cells, since eosinophil production is stimulated by Th2 
cytokines, including IL-4. This notion was further supported in a murine model 
for allergic conjunctivitis, an ocular disease that is characterised by IL-4-
mediated eosinophil infiltration. In mice constitutively expressing SOCS5 under 
the control of the lck proximal promoter and Eμ enhancer reduced conjunctival 
eosinophil infiltration was observed [223]. These mice also showed decreased 
lethality to septic peritonitis and significantly lower bacterial burden compared 
to controls. This was associated with accumulation of neutrophils and 
macrophages, with these cells showing increased bactericidal properties and 
impaired IL-4-induced STAT6 activation [252].  Since STAT6 knockout mice 
have also been found to be resistant to septic peritonitis [253], this suggests a 
regulatory role for SOCS5 on the IL-4/STAT6 pathway. SOCS5 transgenic 
mice also showed increased levels of peritoneal IL-2 and IFN-J, cytokines 
involved in the promotion of Th1 differentiation [252]. Finally, a reduction in 
SOCS5 expression was observed in cancer of the thyroid gland [254], 
suggesting a possible tumor-suppressor function.   
1.3.1.7 SOCS6 
SOCS6 has been shown to be ubiquitously expressed during mouse embryonic 
development, while in the adult mouse expression has been reported in areas 
of the bone marrow containing monocytes and immature granulocytes [22] as 
well as in the retina [247]. SOCS6 was found to be induced by both insulin [255, 
256] and IGF-2 [257]. 
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SOCS6 has been demonstrated to negatively regulate signaling by IGF-1 [257], 
insulin [255], FLT3 [258], Stem Cell Factor (SCF) [259] and TCR [260]. Like 
other SOCS proteins, SOCS6 exerts its regulatory effects primarily through 
ubiquitination and degradation of target proteins [22]. However, SOCS6 
interacts with an alternate E3 ligase component, heme-oxidized IRP2 ubiquitin 
ligase-1 (HOIL-1), which induces the poly-ubiquitination and degradation of 
SOCS6-associated proteins [259]. Like SOCS2, SOCS6 also has the ability to 
degrade other SOCS proteins, including SOCS7 [261]. The SOCS6 N-terminal 
domain has been shown to drive localization to the nucleus, where it appears 
to negatively regulate STAT3, although the exact mechanism by which SOCS6 
mediates this effect has not been identified [29]. 
SOCS6 has been shown to control TCR-mediated T cell activation in vitro 
through negative regulation of p56lck. SOCS6 was shown to bind to the kinase 
domain of active p56lck, targeting it for ubiquitination and subsequent 
degradation, with SOCS6 overexpression resulting in repression of TCR-
dependent IL-2 promoter activity [260]. SOCS6 also appears to negatively 
regulate signaling of several important hematopoietic receptor tyrosine 
kinases. Thus SOCS6 is able to bind to the juxtamembrane region of c-KIT 
following stimulation with SCF, thereby regulating activation of members of the 
MAPK pathway, such as ERK1/2 and p38 [259]. SOCS6 can also bind to FLT3 
and negatively regulate its signaling, reducing downstream ERK1/2 signaling 
and concomitant cell proliferation [258]. 
A potential role for SOCS6 in neural stem cell differentiation has also been 
suggested. Expression of SOCS6 was upregulated during differentiation of 
these cells. SOCS6 overexpression resulted in enhanced neurite outgrowth 
cells, while siRNA-mediated knockdown of SOCS6 decreased neurite 
 37 
extension [257]. Neurite outgrowth was also enhanced by IGF-1, which 
increased SOCS6 levels, but reduced in the presence of a JAK/STAT pathway 
inhibitor that could not be rescued by IGF-1 treatment [257]. There is also a 
large body of in vitro data supporting a role for SOCS6 in glucose homeostasis. 
SOCS6 has been shown to inhibit pathways downstream of the insulin and 
IGF-1 receptors [255]. This was shown to be facilitated by direct binding of 
SOCS6 to the IRS-4 adaptor protein following its phosphorylation in response 
to IGF-1 or insulin and more weakly to IRS-2 in response to IGF-1, allowing it 
to indirectly associate with the p85 regulatory subunit of PI3K following 
stimulation [22, 256]. It has been suggested that the mechanism of regulation 
in this case might be through blocking the recruitment of other downstream 
signaling proteins [22]. SOCS6 has also been found to interact with PIM3, a 
protein upregulated in β-cells in response to glucose stimulation. Pim3 KO mice 
showed greatly reduced levels SOCS6 expression in their pancreatic islets, 
while overexpression of SOCS6 inhibited glucose-induced ERK1/2 activation, 
suggesting a role for SOCS6 and PIM3 in the negative regulation of ERK1/2 in 
response to glucose stimulation [262]. Reduced endogenous SOCS6 in retinal 
pigment epithelia cells was found to coincide with inhibition of insulin signaling. 
It has therefore been suggested that SOCS6 expression may serve to maintain 
high basal insulin/AKT signaling in retina and improve glucose metabolism 
[247].  
Socs6 KO mice displayed an 8-10% reduction in body weight compared to WT 
littermates, thought to be due to perturbation of IGF-1R signaling [22]. 
However, despite the in vitro data, Socs6 KO mice did not display any 
alterations in glucose metabolism [22]. It has been suggested that this may be 
due to compensation by other SOCS family members implicated in the 
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regulation of insulin receptor signaling, such as SOCS7 [22] or SOCS1 [96]. 
However, SOCS6 Tg mice utilizing the elongation factor I promoter displayed 
enhanced Akt activation in response to insulin and increased glucose 
metabolism, supporting an in vivo role for SOCS6 in the regulation of insulin 
signaling [256]. Finally, despite its expression in the bone marrow, no 
hematological phenotypes could be identified in Socs6 KO or SOCS6 Tg mice 
[22, 256]. Again, redundancy between SOCS family members may play a role 
in the absence of such a phenotype in these mice.  
Altered SOCS6 expression has been described in several disease states, 
including cancer. However, similar to other SOCS proteins, SOCS6 does not 
appear to function exclusively as a tumor suppressor. Thus, low SOCS6 
expression has been associated with recurrent primary lung squamous cell 
carcinoma [263] and cancers of the liver and thyroid gland [254]. Loss of 
SOCS6 was also observed in over 50% of patients with gastric or colorectal 
cancer, with SOCS6 inactivation predominantly caused by allelic loss or 
promoter hypermethylation [264, 265]. However, in the case of colorectal 
cancer, this did not correlate with disease-free status or overall survival [266]. 
Ectopic SOCS6 expression suppressed gastric cancer cell growth and colony 
formation in vitro [264]. However, a recent study found that levels of SOCS6 
expression in colon and rectum tissue samples taken from healthy individuals 
varied widely, and demonstrated that SOCS6 expression was indeed increased 
in gastric cancer [254].  
1.3.1.8 SOCS7 
SOCS7 has been shown to be expressed in many murine tissues [22], but the 
relative levels vary between different mouse strains [23]. In the C57BL strain, 
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Socs7 expression was highest in isolated pancreatic islets, whole brain, and 
skeletal muscle, with lower levels detected in the liver, perigonadal fat, skin, 
whole pancreas, testis and spleen [22, 23]. Expression in the 129S6 strain was 
similar overall, but with a 5-fold decrease in whole brain expression, a 6-fold 
increase in spleen expression and a 2,000-fold decrease in expression in 
isolated pancreatic islets, when compared to the C57BL strain [23]. Other sites 
of expression in this strain were the testes, kidney and eye [267]. SOCS7 has 
been shown to be induced by the cytokines GH and PRL [158], as well as EGF 
[268], insulin and IGF-1 [22]. 
SOCS7 has been found to regulate signaling by GH, PRL, leptin [44] and insulin 
[23]. SOCS7 appears to control signaling in a number of ways. It has been 
shown to inhibit PRL and leptin mediated activation of STAT5 and STAT3, 
respectively, through direct interaction of SOCS7 with phosphorylated STAT3 
and STAT5, which in the case of STAT3 prevented its nuclear translocation 
[44]. SOCS7 can similarly inhibit the nuclear transport of the adaptor protein 
NCK [31]. SOCS7 was also demonstrated to interact via its SH2 domain to 
EGFR [268] and insulin receptor [23], along with the adaptor proteins IRS-1 
[23], IRS-2 [22], IRS-4 [22], the p85 subunit of PI3K [22] and GRB2 [268]. In 
these instances, SOCS7 likely regulates signaling activity through recruitment 
of E3 ubiquitin ligase activity and subsequent proteasomal targeting of 
associated proteins [23].   
There have been conflicting reports regarding the in vivo function of SOCS7, 
probably due to differences in the genetic background of the respective mouse 
knockouts. One Socs7 KO mouse line exhibited a 7-10% reduction in body size 
compared to wild type littermates, with no abnormalities in circulating glucose 
or insulin levels [267]. Approximately 50% of these Socs7 KO mice died by 
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week 15 due to hydrocephaly [267]. However, the hydrocephaly was not 
observed when the Socs7 KO allele was on a mixed genetic background, which 
revealed increased insulin sensitivity when compared to WT mice [23]. These 
mice also showed an increased number of pancreatic islets and a hyperplasia 
of islets that was not present at birth, but developed with age [23]. These 
observations suggested an active role of SOCS7 in insulin signaling, consistent 
with the findings that SOCS7 can interact with the insulin receptor and various 
of its adaptor proteins [22, 23]. More recently it was demonstrated that 
approximately 50% of hydrocephaly-resistant Socs7 KO mice developed a 
severe cutaneous disease by 16 months of age, with the dermis appearing 
hyperplastic with an infiltration of leukocytes. The skin of both affected and 
unaffected Socs7 KO mice possessed significantly increased mast cell 
numbers compared to controls, which were hyperactive to IgE-mediated 
stimuli. This resulted in increased production of the pro-inflammatory cytokines 
IL-13, IL-6 and TNFα, with levels of TSLP and a component of its receptor also 
upregulated [269]. 
There has only been very limited examination of the role of SOCS7 in human 
disease. However, a potential tumor-suppressor role has again been indicated, 
with one study demonstrating higher SOCS7 expression was significantly 
associated with earlier stages of cancer and overall survival [243]. A recent 
study has also found there to be associations between SOCS7 haplotypes and 
various metabolic traits, including obesity, insulin resistance and lipid 
metabolism [270].  
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Table 1.1 Function of SOCS proteins revealed by mouse models 
 Knockout   Transgenic 
SOCS 
protein Type Phenotype Affected pathway Reference Phenotype Affected pathway Reference 
CISH 
Complete Spontaneous airway inflammation IL-4/STAT6 [70] Growth retardation GH/STAT5B [68] 
    Lactation failure PRL/STAT5A [68] 
    Reduced γδ T and NK cells IL-2/STAT5 [68] 
    Altered T cell response IL-2/STAT5 [68] 
SOCS1 
Complete Neonatal death IFNγ [106, 107] Spontaneous T cell activation γc cytokines [271] 
Complete Lymphopenia IFNγ [107] Defective T cell development  γc cytokines [271] 
Complete Monocytic organ infiltration IFNγ [106] Fewer γδ T cells γc cytokines [271] 
Complete Fatty degeneration /liver necrosis  IFNγ/STAT1 & 
IL-4/STAT6 
[106]    
Complete+IFNγ-/- Polycystic kidneys ?  [109]    
Complete+IFNγ-/- Chronic inflammatory lesions ? [109]    
Complete+IFNγ-/- Perturbed T cell development γc cytokines [110, 111]    
Complete+IFNγ-/- Sensitive to LPS TLR [85]    
T cell Increased CD8+ differentiation  γc cytokines [114]    
Complete except T&B 
cells 
Splenomegaly IL-4/IFNγ [66]    
Complete except T&B 
cells 
Lymphadenopathy IL-4/IFNγ [66]    
Complete except T&B 
cells 
Spontaneous dermatitis IL-4/IFNγ [66]    
SOCS2 Complete Gigantism GH/STAT5B/IGF-1 [156] Gigantism GH/STAT5B/IGF-1 [159] 
SOCS3 
Complete Embryonic lethal LIF [206, 272] Embryonic lethal/anaemia EPO/STAT5 [272] 
Complete+LIF+/- Death by 190 days ? [208]    
Hematopoietic Neutrophilia/Inflammation G-CSF [197]    
Neuronal Resistance to diet induced obesity Leptin [273]    
Complete except T 
cells 
Perturbed CD8+ T cell 
proliferation 
 IL-6 & IL-27 [196]    
SOCS4 Complete Increased mortality with H1N1 ifection 
 TCR  Not yet reported   
SOCS5 Complete No reported phenotype  [248] Reduced Th2 differentiation? IL-4 [43] 
SOCS6 Complete Mild growth retardation IGF-1 [22] Increased glucose metabolism INS/p85 [256] 
SOCS7 
 
Complete (mixed b/g) Altered glucose homeostasis INS  [23, 267] Not yet reported   
Complete (mixed b/g) Large pancreatic islets ?INS  [23]    
Complete (mixed b/g) Cutaneous disease   [269]    
Complete (C57BL b/g) Hydrocephalus/growth retardation ?INS & IGF-1 [269] [267]     
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Table 1.2 Associations of SOCS proteins with disease 
 
SOCS protein Disease  association Mechanism Reference 
CISH Infectious disease susceptibility SNP at position -29 (blunted induction by IL-2) [72] Osteoarthritis Decreased expression [76] 
SOCS1 
Acute myeloid leukaemia Hypermethylation [132, 133] 
Glioblastoma multiforme Hypermethylation [143] 
Barrett's adenocarcinoma Hypermethylation [141] 
Chronic myeloid leukaemia Hypermethylation [134] 
Breast cancer Hypermethylation [144] 
Ovarian cancer Hypermethylation [144] 
Cervical carcinogenesis Hypermethylation [139] 
Esophageal squamous cell carcinoma Hypermethylation [140] 
Hepatocellular carcinoma Hypermethylation and gene loss [142] 
Chronic myeloid leukaemia Constitutive expression [137] 
Hodgkin lymphoma SOCS1 mutation, enhanced [129] 
Primary mediastinal B-cell lymphoma Hypermethylation [131] 
SOCS2 
Ovarian cancer Hypermethylation [144] 
Acromegaly associated colonic polyps Increased expression [178] 
Osteoarthritis Decreased expression [76] 
Type 2 diabetes 5’ SNP [77] 
SOCS3 
Lung cancer Hypermethylation [230] 
Barrett's adenocarcinoma Hypermethylation [141] 
Hepatocellular carcinoma Hypermethylation [227] 
Malignant melanoma Hypermethylation [228] 
Glioma Hypermethylation [13] 
Prostate cancer hypermethylation [235] 
Ulcerative colitis (areas of dysplasia)  Deceased expression [232] 
Breast cancer with lymph node metastasis Reduced expression [236] 
Atopic asthma/dermatitis (Th2 disease) Increased SOCS3 expression (peripheral T-cells) [213] 
Breast cancer with lymph node metastasis Reduced expression [236] 
SOCS4 Gastric cancer Hypermethylation [244] 
SOCS5 Uveitis Increased expression [251] Thyroid gland cancer Decreased expression [254] 
SOCS6 
Gastric cancer Hypermethylation & gene loss [264] 
Colorectal cancer Gene loss [266] 
Primary lung squamous cell carcinoma Decreased expression [263] 
Liver cancer Decreased expression [254] 
Thyroid gland cancer Decreased expression [254] 
SOCS7 Breast cancer Decreased expression [243] Metabolic syndrome Specific haplotypes [270]  
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1.4 Zebrafish as an experimental model 
The use of appropriate developmental models has been essential to the 
understanding of cytokine and growth factor signaling and its regulation in vivo. 
The zebrafish (Danio rerio) represents a powerful alternative vertebrate 
developmental model due to several favorable factors. 
Husbandry 
Zebrafish are of a small size; with a short generation time and high fecundity. 
Embryos develop externally and remain transparent throughout embryonic 
development-characteristics well suited to gene function research. Zebrafish are 
also relatively inexpensive due to compact housing and relatively easy 
maintenance. 
Conservation 
There is extensive conservation between zebrafish and mammalian development 
and associated genes, providing confidence that investigation into zebrafish 
genes will present insights into their mammalian counterparts [274, 275]. By 
corollary, large scale genetic screens have identified many zebrafish mutant 
phenotypes that mimic human disease phenotypes, providing insight into the 
corresponding pathophysiology of the disease [276]. Growth factor and cytokine 
signaling is also well conserved between zebrafish and mammals, with 
conservation of warious pathway components as well as other downstream 
signaling molecules [24, 277]. Importantly, a suite of SOCS genes have now been 
identified, which show extensive sequence similarity [24, 278] and evidence of 
functional similarity [122]. Teleost fish such as zebrafish have undergone an 
additional round of whole genome duplication events during evolution compared 
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to higher vertebrates [279]. In zebrafish, this frequently manifests as two 
paralogues for a single mammalian gene, including relevant signaling pathway 
members such as Jak2 and Stat5 [280, 281]. Creation of paralogues often results 
in partial loss-of-function in each paralogue, however together they collectively 
retain the full set of sub-functions designated to the original ancestral gene 
providing a unique advantage in the investigation of gene function [282]. This can 
result in more specific (and less devastating) phenotypes when paralogues are 
investigated. Paralogues exist for several socs gene, including socs4 and socs5. 
Resources 
Extensive genome resources are available to zebrafish investigators, including 
the widely accessed Zebrafish Model Organism Database (www.zfin.org), 
Sanger Danio rerio sequencing project 
(http://www.sanger.ac.uk/Projects/D_rerio/) and the National Centre for 
Biotechnology Danio rerio database 
(http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=7955). 
Zebrafish manipulation 
Zebrafish are easily manipulated using a wide variety of techniques. Functional 
analysis of zebrafish genes relies heavily on forward genetics techniques, such 
as ENU (N-ethyl-N-nitrosourea) or insertional mutagenesis as well as reverse 
genetics approaches, such as TILLING (targeting Induced Local Lesions in 
Genomes), anti-sense oligonucleotides known as morpholinos, or genome 
editing technologies such as zinc finger nucleases (ZFNs), Tal Activator-Like 
effector nucleases (TALENs) and clustered regularly interspaced short 
palindromic repeats (CRISPR) [283, 284]. 
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1.4.1.1 Morpholinos 
Morpholinos (MOs) are modified single-stranded, anti-sense oligonucleotides 
that have an altered DNA backbone, in which the ribose moiety is replaced by a 
morpholine moiety, providing the oligonucleotide with increased stability against 
nucleases [285, 286]. MOs are typically oligomers of 25 morpholine bases and 
are utilised to transiently knockdown protein levels [285]. They are delivered by 
injection between the one and eight-cell stage of development, eliciting their 
effects via complementary base pairing with target mRNA, physically inhibiting 
transcript processing or translation [285, 287]. For translational inhibition the MO 
is designed to target the 5′ untranslated region or translational start site of a gene, 
with the degree of knockdown ideally assessed using an antibody to the protein 
of interest [287]. For splicing inhibition, morpholinos are designed to target/span 
both exon and intron sequence, with subsequent morpholino binding inhibiting 
appropriately splicing by the pre-mRNA splicing machinery prior to translation. 
This approach can result in a variety of mRNA sequences, depending on the 
normal splicing pattern of a gene and the presence of splice donor and acceptor 
sites.  
1.4.1.2 TILLING 
TILLING is a combinatorial method entailing the random induction of point 
mutations into the genome via ENU mutagenesis and subsequent screening for 
of mutants within a target region [288]. Typically, a large library of male zebrafish 
are mutagenized, and genomic DNA is isolated from their sperm. This is PCR-
amplified with gene-specific primers, and knockout mutants are identified using 
sequencing or other molecular approaches [289-291]. Mutations can then be 
recovered by out-crossing an identified carrier [292]. However, even with targeted 
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detection, a single mutation at a target sequence in any given F1 fish represent 
only one of thousands of heterozygous mutations in its genome. This approach 
also requires significant liquid-handling capacity to perform multiple consecutive 
reactions on thousands of individual fish and is out of reach for most research 
laboratories.  
1.4.1.3 Zinc finger nucleases  
Zinc finger nucleases (ZFNs) represent a relatively new approach to reverse 
genetics in zebrafish. ZFNs are artificial restriction enzymes that are a chimeric 
fusion between Cys2His2 zinc finger domains (ZFDs) and the non-sequence 
specific FokI endonuclease, enabling the induction of target-specific DNA lesions 
(Fig 1.3) [293]. Each ZFN comprises an array of 3 or more ZFDs, each for a 
specific nucleotide triplet, thereby targeting a 9-15 nucleotide sequence [294]. 
ZFNs are designed in pairs, with each member recognizing a different 
chromosomal strand with a small spacer, allowing FokI assembly with a geometry 
that allows the nuclease domains to dimerize and so cleave the DNA, introducing 
a double-strand break [295]. When the error prone process of non-homologous 
end joining (NHEJ) is induced to repair the cleaved DNA, it most often results in 
small deletions or insertions at the targeted site, many of which will introduce 
frame shift mutations that result in complete knockout [294]. ZFN pairs are 
delivered by injection of an encoding mRNA at the one cell stage of embryo 
development and can give rise to both heterozygous and homozygous knockout 
organisms with a wide variety mutations at the target site that can be analyzed 
from embryos to adults [295-297]. An early study using ZFNs targeting flk1 (krd), 
an essential for gene in vasculature formation in zebrafish, produced a mutagenic 
frequency of ~10% at the target site. Mutations at off-target sites (those varying 
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1-4 bp from target site) occurred in ~1% of morphologically normal embryos but 
at greater frequency in phenotypically abnormal embryos [295]. While custom-
made ZFNs are very costly, cheaper open-source options are available. 
Moreover, ZFNs have clear advantages over ENU mutagenesis and TILLING. 
Their specific targeting means the number of animals required is far reduced, as 
are the screening reagents and the amount of time required to establish knockout 
lines. If delivered at an appropriate concentration ZFNs should induce no DNA 
damage outside of the target region [296]. ZFNs also have many advantages 
over MOs including eliminating off-targeting events and creation of permanent 
knockout allowing functional analysis beyond the initial stages of development. 
This technique can also be used for gain-of-function studies and targeted 
insertion if required.  
  
 48 
 
  
 49 
Figure 1.3 Zinc Finger Nuclease –mediated genome manipulation 
ZFNs pairs bind to target DNA via the specific zinc finger binding domain (A). 
Upon dimerization, the non-specific Fok1 endonuclease domain cleaves dsDNA 
(B). Non-homologous end-joining is induced bringing about fortuitous base-pair 
insertions or deletions, some of which will lead to a change in reading frame and 
gene knockout (C). 
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1.5 Zebrafish hematopoiesis 
The zebrafish has emerged as an advantageous model organism to study 
hematopoiesis, as genes and signaling pathways involved in the process are 
highly conserved between zebrafish and mammals [298, 299]. Zebraﬁsh and 
mammals also share all major blood cell types that are generated from common 
lineages of hematopoietic stem cells [299]. During embryogenesis, blood and 
endothelial cell development are closely associated with each other, with both 
cell types thought to emerge from a common precursor, the hemangioblast [300, 
301]. Hematopoiesis in zebrafish, as with other vertebrates, occurs in two waves, 
termed primitive and definitive (Fig 1.4). These waves take place at different 
primary sites during development to ensure optimal environmental conditions for 
hematopoiesis [302]. 
Primitive hematopoiesis 
During primitive hematopoiesis, putative hemangioblasts give rise to 
hematopoietic and endothelial progenitors that are initially positioned as two 
stripes flanking the paraxial mesoderm of the posterior embryo. The two cell 
masses, referred to as the lateral plate mesoderm (LPM), converge medially 
beginning at the anterior and fuse completely at the midline to form two 
hematopoeitic structures, the intermediate cell mass (ICM) and the anterior 
lateral mesoderm (ALM). In the ALM, or rostral blood island, haemangioblasts 
give rise to endothelial vasculature and myeloid cell precursors, becoming a key 
site of myelopoiesis during primitive hematopoiesis [299]. In the ICM, 
haemangioblasts produce erythrocyte precursors and endothelial vasculature 
precursors  and this becomes the site of erythrocytosis during primitive 
hematopoiesis [303, 304]. The erythroid progenitor cells of the ICM then migrate 
 51 
anteriorly to reach the mid-trunk region where they exit onto the yolk sac and 
mature. This migration occurs before the initiation of circulation at 24 hours post 
fertilization (hpf) [304]. Hematopoietic progenitor cells with multi-lineage potential 
originate from the posterior lateral mesoderm, also termed the posterior ICM 
(pICM). These transient cells give rise to only erythroid and myeloid cells and do 
not possess self-renewing capabilities [303].  
Definitive hematopoiesis 
Multi-potent, self-renewing hematopoietic stem and progenitor cells (HSC) 
characteristic of definitive hematopoiesis arise initially at around 2 dpf in the 
zebrafish aorta-gonad-mesonephros (AGM). HSC then migrate from the AGM to 
other sites of deﬁnitive hematopoiesis, including the caudal hematopoietic tissue 
(CHT) (erythroid, myeloid, and thrombocytic lineages), metanephros (erythroid, 
myeloid, lymphoid B cells and thrombocytic lineages), and thymus (lymphoid T 
cells) [305-307]. 
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Figure 1.4 Sites of hematopoiesis during embryonic development 
Schematic representation of a developing zebrafish embryo displaying areas of 
hematopoiesis. Boxes indicate location of hematopoietic structure and cells 
produced within it. Yellow represents areas of the earliest stages of primitive 
hematopoiesis, pink represents structures involved in primitive hematopoiesis, green 
represents an intermediate wave of multi-lineage hematopoiesis, while blue 
represents definitive hematopoiesis. Hemangioblast cells of the lateral plate 
mesoderm (LPM) converge medially, eventually fusing and giving rise to the anterior 
lateral mesoderm (ALM), the site of endothelial (EC) and myeloid (M) cell production 
and the intermediate cell mass (ICM), the site of erythrocyte (E) and endothelial cell 
production during primitive hematopoiesis. The posterior intermediate cell mass 
(pICM) is the site of multi-lineage hematopoiesis that produces erythrocytes and 
myeloid cells. The thymus is the site of lymphoid (L) cell production during definitive 
hematopoiesis. Endothelial cell and hematopoietic progenitor cell (P) differentiate in 
the aorta-gonad-mesonephros (AGM), with the later cell type going on to seed the 
caudal hematopoietic tissue (CHT) and kidney where they become hematopoietic 
stem cells (HSCs). In the caudal hematopoietic tissue, these cells give rise to 
myeloid, erythroid and thromboid (T) cell lineages while in the kidney sees production 
of all blood lineages, including B cells (adapted from Chen et al. 2008). 
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1.6 Zebrafish central nervous system 
The zebrafish is also a useful neurogenetic model, with well-conserved 
organization of tissues of the brain and spinal cord [308, 309]. Like other 
vertebrates, the central nervous system (CNS) of zebrafish is derived from a 
specialized region of the ectoderm germ layer termed the neural plate. Through 
the process of neurulation, the neural plate models the neural tube and it is from 
this structure that the spinal cord and brain are derived [310].  
Neurulation 
Neurulation occurs in two phases, primary and secondary (Fig 1.5). During 
primary neurulation in most vertebrates, the neural plate of the ectoderm layer 
folds, with the lateral edges coming together at the midline and fusing, forming a 
hollow tube. Cells then pull away from the ectoderm layer, forming the neural tube 
just beneath [311]. The portion of the neural tube formed during this process 
extends from the brain to the cervicothoracic region. The posterior region of the 
tube forms from the tail bud during secondary neurulation, a process by which 
mesenchymal cells condense below the ectoderm, forming a solid medullary cord 
[312]. Hollow cavities form in this cord, eventually coalescing to form a single 
cavity, creating an epithelial tube in the lumbar and tail region [313]. While 
secondary neurulation in zebrafish occurs via this same process, primary 
neurulation takes place via an alternate process to that seen in other higher 
vertebrates. Neurulation in zebrafish is initiated by formation of the neural plate, 
but the cells do not come together at the lateral edges of the plate and instead 
roll together at the midline, creating a solid structure termed the neural keel [312]. 
These cells continue to migrate away from the ectoderm, finally forming a solid 
rod-like structure beneath it. The cells at the centre of the rod pull away from each 
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other to form the lumen in a process that begins with ventral cells and moves 
dorsally [314]. By one day post fertilization both primary and secondary 
neurulation are complete, with the neural tube already differentiated into 
primordia of adult CNS structures [313, 314]. 
Neurogenesis   
Approximately 10 neuromeres form along the neural tube at the initiation of 
segmentation. The three most rostral correspond to the diencephalon, 
telencephalon, mesencephalon. The remaining neuromeres, termed 
rhombomeres go on to subdivide the hindbrain (Fig 1.6) [315]. Following initial 
segmentation, neurons begin to differentiate, with neurogenesis occurring in two 
waves. Primary neurogenesis begins during late gastrulation (9-10 hpf) and 
produces big neurons, referred to as “primary” neurons with long axons [314]. 
Neurons initially present as bilateral clusters positioned towards the centre of 
each neuromere, during primary neurogenesis these early clusters expand and 
new clusters are also formed [315]. Early sensory neurons mediating touch 
sensitivity are located bilaterally in the form of both Rohon-Beard neurons and 
the trigeminal ganglia. Beginning at around 16 hpf the axons of these neurons 
establish a single long tract dorsolaterally along the wall of the neural tube, 
extending peripherally to blanket the skin [314]. Motoneuron axons begin to grow 
in the ventral spinal cord slightly later and are arranged segmentally [316]. Axon 
patterning in primary neurogenesis is extremely precise and creates the first 
simple and functional neuronal scaffold by 1 dpf [315, 317, 318]. Secondary 
neurogenesis occurs from 2 dpf, laying down a complex network capable of more 
intricate functions that takes over from the primary system [319]. 
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1.7 Zebrafish neural crest 
The neural crest is a multipotent population of highly migratory cells (neural crest 
cells) [311]. Initially located at the lateral edge of the neural plate, as the plate 
folds to form the neural tube, the neural crest comes to occupy the roof plate of 
the tube, linking it to the epidermis. Cells then undergo an epithelial to 
mesenchymal transition, separate into thin layers from the neuroepithelium and 
migrate throughout the embryo to give rise to a wide variety of cell types [320]. 
These cell types include craniofacial cartilage cells, pigment cells, the medullary 
cells of the adrenal gland, glial Schwann cells and of the peripheral neurons and 
autonomic nervous system [320].  
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Figure 1.5 Neural tube formation 
Primary neurulation in most vertebrates (A) sees the neural plate of the ectoderm 
layer fold inward, with the lateral edges coming together at the midline and fusing 
to form a hollow tube. Following this, these cells pull away from the ectoderm 
layer forming the anterior portion of the neural tube. Primary neurulation in 
zebrafish (B) sees the cells of the neural plate roll together at the midline, creating 
the neural keel. The cells of the neural keel then migrate away from the ectoderm, 
forming a solid rod-like structure beneath it, with the central cells of this rod pulling 
away from each other to form the lumen and the anterior portion of the neural 
tube. During secondary neurulation (C), the posterior region of the tube forms. In 
this process, mesenchymal cells condense below the ectoderm, forming a solid 
medullary cord with hollow cavities forming, eventually creating a single cavity 
(adapted from Lowery and Sive, 2004). 
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Figure 1.6 Zebrafish CNS primordia 
Schematic representation of zebrafish CNS primordia at 24 hpf, with neurulation 
complete and primary neurons established. Trigeminal ganglia are present (red 
circle), as are the Rohon-Beard neurons (blue circles), the telencephalon (T), 
diencephalon (D), mesencephalon (now the tectum) (M), rhombomeres (1-7) and 
midbrain/hindbrain boundary (MHB) (adapted from Kimmel et al. 1993).  
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1.8 Project Aims and Significance 
Mammalian studies have shown that several of the SOCS family members play 
significant roles in development and hematopoiesis. However, detailed 
understanding of two family members, SOCS4 and SOCS5 remains elusive. This 
Project sought to investigate the functional roles of SOCS4 and SOCS5 during 
early development using the zebrafish developmental model. This involved the 
investigation of a number of Specific Aims. 
This first aim of this Project was to identify the zebrafish homologs of SOCS4 and 
SOCS5, providing insight into their evolution and functional conservation, as well 
as key sequence information necessary for their further study. This utilized a 
variety of bioinformatics techniques to definitively investigate all possible SOCS4 
and SOCS5 homologues.  
The second aim of this Project was to characterize expression patterns for the 
zebrafish SOCS4 and SOCS5 homologues during development using both RT-PCR 
and whole mount in situ hybridization (WISH). This would represent the only analysis 
to date of embryonic expression profiling of these two genes, providing potential 
insights into the spatio-temporal location of transcripts during development. In 
addition, this expression would provide necessary data regarding SOCS4 and 
SOCS5 genes for functional analysis during embryogenesis, and provide functional 
insights. 
The third aim of this Project was to elucidate the in vivo functions of the SOCS4 and 
SOCS5 genes using multiple gene ablation strategies. Where appropriate, gene 
function would be investigated using antisense morpholino (MO) oligonucleotides 
that specifically bind target mRNA in vivo, blocking protein production and effectively 
knocking down the target gene. In addition to this approach, Zinc Finger Nucleases 
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(ZFNs) would be used to introduce DNA lesions to target genes in vivo, ideally 
creating knockout alleles in the target genes, allowing for functional analysis during 
both embryogenesis and adulthood.  Any phenotypes identified would then be further 
investigated using a range of molecular approaches. This would represent the first 
functional analysis of SOCS4 in vivo and the first functional analysis of SOCS5 
during embryogenesis. 
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Chapter 2:          
Materials and Methods 
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2.1 Materials 
Suppliers 
The following companies supplied reagents and equipment used in this work: 
x Ambion, Austin, TX, USA 
x Amresco, Solon, OH, USA 
x Applied Biosystems, Warrington, UK 
x Astral Scientific, Sydney, NSW, Australia 
x BDH Laboratory Supplies, Poole, UK 
x Beckman Coulter, Gladsville, NSW, Australia 
x Bio-Rad, Hurcules, CA, USA 
x Cell Signaling, Danvers, MA, USA 
x Chem-Supply, Port Adelaide, SA, Australia 
x Epicentre, Madison, WI, USA 
x Eppendorf, Hamburg, Germany 
x GE Healthcare, Little Chalfont, Buckinghamshire, UK 
x GeneCodes, Ann Arbor, MI, USA 
x Gene Tools, Philomath, OR, USA 
x Gilson, Guelph, Canada 
x Hitachi, Tokyo, Japan 
x Invitrogen, Groningen, The Netherlands 
x Li-Cor, Lincoln, NE, USA 
x Merck Millipore, Kilsyth, VIC, Australia 
x Nikon, Tokyo, Japan 
x Olympus, Tokyo, Japan 
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x Promega, Madison, WI, USA 
x Roche Molecular Biochemicals, Indianapolis, IN, USA 
x Qiagen, Melbourne, VIC, Australia 
x Sigma-Aldrich, Sydney, NSW, Australia 
x Stratagene, La Jolla, CA, USA 
x Thermo Scientific, Waltham, MA, USA 
x Transgenomic, Omaha, NE, USA 
x Zebrafish International Resource Centre, Eugene, OR, USA
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2.2 Methods 
Bioinformatics applications 
1.1.1.1 Sequence analysis  
Sequence analysis, manipulation, contig assembly and alignment were carried 
out using the Sequencher program version 4.10 (GeneCodes). 
2.2.1.1 Database interrogation 
Gene database searches were conducted on the National Centre for 
Biotechnology Information Website (NCBI) (www.ncbi.nlm.nih.gov) using the 
BLASTN (nucleotide-nucleotide), BLASTX (translated query-protein) and 
TBLASTN (nucleotide-protein) tools.  
2.2.1.2 Phylogenetic analysis 
Evolutionary relationships between genes were examined by aligning encoded 
amino acid sequences using the CLUSTALX algorithm [321] 
(http://www.clustal.org/) with penalties applied for opening and extending gaps in 
the alignment. The Gonet 250 protein weight matrix, with a gap opening penalty 
of 10 and a gap extension penalty of 0.1 was applied for the pairwise alignment 
stage and the Gonet series protein weight matrix, with a gap opening penalty of 
10 and a gap extension penalty of 0.2 was applied for the multiple-alignment 
stage. Phylogenic trees were constructed based on this alignment using the 
bootstapped Neighbour-Joining algorithm [322] of 1000 replicates and NJ-Plot 
software (http://doua.prabi.fr/software/njplot).  
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2.2.1.3 Primer design 
Primers were designed for a variety of PCR applications using Netprimer Launch 
software (http://www.premierbiosoft.com/netprimer/index.html). 
 
DNA applications 
2.2.1.4 Genomic DNA (gDNA) isolation 
Total gDNA was isolated from zebrafish embryos at appropriate time-points or 
from adult fin clips or microdissected organs using QuickExtract DNA Extraction 
Solution (Epicentre). gDNA was extracted by vortexing for 30 sec, incubating at 
68°C for 2 min, vortexing again for 30 sec, incubating at 98°C for 2 min and a 
final vortex for 30 sec. Samples were then pelleted with the supernatant used in 
subsequent PCR assays. 
2.2.1.5 DNA electrophoresis 
DNA fragments were separated by electrophoretic analysis performed on 1% 
(w/v) agarose gels containing 1 x TAE buffer (40 mM Tris-HCl, 190 mM glacial 
acetic acid, 10 mM EDTA; pH 8.0) (BioRad) and Sybrsafe (Invitrogen) (1:10000) 
in a mini-tank apparatus (BioRad) at 100-110 V for 30-80 min, as appropriate. 
DNA fragments under 500 bp were separated by polyacrylamide gel 
electrophoresis (PAGE) on 10%-30% [29:1 acryl:bis-acryl] acrylamide gels, 
containing 1 x TBE buffer (89 mM Tris borate, 2 mM EDTA pH 8.0) and run in a 
minigel apparatus (BioRad) at 100 V for 60 min. Gels were post soaked in 
Sybrsafe (1:10000) (Invitrogen) visualized under UV illumination (excitation 480 
nm, emission 620 nm) on a ChemiDoc XRS (Bio-Rad). 
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2.2.1.6 Densitometry 
Densitometic quantification of DNA fragments was performed using Quantity One 
version 4.6.5 software (Bio-Rad) on gel images obtained from the ChemiDoc 
XRS (Bio-Rad). Bands were normalized relative to the local background and 
standardized relative to a β-actin control.  
2.2.1.7 Purification of DNA fragments 
Digested DNA and PCR reaction products were purified using the QIAquick PCR 
Purification Kit (Qiagen) following the manufacturer’s instructions. DNA 
fragments excised from agarose gels were purified using the QIAquick Gel 
Cleanup Kit (Qiagen) following the manufacturer’s instructions.  
2.2.1.8 DNA ligation 
Ligation reactions used T4 DNA ligase (0.3 U/μl) (Promega) in 1 x T4 ligase buffer 
(30 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 10 mM DTT, 1 mM ATP. 5% 
polyethylene glycol) (Promega) with a 3:1 insert to vector ratio. Reactions were 
incubated overnight at 4°C.  
2.2.1.9 Bacterial transformation of plasmid DNA 
Heat shock transformation of ligation products was performed using XL10-Gold 
ultracompetent cells (Stratagene). Ligation reaction and cells were incubated 
together on ice for 15 min. Heat shock was performed at 42°C for 45 sec followed 
by incubation on ice for 3 min. Cells were recovered in 2 x YT media (Amresco) 
for 1 h at 37°C and plated on 2 x YT 50 μg/ml kanamycin or 100 μg/ml ampicillin 
as appropriate. 
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2.2.1.10 DNA minipreps 
Plasmid DNA was isolated and purified using the Wizard Plus Miniprep DNA 
Purification System Kit (Promega) following the manufacturer’s 
recommendations.  
2.2.1.11 Glycerol stocks 
A 1 ml aliquot of an overnight bacterial culture was added to 250 μl of filter-
sterilized 80% (v/v) glycerol under sterile conditions. The stock was mixed by 
vortexing and snap frozen for long-term storage at -80°C.  
2.2.1.12 Restriction endonuclease digestion 
Plasmid DNA was digested using relevant restriction endonucleases (5-10 U) for 
between 1 and 4 h. Manufacturer’s directions were followed with regards to 
appropriate buffers and incubation temperature.  
2.2.1.13 Genomic DNA mutation detection 
ZFN induced genomic mutations were detected using a Surveyor Mutation 
Detection Kit (Transgenomic) following the manufacturer’s guidelines. gDNA from 
pooled or single embryos were used at varying concentrations as template for 
the reaction and final products were visualized on 10% PAGE gels.  
2.2.1.14 Sequencing of DNA  
Sequencing of purified PCR products and double stranded plasmid DNA was 
performed by Australian Genome Research Facility (AGFR) utilizing BigDye 
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Terminator sequencing (Applied Biosystems) and capillary separation on a 
3730xl 96-capillary sequencer (Applied Biosystems).  
2.2.1.15 Ultraviolet spectrophotometry 
UV spectrometry with a NanoVue Plus Spectrophotometer (GE Heathcare) was 
used to determine nucleic acid concentrations, using the relationships that 1 Abs 
(260 nm) absorbance unit equals 50 μg/μl DNA and 40 μg/μl RNA and confirmed 
ratios based on the following ratios: Abs (260 nm)/Abs (280 nm) = 1.8 (DNA) and 
2.0 (RNA). 
2.2.1.16 5’ rapid amplification of cDNA ends (RACE) 
Appropriate cDNA was generated from total RNA using a 5’ RACE kit (Invitrogen) 
according to manufacturer’s protocol (Invitrogen). A 2 μL aliquot of 5’ RACE 
cDNA with the relevant primers was used in the PCR reaction containing Go-Taq 
mix (Promega) following the manufacturer’s recommendations. 
2.2.1.17 Reverse Transcription – Polymerase Chain Reaction (RT-PCR) 
Total RNA (0.5-1.5 Pg) was reverse transcribed to complementary DNA (cDNA) 
with either an iScript cDNA Synthesis Kit (Bio-Rad) or QuantiTech Reverse 
Transcription Kit (Qiagen) according to the manufacturer’s guidelines. A 2 Pl 
aliquot of the cDNA synthesis reaction was used in PCR reactions containing 1 x 
GoTaq Green polymerase (Promega) reaction mix and 0.4 PM each gene-
specific oligonucleotide (Sigma Aldrich). Typical PCR conditions were an initial 2 
min cycle of 95qC, followed by 35 cycles at 95qC for 1 min, 55qC for 1 min and 
72qC for 2 min, followed by 1 cycle at 72qC for 10 min. Annealing and extension 
temperatures adjusted as required and samples were stored at -20°C.  
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2.2.1.18 Quantitative real time Reverse Transcriptase – Polymerase Chain 
Reaction (qRT-PCR) 
Following confirmation of primer design by RT-PCR, gene expression was 
quantified by qRT-PCR on a Agilent MX??? (Stratagene). Reactions (25 μL) 
contained 12.5 μL PCR Master mix (Bio-Rad), 3.125 μL forward primer (2.4 μM), 
3.125 μL reverse primer (2.4 μM), 3.125 μL cDNA template (1:10 dilution) and 
3.125 μL nuclease-free water. Appropriate control reactions were performed to 
ensure products were not the result of DNA contamination or due to primerdimer 
formation. Typical PCR conditions consisted of 95°C for 3 min, followed by 45 
cycles of 95°C for 5 sec, 56°C for 10 sec, 72°C for 25 sec, then 95°C for 1 min, 
55°C for 30 sec, followed by incremental increases (0.5°C) from 55°C to 95°C to 
establish the melting curve for each sample and finally 95°C for 30 sec.  
 
RNA applications 
2.2.1.19 Total RNA Isolation 
Guanidinium thiocyanate-phenol-chloroform extraction was used to isolate total 
RNA from zebrafish embryos at appropriate time-points using TRIzol reagent 
(Invitrogen) following the manufacturer’s guidelines. Purified RNA was 
resuspended in nuclease-free water.  
2.2.1.20 In vitro RNA synthesis 
Digoxygenin (DIG)-labeled RNA probes for in situ hybridization were produced 
by incubating linearized template DNA (1.2 μg) with 1 x DIG labeling mix (1 mM 
ATP, CTP, GTP (each), 0.65 mM UTP, 0.035 mM DIG-11-UTP) (Roche), 1 x 
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Transcription buffer (40 mM Tris-HCl (pH 8.0), 6 mM MgCl2, 10 dithiotreitol (DTT), 
2 mM spermidin) (Roche), 2 U/μl RNase inhibitor (Roche) and 2 U/μl RNA 
polymerase in nuclease free water (Ambion). Reactions were incubated at 37°C 
for 2 h after which 10 U/μl DNase I (Roche) was added and reactions incubated 
at 37°C for a further 15 min. Reactions were then terminated by adding 2 μl of 
0.2 M EDTA (pH 8.0). Fluorescein (Flu)-labeled RNA probes were also produced 
in this manner, with 1 x FLU labeling mix used in place of 1xDIG labeling mix. 
2.2.1.21 Purification of RNA 
DIG-labeled or FLU labeled RNA was purified from unincorporated nucleotides 
using G-50 size gel filtration exclusion microcolumns (GE Health) following the 
manufacturer’s guidelines. 
2.2.1.22 RNA electrophoresis 
RNA products were analyzed on 1.2% (w/v) agarose gels prepared using 
Formaldehyde-Free RNA Gel Kit (Amresco) as per the manufacturer’s protocol. 
Electrophoresis was carried out at 80 V for between 1-1.5 h in a mini-tank 
apparatus (Bio-Rad). Gels were post-stained in 10 x Sybr Safe (Invitrogen), with 
RNA fragments visualized under UV illumination on a ChemiDoc XRS (Bio-Rad). 
 
Cell biology methods 
2.2.1.23 Transfection 
HEK 293T cells were transiently transfected with expression constructs using 
Fugene HD reagent (Roche). A μl aliquot of Fugene HD was diluted in 100 μl of 
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serum free media (SFM) and incubated with 5 μl of DNA (0.2 μg/μl) for 15 min at 
RT and 100 μl of this solution added to a 6-well plate containing 80% confluent 
cells. Plates were incubated at 37°C, 10% (v/v) CO2 for 46-48 h prior to 
stimulation by 20 μg/ml epidermal growth factor (EGF) (Sigma). Cell lysates were 
collected at 48 h post transfection for Western blot analysis. 
 
Protein methods 
2.2.1.24 Total cell lysate preparation 
Cells were harvested using a cell scraper and suspended in 0.2 ml of RIPA Lysis 
Buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 
1% (v/v) NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM 
E-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin) (Sigma) and phosphatase 
inhibitor cocktail (5 mg/ml). Cells were placed on ice for 5 min, followed by 
centrifugation at 14,000 g for 15 min at 4°C. Supernatant containing extracted 
proteins was collected and stored at -80°C. 
2.2.1.25 SDS-PAGE  
Protein lysates were denatured at 100oC for 3 min and placed on ice for 5 min 
prior to loading onto a 4% [29:1 acryl:bis-acryl] acrylamide, in 0.1 M Tris-HCl (pH 
6.8), 0.2% SDS stacking gel, cast on a 10% [29:1 acryl:bis-acryl] acrylamide in 
0.3 M Tris-HCl (pH 8.8), 0.2% SDS resolving gel. Electrophoresis was 
undertaken in 1 x Running buffer (0.3% (w/v) Tris-base, 1.4% (w/v) glycine and 
0.1% (w/v) SDS; pH 8.3) at 30 mA for approximately 80 min. Following 
electrophoresis, proteins were transferred to a nitrocellulose membrane (Licor) 
using 1 x Transfer buffer (0.3% (w/v) Tris-base, 1.4% (w/v) glycine and 20% (v/v) 
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methanol) for 90 min at 220 mA. 
2.2.1.26 Western blot analysis 
Membranes were blocked for 1 h at room temperature in 5% (w/v) Bovine serum 
albumin (BSA) (Sigma) in Tris-Buffered Saline-Tween (TBST) (122 mM) Tris pH 
7.6, 900 mM NaCl, 0.001% (v/v) Tween-20), followed by incubation in 1:200 
mouse anti-total EGFR (Santa Cruz), 1:800 rabbit anti-phospho-EGFR (Santa 
Cruz), 1:1000 rabbit anti-total ERK (Cell Signaling), 1:1000 rabbit anti-phospho 
ERK (Cell Signaling), 1:2000 rabbit anti-Llag (Sigma), 1:10000 anti-GAPDH 
(LifeTechnologies) in 5% (w/v) BSA/TBS-T overnight at 4°C with gentle agitation. 
Membranes were subsequently washed three times TBST for 10 min and then 
incubated with secondary antibody, IRDye 800CW Goat anti-Mouse IgG or IRDye 
680 Goat anti-Rabbit IgG (1:10000) (LI-COR), in 5% (w/v) BSA/TBST for 1 h at 
RT. Unbound antibody was then removed by washing the membranes twice in 
TBST for 15 min. Antibody binding detected and imaged using an Odyssey 
Imager (LI-COR). 
 
Zebrafish methods 
2.2.1.27 Zebrafish breeding and embryo collection 
Wild-type, transgenic and mutant zebrafish lines were housed in an Aquatic 
Habitats aquarium facility at the Deakin University Upper Animal House, which 
functions on a 14 h light/10 h dark light-cycle. Fish were fed three times daily on 
a diet that included brine shrimp and high protein pellets. Spawning was 
stimulated at the beginning of the light cycle with resultant embryos manually 
collected and placed in egg-water (60 μg/ml stock salts at 28.5qC) containing 0.5 
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μl/ml methylene blue (Sigma) and allowed to develop at 28.5°C. Embryos 
required for staining methodologies were transferred to egg-water containing 
0.003% (w/v) 1-phenyl-2-thiourea (PTU) at 9 hours post fertilization (hpf) to inhibit 
pigment formation, thereby enhancing embryo transparency. 
2.2.1.28 Zebrafish tail fin clip 
Adult zebrafish were anesthetized in 0.01% (v/v) benzocaine and a small section 
of the tail fin was cut using a clean razor blade before fish were allowed to recover 
in clean aquarium water.  
2.2.1.29 Dissection of adult zebrafish 
Adult fish (6 males and 6 females) were euthanized with an overdose of 0.01% 
(v/v) benzocaine and were dissected to collect the following organs: skin, muscle, 
eyes, brain, thymus, heart, kidney, spleen, liver, eggs and testis. Dissected 
organs of each type were pooled together, rinsed with PBS and homogenized in 
1 ml Trizol reagent (Invitrogen) for future RNA extraction. 
2.2.1.30 Isolation of embryonic and adult blood cells 
Embryos at 2 dpf or 5 dpf were allowed to acclimatize briefly in 1 mM EDTA/1 x 
PBS solution and were then anaesthetized in 0.01% (v/v) benzocaine. 
Anaesthetized embryos were subsequently moved into 1 mM EDTA in 1xPBS 
with 2% (v/v) fetal calf serum. The ventral section of embryonic tails were nicked 
using watchmakers forceps and bled into the solution, which was loaded onto 
slides and centrifuged at 700 rpm for 5 min using a Cytospin 4 (Thermo Scientific). 
Slides were air dried and fixed with 100% (v/v) methanol prior to Giemsa staining. 
Adult fish were euthanized in 0.01% (v/v) benzocaine and immediately post 
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euthanization tails fins were removed using clean scalpel blades. Blood vessels 
were then massaged and bled directly onto slides. Samples were then smeared, 
air dried and fixed with 100% (v/v) methanol prior to Giemsa staining. 
2.2.1.31 Microinjection 
Needles used for microinjection were pulled from filamented 1.0 mm glass 
capillary tubes (SDR Clinical Technologies) on a Flaming Brown micropipette 
puller model P-87 (Sutter Instruments) using the following settings: heat 339, pull 
45, velocity 80 and time 150 and were modeled manually to fit the injection 
apparatus. Morpholinos (Genetools) were diluted to 1.0-5 mM in 1×Danieau 
buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM CaCl2, 5.0 mM 
HEPES; pH 9) containing 1% (w/v) phenol red and loaded into the needles using 
a drawn Pasteur pipette.  Zinc finger nuclease RNA (Sigma) was diluted to 150 
pg/nl containing 1% (w/v) phenol red. Needles were mounted into a Narishige 
MN-151 micromanipulator attached to a Nikon SMZ 645 dissecting microscope. 
Embryos at the 1-8 cell stage were held with watchmakers’ forceps and 
positioned so that the needle entered the yolk through the cell mass. An aliquot 
of morpholino or zinc finger nuclease was injected using an ASI MPPI 2 pressure 
injector. Typical conditions included a pulse duration of 0.3 sec and a gas 
pressure of 400 kPa. Injected embryos were then incubated on a 28.5°C heat 
block until they had reached the required developmental stage or until transferred 
to the Aquatic Habitats aquarium to be reared to adulthood. 
2.2.1.32 Embryo fixation 
Embryos were euthanized using 100 mg/L benzocaine (Sigma) prior to fixation in 
4% (w/v) paraformaldehyde (PFA) in 1 x phosphate buffered saline (PBS) (137 
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mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4) (PFA/PBS). Fixed 
embryos were stored at 4°C for a minimum of 1 days, after which embryos were 
dehydrated with 100% (v/v) methanol for long-term storage at -20°C.  
2.2.1.33 Whole-mount in situ hybridization (WISH) 
Fixed embryos (stored in 100% (v/v) methanol) were rehydrated via a series of 5 
min washes in 50% (v/v) methanol, 30% (v/v) methanol and 1 x phosphate 
buffered saline-tween (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM 
KH2PO4) containing 0.1% (v/v) Tween 20) (PBS-T) before re-fixing for 20 min in 
PFA/PBS-T, followed by 2 x 5 min washes in PBS-T. Embryos at 24-36 hpf were 
further incubated with 10 μg/ml proteinase K for 10 min while embryos at 36 hpf 
- 8 dpf were incubated at room temperature (RT) with 20 μg/ml proteinase K for 
20 to 30 min. Following this, embryos were briefly rinsed in PBS-T and fixed in 
4% PFA/PBS for a further 20 min, followed by 2 x 5 min washed in PBS-T. 
Embryos younger than 24 hpf were not treated with proteinase K. Prior to 
hybridization embryos were incubated in 500 μl of HYB- (50% (v/v) formamide, 5 
x sodium chloride/sodium citrate (SSC), 0.1% (v/v) Tween20) and incubated at 
70°C for 5 min. This was replaced with 500 μl of HYB+ (HYB- containing 5 mg/ml 
ribonucleic acid, 0.05 mg/ml heparin (Sigma)) and incubated at 70°C for a 
minimum of 3 h. The HYB+ solution was then replaced with 300 μl of probe 
solution, which consisted of DIG-labeled RNA probes diluted 1/100 to 1/300 in 
HYB+, with hybridization overnight at 70°C. After this, the probe solution was 
removed and the embryos were washed twice with 50% (v/v) formamide/2xSSC-
T for 30 min and 60 min at 70°C. Embryos were then washed for 15 min in 2xSSC-
T followed by 2 x 15 min washes in 0.2xSSC-T, all performed at 70°C. Following 
this, embryos were washed three times at RT in PBS-T before being incubated 
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in blocking solution (0.02% (w/v) bovine serum albumin (BSA), 5% (v/v) foetal 
calf serum (FCS) in PBS-T) for 2 h at RT. Embryos were then placed into blocking 
solution containing (0.15 U/μl ) of alkaline phosphatase (AP) conjugated anti-DIG 
antibody (Roche) and incubated at 4°C overnight. Following this, embryos were 
washed 8 x 30 min in blocking solution at room temperature followed by 3 x 5 min 
washes in staining buffer (0.1 M Tris (pH 9.5), 0.05 M MgCl2, 0.1 M NaCl, 0.1% 
(v/v) Tween20) containing 25 μg/ml levamisol. Embryos were then stained for an 
appropriate time (usually overnight) in staining solution (0.225 mg/ml nitroblue 
tetrazolium (NBT) and 0.175 mg/ml 5-bromo,4-chloro,3-indolyl phosphate (BCIP) 
in staining buffer per well) at RT in the dark. When staining was apparent, 
embryos were washed in PBS-T, fixed in 4% PFA/PBS and stored at 4°C. 
2.2.1.34 Double fluorescent whole-mount in situ hybridization (DFWISH) 
Method followed the WISH protocol with the following alterations after the 
overnight pre-hybridization step. For double staining, DIG-labeled and 
fluorescein-labeled RNA probes were diluted 1/50 in HYB+, with hybridization 
overnight at 65°C. After this, the probe solution was removed and the embryos 
washed twice with 50% (v/v) formamide/2 x SSC-T for 30 min at 65°C. Embryos 
were then washed for 15 min in 2 x SSC-T followed by a 30 min wash in 0.2 x 
SSC-T, all performed at 65°C. Following this, embryos were incubated in 500 μl 
blocking solution (2% (v/v) blocking reagent/1 x maleic acid (150 mM maleic acid, 
100 mM NaCl (pH7.5))(Bio-Rad)) for 1 h at RT. Embryos were then placed into 
blocking solution containing 1.5 U/μl of anti-fluorescein-POD antibody (Roche) 
and incubated at 4°C overnight. Following this, embryos were washed 4 x 20 min 
in 1 x maleic acid buffer at room temperature followed by 2 x 5 min washes in 
PBS. Embryos were then incubated for an appropriate time (usually 45 min) in 
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TSA Plus Fluorescein solution (Perkin Elmer) at RT in the dark. Embryos were 
dehydrated via a series of 5 min washes in 25% (v/v) methanol, 50% (v/v) 
methanol, 75% (v/v) methanol and PBS. Following this, embryos were incubated 
for 30 min in 1% (v/v) hydrogen peroxide in 100% methanol. Embryos then 
underwent another series of 5 min washes in 25% (v/v) methanol, 50% (v/v) 
methanol, 75% (v/v) methanol and PBS, followed by 2 x 10 min washes in PBS. 
Following this, embryos were incubated in 500 Pl blocking solution for 1 h at RT, 
and were then placed into blocking solution containing 0.75 U/μl of anti-
fluorescein-POD antibody (Roche) and incubated at 4°C overnight. After this 
incubation embryos were washed 4 x 20 min in 1 x maleic acid buffer followed by 
2 x 5 min washes in PBS. Embryos were then incubated for an appropriate time 
(usually 45 min) in TSA Plus Cy5 solution (Perkin Elmer) at RT in the dark 
followed by 3 x 10 min washes in PBS-T. When sufficient staining was achieved, 
embryos were de-yolked, imaged and fixed in 4% PFA/PBS and stored at 4°C in 
the dark.  
2.2.1.35 Sectioning of embryos  
Embryos were subjected to 2 x 15 min washes in 1×PBS, followed by a series of 
15 min ethanol washes (30% (v/v), 50% (v/v), 70% (v/v), 90% (v/v), 95% (v/v), 
100% (v/v), 100% (v/v), 100% (v/v)) to dehydrate embryos. This was followed by 
2 x 30 min washes in 100% (v/v) Histosolve (Chem-Supply). Embryos were then 
subjected to a 2 h and then an overnight wash in 100% (v/v) paraffin at 60oC. 
Samples were then embedded in 100% (v/v) parrafin and allowed to set.  
Sections were then cut to 5 μm using microtome (Leica RM2125 RTS) and 
mounted on standard glass slides. 
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2.2.1.36 Nuclear Fast Red staining 
Mounted paraffin-embedded sectioned embryos were stained with nuclear fast 
red (Sigma). Slides were washed 3 times for 5, 3, and 1 min respectively in 100% 
(v/v) Histosolve, followed by 3 x 1 min washes in 100% (v/v) ethanol. Slides were 
then rinsed in dH2O and incubated in Nuclear Fast Red solution for 15 min. 
Following this slides were rinsed in dH2O, washed 3 x 1 min in 100% (v/v) ethanol 
and 3 x 1 min in 100% (v/v) Histosolve before being cover-slipped with 
dopexamine hydrochloride.   
2.2.1.37 Hemoglobin staining 
Euthanized embryos were incubated in 0.5 mg/ml O-dianisidine (Sigma-Aldrich), 
40% (v/v) ethanol, 6% (v/v) H2O2 (BDH), 0.01 M NaOH) for 15 min in the dark. 
This was followed by 3 x 5 min 1x PBS-T washes before fixation in 4% PFA/PBS-
T. 
2.2.1.38 Giemsa staining 
Adult and embryonic blood smears were stained in giemsa (Merck Millipore) 1:10 
in dH2O for 2 min. Slides were then rinsed in dH2O and air-dried. 
2.2.1.39 Neuromast staining 
Live embryos were incubated in 200 nM MitoTracker Red CMX Ros (Invitrogen) 
for 2 h at 28.5qC. This was followed by washing in 1x PBS-T before fixation in 4% 
PFA/PBS-T. 
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2.2.1.40 Digital photography 
Embryos were visualized using a SZX-ILLK200 microscope (Olympus). Digital 
images were captured with a DP90 camera (Olympus) and saved using DP 
Controller (version 2.1.1.183) and DP Manager (version 2.1.1.163) software 
(Olympus). 
 
2.3 Statistical analysis 
Statistical analysis for WISH experiments and phenotype comparison was 
performed using GraphPad Prism software. Statistical analysis of quantitative 
RT-PCR was performed using Microsoft Excel. The Unpaired independent 
student t-test was employed to determine the statistical significance of various 
treatments. Statistical analysis conducted for WISH experiments typically had 
sample populations of at least 20 embryos from three independent injections.  
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Chapter 3: 
Characterization of the 
zebrafish socs4 and 
socs5 genes 
 
Parts of this Chapter have been published in: 
Liongue, C., O’Sullivan, L. A., Trengove, M. C. and Ward, A. C. 2012. Evolution 
of the JAK-STAT pathway components: mechanisms and role in immune 
system development. Plos ONE. 7;7(3):e32777.  
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3.1 Introduction 
The mammalian SOCS family contains eight members, with SOCS4 and SOCS5 
being the least well understood. This Chapter aimed to use bioinformatic 
techniques to identify and characterize the SOCS4 and SOCS5 orthologues 
present in zebrafish. It was anticipated that this will provide important evolutionary 
insights and was also an essential first step toward using zebrafish to study the 
in vivo function of SOCS4 and SOCS5. 
 
3.2 Characterization of zebrafish socs4 and socs5 genes 
Identification of zebrafish socs4 and socs5 genes 
Identification of potential zebrafish SOCS4 and SOCS5 orthologues was 
achieved by extensive bioinformatics analysis of relevant sequence databases. 
These were searched with BLAST to identify zebrafish mRNAs or ESTs showing 
sequence similarity to mammalian SOCS4 and SOCS5. The zebrafish 
sequences were then assembled into contigs using sequence analysis software 
(Sequencher), allowing identification of open reading frames (ORF). This process 
revealed the presence of two zebrafish genes encoding proteins with strong 
SOCS4 sequence similarity and two zebrafish genes whose products showed 
strong SOCS5 sequence similarity. In order to extend these sequences and 
confirm the translational start site of each gene, 5’RACE was utilized. RT-PCR 
with specific primers also confirmed the transcription of these putative zebrafish 
SOCS4 and SOCS5 genes during embryogenesis (data not shown), with 
products sequenced to provide additional confirmation of the sequence. This 
thorough analysis identified the presence of two potential zebrafish SOCS4 
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paralogues, termed socs4a and socs4b, and two potential zebrafish SOCS5 
paralogues, termed socs5a and socs5b (Fig 3.1).  
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A  socs4a 
 
  
1 GTTGACGCTG AGCTCTCGCT GCACAAACTT CAGGCATGGA
41 AACATTCACC ACTCTTCTGT GAGAACATCG ATTTTCTTTC
81 TGAAGCTCTT TTTGGAAAAG GGCCTGAGGC AATGTCTGAG
M S E
121 AGGAAGACCA AAAACTCGGA CACACGTCCC AAGAACCTGC
R K T K N S D T R P K N L R
161 GGAGCTGGAG TGCAGATAGT TACATCCGCA GTATTAAAAA
S W S A D S Y I R S I K K
201 GCGCTCACGT GGTTCACGCC ATGAGACAGC GCCCAGAGGA
R S R G S R H E T A P R G
241 GAAGAAGGAG ATGGAGCGGA CGAACAGACT GCTCGATCTG
E E G D G A D E Q T A R S A
281 CCTCCTGTCC TCGCAGACGT CGAGAGCGAA TGTGCAGCTG
S C P R R R R E R M C S C
321 CACGATCCCT GGAGAAACTG ATTCCGACTC TCCCTGCAGG
T I P G E T D S D S P C R
361 AAAGCCCTGT CCCGTCGCTC TCTGAGACAG AAGTTTCAGG
K A L S R R S L R Q K F Q D
401 ACGCAGTCGG CCAGTGTCTC CCTCTCCGCA ATCACCACCA
A V G Q C L P L R N H H H
441 CCACCATCAC CACYCATCAG GCTCCTCACG CCCRTTCTCC
H H H H ? S G S S R P F S
481 GTCCTCCTCT GGTCCAAACG GAAGATCCAC GTCTCCGAGC
V L L W S K R K I H V S E L
521 TCATGGAGGA CAAATGCCCA TTCTCTCCGA AATCTGAACT
M E D K C P F S P K S E L
561 CGCTCAGTGC TGGCATCTGA TCAAAAAGCA CGGCACTAAC
A Q C W H L I K K H G T N
601 ACCAAACCTT CTCTAAGTAT CGAAACCGAA CCCAAAGGGC
T K P S L S I E T E P K G P
641 CCTTGTTATC CTCAACACCT CCAACACTCC TTTCCTGGGA
L L S S T P P T L L S W E
681 GCAAATCGGC TCCACTGGGG CTTCCAGTCT GGACGATTGG
Q I G S T G A S S L D D W
721 GATCCATCTT TTGCTCTTGG AGACTCCCAG TGCTGCGCTC
D P S F A L G D S Q C C A H
761 ATACTGACTA CATCCTGGTC CCGGATCTGC TTCAGATCAA
T D Y I L V P D L L Q I N
801 CAACAGCCCT TGTTATTGGG GCGTTCTGGA TCGTTTCGAG
N S P C Y W G V L D R F E
841 GCTGAGCAGC TTTTAGAAGG GCAGCCAGAG GGGACTTTTC
A E Q L L E G Q P E G T F L
881 TGCTCAGAGA CTCTGCCCAG GATGAATATC TGTTCTCGGT
L R D S A Q D E Y L F S V
921 TAGCTTCAGG CGCTACAGTC GTTCCCTCCA TGCTCGGATA
S F R R Y S R S L H A R I
961 GAGCAAAACG GGAAGCGTTT TAGCTTTGAC GGTCGTGACC
E Q N G K R F S F D G R D P
1001 CTTGTATGTA CAGGGACTCC AGTGTCACGG GCCTGTTAAA
C M Y R D S S V T G L L K
1041 GCATTATAGT GACCCATCCA CATGCCTGTT TTTCGAGCCT
H Y S D P S T C L F F E P
1081 CTCCTCTCTC GTCCCCTACC TAGGAACTTT CCGTTCACTC
L L S R P L P R N F P F T L
1121 TGCAGCACTT GTGCAGGGCG GTTATCTGTA GCTGCACCAC
Q H L C R A V I C S C T T
1161 ATATCAGGGG ATTGAAGCGC TACCTTTACC CTACACTTTG
Y Q G I E A L P L P Y T L
1201 AGACACTTTC TTAGGCAATA CCACTATAGA TGCAATGGAG
R H F L R Q Y H Y R C N G A
1241 CGTGTGCTGT TTGAGGATTG TTGAAAGGGG ATGAAACGTG
C A V .
1281 CTGCTTGATT TGCTGCTTAC ACCTCAGAGT GAGATGCATT
1321 TTTGTTGGAC CAATCACAAA TGGATGATAC TAAAAACAGT
1361 TCAATCAAAA CATTTTAATT GACTCACTAT ATACTCTCAA
1401 GTGGTTCCGA ACCTTTATGA TTCTCTTTCT TCTGTTGAAC
1441 ACAAACAAAG ATATTTAGA
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1 AATTATCAAA CAAGTTTGTA CAAAAAAGTT GGCGGCCGCC
41 CGCTACTGTA AGCCAGGGTG GTGTGAGTTA GCTCGAGTTA
81 AAGCGACTTT TTCGATTAAA GTTCTGTTAT TATTGAACAG
121 ATTATTTATT AAAGTCATAA TCACGGCTCT GAAGTGACGC
161 GACGTCATCG GGAGCGAGCT GGCGCGTTTC CGGCGGTGCA
201 GGATGATGAT TATTGGCTGG ACTGAGTGAG TGTGGTCTGA
241 AGCCTCATCA TGTCTCTGCC GGAGGACACA GGGGATCGTG
M S L P E D T G D R G
281 GAAAGGAGCG GGAGCGCGGC GCACGGCCCA AAGTGCGGCA
K E R E R G A R P K V R Q
321 GAGTCGCTCT GAGGAGAGGC GAGACGGAGG ACGGAGAAAA
S R S E E R R D G G R R K
361 CCTGGACGAG GGAAGAAGAA GAGCCACCCG TCACAGGATC
P G R G K K K S H P S Q D L
401 TGCGCCCGCT GAGTGACGGG TTTGAGTACG GAGATCTGCT
R P L S D G F E Y G D L L
441 GAGTGGTGAT CTGCTGTCCG GTGAGGGGGC GGCGCTGTCC
S G D L L S G E G A A L S
481 CAGACAGCCT CCAGCAGACC CCCGCTTGTG CCAGACTCCG
Q T A S S R P P L V P D S G
521 GCACAAGCCG CACACTCCGA CAGAAGATCC AGGACGCAGT
T S R T L R Q K I Q D A V
561 GGGACAGTGC TTCCCCATCA AAACTCACAG CCTGAGCCCA
G Q C F P I K T H S L S P
601 GCGCCGGCCC CGTCCCGCAG GAAGATCCAC CTCAGCGAGC
A P A P S R R K I H L S E L
641 TCATGCTGGA CCGCTGCCCC TTCCCCGTCG GCTCCGACCT
M L D R C P F P V G S D L
681 GGCTCAGAAG TGGTACTTGA TAAAGCAGCA CACGGCTCCG
A Q K W Y L I K Q H T A P
721 CTGGAGTGTG CGAACACCCC GGTACTGGAG TGTGTGAGCG
L E C A N T P V L E C V S A
761 CACCGCTGGA GTGTGTGAGT GCACCTCTGG AATGTGTAAG
P L E C V S A P L E C V S
801 CGCACCGCTG GAGTGTGTGG GCGCACCTGT GGAGTGTGTG
A P L E C V G A P V E C V
841 AGTGCACCGG TGCTAGAGTG TGTGAGCGCA CCTCTGGAGA
S A P V L E C V S A P L E N
881 ATGAGGAGGA CCGGCTACGC GAGCGGCGCA GGATTAGCAT
E E D R L R E R R R I S I
921 TGAGCAGGGC GTGGAGCCGC CGCCGAACGC TCAGATACAC
E Q G V E P P P N A Q I H
961 ACCTTCGAGG TCACCGCACA AATAAACCCT CTGTACAAAC
T F E V T A Q I N P L Y K L
1001 TGGGACCCAA ACTAGCGCAC GGTATGAATG AGCTAGCGGG
G P K L A H G M N E L A G
1041 AGACGAGCGC GCTACGCTAC ACCAGCTGCT CCTGCAGACC
D E R A T L H Q L L L Q T
1081 TGTCTGGACA CGCTGGACGA AGTGGCGGCG TCTGCCACCG
C L D T L D E V A A S A T V
1121 TCTCTGCGTC CGCCGTTCCA GACGTGGAGA TCTGCACTGC
S A S A V P D V E I C T A
1161 GGCTCCGTCC GTCATCCGAT CAGAGAGTCC CAAAACACAG
A P S V I R S E S P K T Q
1201 GATTACCAGC ACCGCGTTCA CACACAGATC GACTACATCC
D Y Q H R V H T Q I D Y I H
1241 ACTGCCTCGT TCCTGATTTG CTTGAGATCA CGAATCTGTC
C L V P D L L E I T N L S
1281 GTGCTACTGG GGCGTGATGG ACCGCTACGA GGCCGAGACT
C Y W G V M D R Y E A E T
1321 CTTCTGGAGG GGAAACCCGA GGGCACGTTC CTGCTGCGCG
L L E G K P E G T F L L R D
1361 ACTCTGCCCA GGAGGATTAC CTGTTCTCGG TGAGCTTCCG
S A Q E D Y L F S V S F R
1401 CAGGTACGGC CGGTCTCTAC ACGCGCGCAT CGAGCAGTGG
R Y G R S L H A R I E Q W
1441 AACCATAACT TCAGCTTCGA CGTGCACGAC CCGAGCGTGT
N H N F S F D V H D P S V F
1481 TCCACGCGCC CACCGTCACC GGCCTGCTGG AGCACTACAA
H A P T V T G L L E H Y K
1521 GGACCCGAAC TCCTGCATGT TCTTCGAGCC GCTGCTGTCC
D P N S C M F F E P L L S
1561 AACCCGATCC ACCGCACACA GCC GTTCAG CCTGCAGCGC
N P I H R T Q P F S L Q R
1601 ATCTGCCGCG CCGTCATCAG CAGCCGCAGC TCGTACGACG
I C R A V I S S R S S Y D G
1641 GGATCGGGAC ACTGCCTCTG CCCGCCGCGC TCAAGGAGCA
I G T L P L P A A L K E H
1681 CCTGAAGGAG TACCACTACA AGCAGCGGGT GCGCATCCGC
L K E Y H Y K Q R V R I R
1721 AGACTGGACA CCTGGTGGGA GTGACAGCGC TCAGGGGCAG
R L D T W W E .
1761 AGCACCAGTG CCTTTACATC CGATCACAGC ACACCGTCAC
1801 CACTCAAGCA GAATAATCCT CCTGCTCTCC TCCAACCCTG
1841 CTCCTGGAGA TCCGCCTTCC TGCAGAGTTC AGCTCCAACA
1881 CGCCTACCTG GAGTCTTTAG GTGCTGTCCC GCTCTTCACA
1921 CTGCTTCAGG TGTGTTGGAT CAGGGCTGGA GCTGAACTCT
1961 GCTGGAAGGC CTGTCTCCCT GCTGCTTTAT TGTGAGTGTG
2001 TTGAGCACAA AGGAAGATGT TTTGAAGATA GCCGGGAGTA
2041 AACTGACAGT AGTGTAGTAA TCAGGTGTGC TTCGCATCCA
2081 CAGAATCCTC CTCTTTAGTG TTCAACAGTA CAAAGACACT
2121 CTGAAAGCTT CACAATAAAT GAAGGAAGAA TCCCCGATGA
2161 GCGCAAAAAA AAA
T
B  socs4b 
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C  socs5a 
 
  
1 GCTTCGTGCA ATTGGAGTTT CCCGATGTCA GTCAACAGCA
41 GCTTTGCCAC CACCTCTCCT GATTCTCGAC TCCGCTGCTG
81 CTGCACTTGG CGACCATATC GGCCGTCAGG GAAAGAAATG
121 CCAACGGGAT GAGGGGATCG TAGGCCATGT AAATACAAAG
161 TATCAAATGT TTACGCCTTC ATCGACAAAC CGATGCGCAG
201 TTTGCTTTTC GATTATCGCA GTTATGCTCC CGGTCGTCTC
241 CCGTCCGTCT GTTTTATCTA GCGCCGTGTC TAGCCTCGGG
281 AAAATGTACC CGACTATTCT TGATAGCCTT TTTTTCGCAA
321 ACAAAAGAAG ACACCCGAAA AAACAATAAA AGAGCACGAC
361 AGAAGGATCG TTCCAGGTGC CCCCGCCTCA TGGAGAAGGT
M E K V
401 TGGCAAGGTG TGGAGCAACC TGAAGAGAGG GTGTCAGTCT
G K V W S N L K R G C Q S
441 CTGCTTCACA CAGATGGGGG TTCTCGTGTT GAAACATCAC
L L H T D G G S R V E T S P
481 CACAGCATCA ACCACAAACA GACACGGTAT GCCACAGTGT
Q H Q P Q T D T V C H S V
521 GGACGGAGCC CAGGGCGACA TCACCCTAGA TGCCAACTGT
D G A Q G D I T L D A N C
561 CCCTCTAGCA GTGTAGCAGC ACTTCCTCTA GTGGCATGGA
P S S S V A A L P L V A W R
601 GGACCAGTGG GAGTGTGACA CGGCGGGGCC ATAACTGTGT
T S G S V T R R G H N C V
641 AGCAGATGTA CCCCAGATAC TGGAGATCAC TGTCGAGCAG
A D V P Q I L E I T V E Q
681 GATGCTGATG ATGCTCGTGC TCCACTGGGA GCCCGCAGAG
D A D D A R A P L G A R R D
721 ACTCTTATTC ACGTCATGCA CCTTGGAGCG GAAAAAAGAG
S Y S R H A P W S G K K R
761 ACACTCGTGT TCTACTAAGG CTCAGAGTTC TCTAGAAACC
H S C S T K A Q S S L E T
801 ACCGATCGAC GATCAGGCCG GTCTCGACGC AGACATGGGA
T D R R S G R S R R R H G T
841 CTAGTAACAG CCCTGAGGAG TTGGAGTCAG GGACAACACG
S N S P E E L E S G T T R
881 TTCAATTCGC CAGCAAATCC ATGATACGGT GGGACTATGC
S I R Q Q I H D T V G L C
921 CTCCCACTAC GCTCATCTTC TCGAAATACT CACCTACCAC
L P L R S S S R N T H L P P
961 CACCCAAACG CAAGATACAA ATTACGGAGC TGATGCTGGA
P K R K I Q I T E L M L E
1001 GACATGTCCA TTTGCACCAG GATCAGACCT TGCCAGAAAA
T C P F A P G S D L A R K
1041 TGGCACCTTA TTAAACAACA CACTGCACCT ATCAACGTGA
W H L I K Q H T A P I N V I
1081 TTCCATTGGA TTCATCCCCG GATGCATGTG GTGCTACCTG
P L D S S P D A C G A T C
1121 TGCATCCCCG GAAGATGAAG AGGAGCGTTT GCGAGAAAGA
A S P E D E E E R L R E R
1161 AGGCGACTTA GCATTGAGGA GGGCGTGGAC CCACCTCCAG
R R L S I E E G V D P P P D
1201 ATGCTCAGAT CCACACAGTG GAGGCCATCA CAGCCCCTTT
A Q I H T V E A I T A P L
1241 AGCTTCTCTT TATAAGCTAG GACCGAAGCT TGCCCCTGGA
A S L Y K L G P K L A P G
1281 ATGGGTGAGG CCGTAGGCGA TAGCCGAGGT GCAGCAGCAG
M G E A V G D S R G A A A A
1321 CTAACTGTGA CTCTGAGGAC GATGAAACCA CCACACTTTG
N C D S E D D E T T T L C
2041 GTGAAAGAAT TACACACTTT TTGGGAAGGG GTCAGATGTT
E R I T H F L G R G Q M F
2081 TGGGGTTGGA AGAAAGGAGG GACCTGAAAC TGAACACTAA
G V G R K E G P E T E H .
2121 GTTTCTATCA TTATTTTTTT TTGTTATCAC TCTAACAAAC
2161 AAATAAGTTA CATATACAAG CTCTCCAGTG TGCACATTTC
2201 ACTACAGCTT CTGGACTAGG ATGAAGCAGC CGAGGTCTTG
2241 GTCTCATTTT CTTTCTTTCT CAGTTCCCAT GGCCGTTTTC
2281 TAAGGGGGAT TTACAGATTC AGCTATTTTT ATGCCTCTCC
2321 ACCCTTTAAA TGTTTGACTG GTTTATAGCC ATTTCACTTT
2361 TTTTTCTGTT GTACCGTTCA CCTCCCTGCC TCCCCATAAT
2401 TCCCTTGCAT CGAAATTGCA TTGTTAGTGT TTATTTAAAG
2441 TAACATTGTG GACAAATTCT GAGGGCAGAG GAGAAGTTTG
2481 GTGATGTCCA AATATTGCTT TTTCCAGCTT CTTTCATCAT
2521 CCTTAGATTT CTTGGTGCTC TGTC
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1 ATCGGCCTCT TCTTCACGCC TTTGCTCGAC TTGTCAAGCA
41 GGAGTACTGG CTCGGTGGAC CGGAGATTGG CGTTGGATTA
81 TGCTGCTTTT CCATCCGACT AGAATGACGC GAGATTCAGC
121 CGTTCGCCTG CTTTATAAAA GCCAACCTCG GGAACGAGCA
161 CTTCTGCCCC GTCGCTCGTG TTTTATCCGC CAGGACTGAG
201 CGTATGCGGG ACAGTAGCGA GTATAACAGC TATAACAGCC
M R D S S E Y N S Y N S L
241 TTCTATTGCA GACAAAGGAC GGCTGCGAAG TAACATACAC
L L Q T K D G C E V T Y T
281 AATAAAAAAA GGTTGTGGTC TCCAATCTGT GGAGAACGTG
I K K G C G L Q S V E N V
321 GGCAAGATGT GGGGTAATCT CAGAAGCCGA TGCCAAGCTC
G K M W G N L R S R C Q A L
361 TCTTCCACAG TGACGGCTCA GAGTCCCATC TGTGTAGTCA
F H S D G S E S H L C S Q
401 AGATTTAGAT TGTGCTCACT GTGTGCTGGA TTTGGACAGG
D L D C A H C V L D L D R
441 GGAGCACATG CAGAACCCTA TGAAACCAGG TCTTCCACAC
G A H A E P Y E T R S S T P
481 CTTCACGCAA CTTGTCACCT CTTCCATTGG CTACTGGTGG
S R N L S P L P L A T G G
521 ACGCAGAAGC CATAATTGTG TGGCGGATAT TCCTCAAATA
R R S H N C V A D I P Q I
561 GTAGAAATCT CCATTGAC:A AAGAGAGTGA AGATGCACGG
V E I S I D K E S E D A R
601 AGAGGCCCAC TTGTTCGCAG GGACTCCTAT TCACGTCATG
R G P L V R R D S Y S R H A
641 CTCCCTGGGG AGGTAAAAAG AAGCATTCTT GCTCAACTAA
P W G G K K K H S C S T K
681 AACACAAAGT TCTCTTGAGG CTGACAGGCG AACAGGACGC
T Q S S L E A D R R T G R
721 TCAAGAGGAA GTACAGCCAG AAGGGAGCGT CGTTATGCCG
S R G S T A R R E R R Y A V
761 TCAGCTCCAT TCAAGAAATT AATGATTCTG TAGAAGTTGG
S S I Q E I N D S V E V G
801 CAGCAGCGGG CGTAGCCTTA GCAGCCGTTC TCTGCGACAA
S S G R S L S S R S L R Q
841 CGACTTCGAG ACACCGTGGG CTTGTGCCTT CCTCTCCCCA
R L R D T V G L C L P L P T
881 CACACCGGCG CTCTCAGTCA GCCAAAGGTC AAGTATCCTC
H R R S Q S A K G Q V S S
921 AAAACGTAAG ATCCACCTGA CAGAACTGAT GCTCGAAACA
K R K I H L T E L M L E T
961 TGCCCTTTTC CTCCAGGTTC TGATCTGGCC AACAAGTGGC
C P F P P G S D L A N K W H
1001 ACCTAATTAA GCAACATACA GCACCAGTCA GCCCCCATTC
L I K Q H T A P V S P H S
1041 CTCTTCTGCT CTTTTTGATG CTTTTGATTC AGCCCATTCT
S S A L F D A F D S A H S
1081 TCCCCTGAGG ACGAGGAGGA GAGGCTGCGT GAACGACGTA
S P E D E E E R L R E R R R
1121 GACTTAGCAT CGAGGAAGGA GTAGACCCAC CTCCAAATGC
L S I E E G V D P P P N A
1161 GCAGATCCAT ACATTGGAGG CAACTTCAAA GAGCTCTTCC
Q I H T L E A T S K S S S
1201 CTCTATAAAC TAGGACCAAA GATGGCTCCT GGTGTTGGGG
L Y K L G P K M A P G V G E
1241 AAACACTTGG GGAGGGCAGG AGCCTAGGAA CAGTCTCCTC
T L G E G R S L G T V S S
1281 CATTTCTGGG GGATTATCAG GGATCGCCGC ACAGGTTCCA
I S G G L S G I A A Q V P
1321 ACAAGTATGG CAGTGCCATC CCACACGGTT GACTGTGACT
T S M A V P S H T V D C D S
1361 CTGAGGAGGA CTCAACTACC CTTTGCTTAC AGACACGAAG
E E D S T T L C L Q T R R
1401 GCCCAAGCAG AGGCATGCCT CTGGAGACAC TCACTGCTCC
P K Q R H A S G D T H C S
1441 AGACAGCCAG GGCCTTGGAA GGTCCACACA CAGATTGACT
R Q P G P W K V H T Q I D Y
1481 ACATCCATTG TTTAGTACCT GACCTACAGG CCATAACTGC
I H C L V P D L Q A I T A
1521 ACTTCCTTGT TATTGGGGAG TGATGGACCG GTACCAAGCT
L P C Y W G V M D R Y Q A
1561 GAAGCCCTGC TGGATGGACG GCCAGAAGGC ACCTTCCTTC
E A L L D G R P E G T F L L
1601 TACGCGACTC CGCACAGGAG GACTACTTGT TCTCTGTTAG
R D S A Q E D Y L F S V S
1641 TTTTCGACGT TACAATCGGT CACTGCATGC ACGCATTGAA
F R R Y N R S L H A R I E
1681 CAATGGAATC ACAACTTCAG CTTTGATGCA CATGACCCAT
Q W N H N F S F D A H D P C
1721 GTGTCTTCCA CTCCTCCACA GTAACAGGTT TACTGGAGCA
V F H S S T V T G L L E H
1761 TTATAAAGAC CCCAGTGCTT GTATGTTCTT TGAACCCCTG
Y K D P S A C M F F E P L
1801 CTCACTGCTC CCTTACACCG GACCTTCCCT TTCAGCCTTC
L T A P L H R T F P F S L Q
1841 AGCACCTGGC ACGATCCTCC ATCTGTAGAC ACACCACCTA
H L A R S S I C R H T T Y
1881 TGATGGCATT GGTGCCCTGC CACTGCCTCC AACCATGCAG
D G I G A L P L P P T M Q
1921 GACTTCCTCA AGGAGTATCA CTACAAACAA AAAGTTCGTG
D F L K E Y H Y K Q K V R V
1961 TGCGCTGGTT AGAGAGAGAG CCACCATTCA AGGTCAAATG
R W L E R E P P F K V K .
2001 A
D  socs5b 
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Figure 3.1 Sequence of zebrafish socs4a, socs4b, socs5a and socs5b 
Full-length sequences and conceptual protein translations of zebrafish socs4a 
(A), socs4b (B), socs5a (C) and socs5b (D).  
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SOCS splice site preservation 
Splicing patterns of SOCS4 and SOCS5 genes were investigated in order to 
provide further evidence of evolutionary conservation. Identification of splice sites 
was carried out by comparing the cDNA sequence of each SOCS gene in both 
zebrafish and human against the relevant genomic sequence, but with positions 
of intron/exon boundaries confirmed by application of the GT-AG rule [323]. 
Human SOCS4 and zebrafish socs4a and socs4b showed conservation of splice 
sites, with none of the orthologues containing introns in their coding regions with 
a single intron within the 5’UTR (Fig 3.2). Conservation of splice sites was also 
observed when comparing human SOCS5 and zebrafish socs5a, with neither 
gene containing introns in their coding regions and both possessing an intron in 
the 5’UTR. In contrast, zebrafish socs5b possessed an extended coding 
sequence such that this intron was positioned within the coding region.  
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Figure 3.2 Splicing of SOCS4 and SOCS5 genes 
Schematic representation of the splice structure of human (hs: Homo sapiens) 
and zebrafish (dr: Danio rerio) SOCS4 and SOCS5 genes. Splice sites are 
indicated by open triangles, non-coding regions are shown in light blue while 
coding exons are shown in grey, with specific domains further delineated: NTCR 
in purple, SH2 domain in green and the SOCS box in dark blue. 
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Synteny analysis of SOCS4 and SOCS5 
The putative zebrafish SOCS4 and SOCS5 orthologues were next analyzed for 
conserved synteny to the SOCS4 and SOCS5 genes from human and pufferfish 
(Fig 3.2). Several genes showed conserved syntenic relationships between 
zebrafish socs4a and human SOCS4 (WDHD1, GCH and SAMD4), which were 
also seen for pufferfish socs4a. In contrast, zebrafish socs4b did not demonstrate 
such clear synteny with the human SOCS4 locus. Indeed, comparison of 
zebrafish socs4b and pufferfish socs4b loci exposed conserved synteny of a 
single gene (PAF1). However, both the zebrafish socs4b and pufferfish socs4b 
loci were flanked by separate homologues of genes located at the human SOCS4 
loci, specifically gmfγ in zebrafish and samd4b in pufferfish matching GMFβ and 
SAMD4a homologues, respectively, flanking the human SOCS4 gene. 
Examination of the location of these paralogues in humans revealed a region on 
chromosome 19 that showed conserved synteny to both zebrafish and pufferfish 
socs4b loci. This site showed conserved synteny of PAF1 and GMFγ with 
zebrafish socs4b and PAF1, SAM4DB and LRFN1 with the pufferfish socs4b. In 
contrast, there was no evidence of conserved synteny when socs4b was 
compared to the human SOCS5 locus, strongly suggesting it was a SOCS4 
paralogue.   
A number of genes showed conserved synteny between zebrafish socs5a and 
human SOCS5 (RHOQ, PIGF, CRIPT, CALM2, MSH2, EPAS1 and PRKCE) and 
between zebrafish socs5b and human SOCS5 (MCFD2, TTC7A, CALM2, 
C2orf61, EPCAM, PRKCE and EPAS1). The sole pufferfish socs5 gene showed 
stronger synteny conservation with zebrafish socs5b. 
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Figure 3.3 Synteny analysis of SOCS4 and SOCS5 gene loci 
Schematic representation of zebrafish (dr: Danio rerio), pufferfish (tr: Takifigu 
rubripes) and human (hs: Homo sapiens) SOCS4 (A) and SOCS5 (B) gene loci 
with location and orientation of surrounding genes indicated.  Genes with 
conserved synteny between human and zebrafish or pufferfish are represented 
in black, those with synteny between zebrafish and pufferfish only are 
represented in green or with a green edging while non-syntenic genes are 
represented in grey. Fish genes with homologues on human chromosome 19 only 
are shown in yellow, while human genes on chromosome 14 that have 
homologues on chromosome 19 have yellow edging.  
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3.3 Characterization of zebrafish Socs4 and Socs5 proteins 
Sequence alignment 
The extent of amino acid conservation between the encoded proteins of the 
putative zebrafish and human SOCS4 and SOCS5 genes was closely examined 
using the CLUSTALX alignment program. All zebrafish SOCS4 and SOCS5 
sequences showed broad conservation, including the classical domain 
comprising the N-terminus, SH2 domain and SOCS box (Fig 3.4).  
More detailed analysis indicated that zebrafish Socs4b displayed 50% identity 
with human SOCS4 in the NTCR4-5 domain within the N-terminus, with 
conservation within this domain slightly lower for zebrafish Socs4a, with 43% 
identity. Interestingly, the lower % identity value for zebrafish Socs4a was largely 
due to a stretch of approximately 19 amino acids containing a set of 7 histidine 
residues towards the center of the domain that were not conserved with any other 
SOCS4 (or SOCS5) protein. The remainder of the N-terminal region showed little 
conservation between zebrafish and human SOCS4 orthologues, with Socs4a 
having a shorter domain and Socs4b having a longer domain when compared to 
human SOCS4. Analysis of the SH2 domain of SOCS4 orthologues highlighted 
very strong conservation between all SOCS4 genes. There was 72% amino acid 
identity and 93% similarity between zebrafish Socs4a and human SOCS4 SH2 
domains, while zebrafish Socs4b showed even greater conservation with 88% 
identity and 93% similarity to human SOCS4. For the SOCS box domain 
zebrafish Socs4a displayed 62% identity and 92% similarity compared to the 
human SOCS4. Conservation of the zebrafish Socs4b SOCS box with human 
SOCS4 was slightly less at 59% identity and 89% similarity.  
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Conservation of these three domains was also examined in the SOCS5 zebrafish 
homologues. Overall conservation of the N-terminal domain of the SOCS5 
homologues was greater than that seen in SOCS4, with several stretches of 
amino acid sequence showing high identity. This was especially evident within 
the NTCR4-5 domain, where zebrafish Socs5a and Socs5b displayed 75% and 
63% identity and 88% and 89% similarity, respectively, compared with human 
SOCS5. While both Socs5a and Socs5b showed good conservation across the 
rest of the N-terminal domain, Socs5b possessed two additional stretches of 20-
35 amino acids that did not show conservation with either Socs5a or human 
SOCS5. One of these stretches was at the very N-terminal part of the Socs5b 
coding region, with these additional 35 amino acids encoded by sequences 
extending into the first exon of this gene. Conservation of the SH2 domain was 
striking between zebrafish and human, with zebrafish Socs5a displaying 96% 
identity and 100% similarity, and Socs5b showing 93% identity and 100% 
similarity to human SOCS5. Conservation of the SH2 domain was not quite as 
strong, with 70% identity and 89% similarity between zebrafish Socs5a and 
human SOCS5, with zebrafish Socs5b again slightly less well conserved with 
62% identity and 86% similarity.  
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Figure 3.4 Alignment of SOCS4/5 proteins 
Alignment of human (hs: Homo sapiens) SOCS4 with zebrafish (dr: Danio rerio) 
Socs4a and Socs4b (A) and human SOCS5 with zebrafish Socs5a and Socs5b 
(B). Domains are shown, including the SOCS4/5 specific domain termed N-
terminal conserved region 4-5 (NTCR4-5) and the Src-homology 2 (SH2) and 
SOCS box domains. Asterisks (*) represent identical residues, colons (:) 
represent highly related residues and periods (.) represent moderately related 
residues.  
Applied Colour { Threshhold, Residue group } 
BLUE {+60%, WLVIMAFCHP} 
RED {+60%,KR},{+80%, K,R,Q} 
GREEN {+50%, N}, {+85%, N,Y} 
BLUE {+60%, WLVIMAFCHP} 
PINK {100%, C} 
GREEN {+60%,KR},{+50%,QE},{+85%,Q,E,K,R} 
MAGENTA {+60%,KR},{+50%,QE},{+85%,E,Q,D} 
MAGENTA {+60%,KR}, {+85%, K,R,Q}, {+50%,ED} 
ORANGE {+0%, G} 
CYAN {+60%, WLVIMAFCHP}, {+85%, W,Y,A,C,P,Q,F,H,I,L,M,V} 
YELLOW {+0%, P} 
GREEN {+60%, WLVIMAFCHP}, {+50%, TS}, {+85%,S,T} 
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3.4 Phylogenic analysis 
The evolutionary relationships amongst the SOCS4 and SOCS5 family members 
were investigated by phylogenic analysis. The CLUSTALX program was used to 
align amino acid sequences from SOCS4 and SOCS5 sequences from several 
species, along with human and zebrafish representatives of the other SOCS 
members, and the Neighbor-Joining algorithm used to create a phylogenic tree 
(Fig 3.5). The robustness of each branch of the tree was assessed using 
bootstrap values, with the majority of branches producing high levels of 
confidence (>80%).  
The tree showed typical clustering of SOCS family members into pairs; SOCS1/3, 
SOCS2/CIS, SOCS4/5 and SOCS6/7. Within the SOCS4/5 clade, while zebrafish 
and pufferfish Socs4a and Socs4b proteins separately clustered together, none 
of these sequences grouped strongly with the other SOCS4 genes, with the 
Socs4a sequences being most divergent. 
In contrast, both zebrafish Socs5a and Socs5b sequences clearly formed a clade 
with SOCS5 genes from other species, including humans, further confirming 
them as paralogues of SOCS5. The single pufferfish Socs5 clustered with 
zebrafish Socs5b.  
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Figure 3.5 Phylogenic analysis of SOCS family proteins 
Phylogenic analysis of SOCS family proteins from human (hs; Homo sapiens), 
mouse (mm: Mus musculus), fruit fly (dm: Drosophila melanogaster), chicken (gg: 
Gallus gallus), African clawed frog (xt: Xenopus tropicalis), pufferfish (tn: 
Tetraodon nigroviridis), sea squirt (ci: Ciona intestinalis) and zebrafish (dr: Danio 
rerio). Protein sequences of the SH2 and SOCS box domains were aligned using 
ClustalX and the phylogenic tree generated using the Neighbor-Joining algorithm, 
with bootstrap values above 80% (of 1000 replicates) indicated by bolded 
branches. 
The blue box indicates CISH and SOCS1-3 homologues, which are most often 
associated with cytokine receptor (CytoR) signaling. The pink box highlights 
SOCS4-7 homologues, which are more commonly associated with receptor 
tyrosine kinase (RTK) signaling. SOCS4 homologues are further delineated by a 
purple box and SOCS5 homologues by a yellow box. 
 
 
 
 
 
 
 
 
 
3.5 Discussion 
Zebrafish has proved to be a relevant and informative model for the functional 
analysis of SOCS genes [71, 122, 324]. To facilitate a detailed examination of the 
functional role of SOCS4 and SOCS5 in this animal model, accurate identification 
and characterization of the zebrafish orthologues was essential. Therefore, a 
comprehensive bioinformatics analysis was performed that identified four 
zebrafish genes related to SOCS4 and SOCS5, which were named socs4a, 
socs4b, socs5a and socs5b, with evidence that they represented pairs of 
paralogues for each mammalian gene.  
Determining the zebrafish SOCS4 repertoire was somewhat challenging, with 
phylogenic analysis revealing ambiguous evolutionary relationships, with neither 
zebrafish Socs4a or Socs4b clustering with mammalian SOCS4 proteins. Indeed, 
the designation of these socs genes has been debated in the literature. Jin et al 
originally named Socs4b as Socs9 since it failed to group with a specific SOCS 
family member[325]. Wang et al instead suggested that this gene was in fact 
another zebrafish SOCS5 paralogue and termed it Socs5b, and the more closely-
related SOCS5 homologues as Socs5a1 and Socs5a2 [326]. In order to 
confidently designate this gene, synteny analysis was performed. 
There was a clear syntenic relationship between the zebrafish socs4a locus and 
the human SOCS4 locus, with genes SAMD4A, GCH1 and WDHD1 all showing 
conserved synteny. However, no genes with conserved synteny could be 
identified between human SOCS4 and the putative zebrafish socs4b. However, 
comparison of the loci in both zebrafish and pufferfish highlighted paf1 as having 
conserved synteny between both species. Moreover, the pufferfish socs4b locus 
was flanked by samd4b, a paralogue of SAMD4A, a gene flanking the human 
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SOCS4 locus. In addition the zebrafish socs4b locus was flanked by gmfg, a 
paralogue of GMFB, also located in the vicinity of the human SOCS4 locus. To 
understand this further, the location of SAMD4B and GMFG in the human 
genome was investigated. Both were found adjacent on chromosome 19 and 
were further flanked by the PAF1 and LRFN1 genes, both of which exhibited 
conserved synteny with the pufferfish socs4b gene locus. In contrast, there was 
no evidence of conserved synteny between socs4b and human SOCS5. 
Collectively, this suggests socs4b shares an evolutionary relationship with 
SOCS4 genes, supporting its designation as a paralogue. Close examination of 
the paralogue rich domain on human chromosome 19, failed to detect the 
presence of a human SOCS4 pseudogene (data not shown), suggesting a 
specific gene duplication in the teleost lineage rather than gene loss.  
Examination of amino acid alignments showed strong conservation in the SOCS4 
paralogues. The N-terminal conserved region 4-5 (NTCR4-5) was well conserved 
between the SOCS4 orthologues, with the exception of a small histidine rich 
region in Socs4a, which was not evident in human SOCS4. The NTCR has 
recently been termed the JAK inhibitory region (JIR), due to mammalian in vitro 
data showing this region is critical for the ability of SOCS5 to reduce JAK1 and 
JAK2 autophosphorylation [327]. Conservation between zebrafish Socs4b and 
human SOCS4 gene in this domain suggests it may retain this function, which 
may not be the case for Socs4a. Analysis of the SH2 domain revealed even 
higher conservation amongst SOCS4 genes indicating that zebrafish Socs4a and 
Socs4b proteins likely bind the same or related target proteins to those bound by 
mammalian SOCS4. Strong conservation was also evident in the SOCS box 
domain, a feature reflected across the entire SOCS family that is responsible for 
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recruitment of E3 ubiquitin ligase complexs, which mark proteins for degradation 
and recycling.  
Designation of the SOCS5 paralogues socs5a and socs5b was more 
straightforward. Phylogenic analysis revealed a distinct SOCS5 cluster with 
robust associations between all vertebrate genes. Both zebrafish socs5 genes 
also showed conserved synteny, with at least 7 adjacent genes from both the 
socs5a and socs5b loci also flanking the human SOCS5 locus.  
Amino acid alignment of the SOCS5 orthologues identified strong conservation 
within the NTCR4-5, indicating likely retention of its role in binding of target 
proteins such as JAKs. In addition, the SOCS5 orthologues showed several 
stretches of strong conservation within the remainder of their N-terminal domain 
which often lack conservation between SOCS orthologues. There was striking 
conservation in both putative zebrafish Socs5 proteins within the SH2 domain, 
with 90% identity and 100% similarity in both socs5a and socs5b when compared 
to human SOCS5. As the SH2 domain is responsible for binding specificity to 
target proteins, this data suggests zebrafish SOCS5 proteins likely bind the same 
or closely related target proteins to those bound by human SOCS5. Good 
sequence conservation was also identified in the SOCS box domain, which 
facilitates the function of SOCS5, again indicating functional similarity. The only 
major divergence was the presence of unique N-terminal extension of 35 amino 
acids in Socs5b due to the presence of an in-frame start codon within exons of 
this gene. The role of this extra sequence is presumably zebrafish specific. 
The data presented in this Chapter identified two zebrafish paralogues for both 
SOCS4, termed socs4a and socs4b, and SOCS5, termed socs5a and socs5b. 
Such gene duplications are common amongst SOCS genes, with paralogues also 
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present for CISH, SOCS3 and SOCS6. Duplication events can be either local, 
typically tandem duplications, or global, typically in the form of whole genome 
duplications (WGDs) [328, 329]. There have been three WGDs during vertebrate 
evolution, with the first two occurring after the divergence of urochordates but 
before the divergence of lobe-finned fishes and ray-finned fishes [329], with the 
third WGD limited to teleost fish within the ray-finned fish lineage [330] (Fig 3.6A). 
WGDs have been the key driver for evolution of JAK-STAT-SOCS pathway 
components throughout chordate/vertebrate evolution, with additional complexity 
provided by more limited local duplication [24]. Against this background, the 
evolutionary history of the four zebrafish SOCS4 and SOCS5 orthologues can be 
considered. Wang et al proposed a model by which zebrafish possess one 
SOCS4 orthologue and three SOCS5 paralogues (Fig 3.6B). In this model, a 
combination of teleost specific WGD and local chromosomal or gene specific 
duplication would be required [326]. Liongue et al proposed an alternate model 
in which zebrafish possessed a set of paralogues for each of SOCS4 and SOCS5 
and suggested that each set of paralogues likely arose from the teleost specific 
WGD (Fig 3.6C) [24]. The identification of a paralogue rich stretch on human 
chromosome 19 with synteny with both the pufferfish and zebrafish socs4b loci 
and the human SOCS4 locus suggests an alternate evolutionary pathway is also 
possible, in which a duplication event prior to the divergence of human and fish 
followed by gene loss (of socs4b) in mammals is possible, although no evidence 
in the form of a pseudogene could be found. While further evolutionary evidence 
is required to differentiate between the latter models, data produced in this study 
supports the designation of these genes as socs4a, socs4b, socs5a and socs5b. 
This Chapter has thoroughly characterized the zebrafish socs4 and socs5 genes. 
This was essential for the application of techniques such as WISH, morpholinos 
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and ZFNs to investigate their in vivo function in the following Chapters. The strong 
conservation of these genes between human and zebrafish, particulary in the 
protein binding SH2 domain, further suggests that the function of the zebrafish 
SOCS4 and SOCS5 genes will likely be insighful for understanding the role of the 
human genes. Importantly, the identification of a pair of paralogues for both 
SOCS4 and SOCS5 in the zebrafish means that each member must be examined 
to achieve comprehensive understanding of the overall function of SOCS4 and 
SOCS5. This is particularly the case since gene duplications can lead to simiar 
roles for each of the paralogues, the original gene function can be split between 
the two, with each taking on part of the role, or one gene may become more 
divergent and take on a new or novel function [24]. 
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Figure 3.6 Alternate models for the evolution of SOCS4 and SOCS5. 
(A) Evolutionary timeline summarizing some key events in chordate and 
vertebrate evolution, including the divergence of protostomes (solid grey line) 
from deuterostomes, the subsequent divergence of urochordates (broken grey 
line) from other chordates, and finally ray-finned fish (including teleost’s) (dotted 
black line) from lobe-finned fish (including tetrapods) (black line), with relevant 
present-day groupings (insect, urochordate, teleost, and tetrapod) indicated. 
Whole genome duplications (1R, 2R, 3R) are indicated with short red lines. (B-D) 
Alternative models for the evolution of SOCS4 and SOCS5 as described by Wang 
et al. (B), Liongue et al. (C) and this study (D).  
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4.1 Introduction 
SOCS4 is widely expressed in mice, with higher expression identified in the 
olfactory bulb (http://biogps.org/#goto=genereport&id=122809). In porcine 
tissues, expression of SOCS4 has been shown to be particularly high in the 
intestine and thymus indicating a potential role in immunity [239]. SOCS4 is also 
thought to be post-transcriptionally regulated by the micro RNAs miR-98 and let-
7, which cause translational repression through targeting of the SOCS4 3’UTR 
region. In vitro studies suggest that SOCS4 has a role in the regulation of EGFR 
signaling [6, 225], which appears to be mediated through docking of SOCS4 to 
phosphotyrosine residues on the activated EGFR, subsequently targeting the 
receptor for proteasomal degradation by recruitment of E3 ubiquitin ligase activity 
[6, 11]. However, until very recently the in vivo role of SOCS4 remained 
undiscovered. 
The data in Chapter 3 revealed the presence of two zebrafish SOCS4 
paralogues, socs4a and socs4b.  This Chapter aimed to characterize zebrafish 
socs4a. This included elucidation of potential regulatory elements in the socs4a 
gene promoter, examination of the spatio-temporal expression pattern of the 
gene during embryogenesis and use of morpholino-mediated knockdown 
technology to examine functional roles for socs4a during embryogenesis.  
4.2 Analysis of the socs4a gene locus  
Promoter analysis  
To investigate transcriptional regulation of socs4a, potential transcription factor 
sites were identified in the 3000 bp preceding the transcription start zebrafish 
socs4a and mouse SOCS4 using TESS. Sites for a range of general transcription 
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factors (eg. YY1 and Hb) were found in the promoter regions of both genes. 
Interestingly, the remaining conserved transcription factors identified fell into two 
categories: neuronal (eg. POU1F1a and UNC-86) and hematopoietic (eg. c-MYB 
and LEF1) (Fig 4.1). In addition, the presence of STAT consensus sites was also 
examined in this region, since SOCS proteins are known to be directly regulated 
by STATs acting downstream of cytokine receptors. This analysis identified the 
presence of 54 generic STAT sites promoter sites upstream of the socs4a 
transcription start site, including 6 STAT3 sites.   
MicroRNA analysis  
Expression of human SOCS4 has been shown to be regulated in vitro by miR-
98, a member of the let-7 family of microRNAs, via a partially complementary 
sequence in the 3’ UTR [62]. Therefore, the 3’ UTR of mouse Socs4 and zebrafish 
socs4a mRNAs were analyzed for the presence of potential binding sites for 
species-specific microRNAs of the let-7 family using an online prediction tool, with 
a cut-off ΔΔG value of -5 kcal mol-1 employ to predict the microRNAs most likely 
to interact. A single binding site was found in the mouse Socs4 3’ UTR for multiple 
let-7 family members, similar to that seen in the human gene, with binding of 
mmulet-7e and mmulet-7g predicted with ΔΔG values of <10 kcal mol-1. In 
contrast, the zebrafish socs4a 3’ UTR region did not contain any significant let-7 
family binding sites (Fig 4.1).  
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Figure 4.1 Characterization of the zebrafish socs4a gene locus and mRNA 
Mouse Socs4 (A) and zebrafish socs4a (B) genes were analyzed for conserved 
transcription factor binding sites in their promoter and microRNA binding sites in 
their encoded mRNA using online prediction tools. The frequency and position of 
potential sites for neuronal, general and hematopoietic transcription factors in the 
promoter regions are represented by the numbers inside the shapes, which are 
color coded, as indicated. Untranslated regions of genes are shown in grey, while 
coding regions are shown in blue. The position and details of potential let-7 
binding sites in the 3’ UTR of Socs4 are shown, with corresponding free energy 
associated with microRNA binding (ΔΔG). No binding sites were present in the 3’ 
UTR of socs4a. 
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4.3 Expression analysis of zebrafish socs4a during 
embryogenesis 
To gain insight into potential in vivo roles of socs4a, its expression was 
investigated using semi-quantitative RT-PCR. RNA was extracted from pooled 
groups of wild type (WT) embryos (n=30) at key time-points in development, 
including 1 cell, 8 hpf, 12 hpf, 16 hpf, 24 hpf, 31 hpf, 48 hpf, 3 dpf, 4 dpf, 5 dpf 
and 6 dpf as well as from a variety of adult zebrafish tissues. Purified RNA was 
reverse transcribed to cDNA, which was then used as template for RT-PCR with 
primers specific for a region of socs4a or the house keeping gene β-actin. In 
parallel, samples in which reverse-transcriptase was omitted were used as 
negative controls. Bands of the expected size were visualized on agarose gels 
and their identity confirmed by sequencing. Expression of socs4a was seen at 
all-time points during embryogenesis, but with a dynamic expression profile (Fig 
4.2A). Transcripts of socs4a were evident at the 1 cell stage, indicating maternal 
derivation, with these transcripts declining by 12 hpf. Levels of socs4a then 
increased by 16 hpf, as a result of zygotic expression and peaked at 31 hpf, after 
which levels then decreased again before reaching a steady level of expression 
from 72 hpf. Expression of socs4a was also observed in the adult brain, spleen, 
kidney, liver, gall bladder, skeletal muscle and heart tissue, with highest transcript 
levels identified in the brain, followed by the eggs, gall bladder, heart and skeletal 
muscle, respectively (Fig 4.2B). 
Having confirmed embryonic expression of zebrafish socs4a, whole-mount in situ 
hybridization (WISH) was employed to determine its spatio-temporal expression 
during embryogenesis. An anti-sense (AS) RNA probe was generated against 
the full-length socs4a coding region and used in WISH on staged WT embryos. 
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Ubiquitous expression was seen at early time-points including within the shield at 
6 hpf (Fig 4.2C), but by 17 hpf a distinct expression pattern had emerged, with 
bilateral expression in presumptive cranial ganglia, the paired precursor dorsal 
root ganglia (pDRG) in the trunk and in neurons within the developing tail (Fig 
4.2D). By 24 hpf, the expression domain had further expanded, with bilateral 
expression noted in several sensory cranial ganglia, including the trigeminal 
ganglia (TgG), anterior and posterior lateral line ganglia (ALLG, PLLG), 
statoacoustic ganglia (SAG) as well as the fifth (V), sixth (VI) and seventh (VII) 
cranial nerves, while expression in the pDRG also persisted (Fig 4.2E-H). 
Expression in the majority of these structures waned at 48 hpf (Fig 4.2I) and was 
extinct by 3 dpf, with expression remaining only in the ALLG and PLLG from 3-7 
dpf (Fig 4.2J-K). A socs4a sense probe was used at all time-points as a negative 
control and failed to produce non-specific staining (Fig 4.2E and data not shown).  
The discrete bilateral expression pattern of socs4a was consistent with 
expression in developing neuronal structures. To confirm the exact identity of 
these structures, double fluorescent in situ hybridization (dFISH) was employed. 
This utilized a fluorescein-labeled probe targeting socs4a and a digoxigenin-
labeled probe targeting the well-characterized neuronal markers huc, neurod and 
isl1 [331-333]. Analysis of wild-type embryos at 24 hpf by dFISH with socs4a and 
the pan-neuronal marker huc showed clear co-expression in a subset of the 
neuronal cells within the PLLG, with independent expression elsewhere (Fig 
4.2L). Similar analysis with socs4a and the differentiating neuronal marker 
neurod showed co-expression in a sub-section of the PLLG. However, overlap of 
expression was not complete, with both socs4a and neurod shown to stain 
independent sections of the PLLG (Fig 4.2M) in addition to some areas of overlap. 
Closer analysis using 3 dimensional reconstruction also revealed areas of 
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adjacent staining, suggesting that socs4a is likely expressed in both immature 
and mature neuronal cells within the PLLG (data not shown). Finally, dFISH 
analysis with socs4a and the sensory and motor neuronal specific marker isl1 
revealed co-expression in the fifth cranial nerve (V), the TgG and the ALLG within 
the hindbrain (Fig 4.2N). In contrast, expression of socs4a was adjacent, but 
distinct from the isl1+ sensory motor neurons of the spinal cord (data not shown). 
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Figure 4.2 Spatio-temporal expression profile of socs4a  
RT-PCR from total RNA extracted from embryos at the indicated times post 
fertilization (A, upper panel) or from adults tissues (B, upper panel). Levels of 
socs4a were quantified using densitometry and standardized to the control β-
actin gene with the embryonic expression profile shown relative to expression at 
1 cell (A, lower panel) and the adult profile relative to expression in the gills (B, 
lower panel). Whole-mount in situ hybridization analysis of socs4a on embryos at 
6 hpf (C), 17 hpf (D), 24 hpf (E-H), 48 hpf (I), 3 dpf (J) and 7 dpf (K) using either 
sense (Ctl) or anti-sense (socs4a) probes. dFISH on 24 hpf embryos with anti-
sense probes for socs4a and either huc (L), neurod (M) or isl1 (N), as indicated. 
The embryo in panel C is imaged in superior view. All other embryos are 
positioned with their anterior to the left and images are of lateral view (D-F, J-M), 
dorsal view (C, G, I, N) or cross-section (H). ALLG, anterior lateral line ganglion; 
CG, cranial ganglion; N, neuron; pDRG, precursor dorsal root ganglion; PLLG, 
posterior lateral line ganglion; SAG, statoacoustic ganglion; TgG, trigeminal 
ganglion; V, fifth cranial nerve; VI, sixth cranial nerve; VII, seventh cranial nerve.  
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4.4 Targeted knockdown of Socs4a  
To examine the in vivo function of Socs4a during zebrafish embryogenesis, anti-
sense morpholino (MO) mediated knockdown was employed to investigate the 
consequences of socs4a gene ablation. Two independent MOs were designed to 
target socs4a, one binding to the 5’UTR (UTR MO) and the other to the start 
codon (ATG MO) in order to block translation of Socs4a (Fig 4.3A). To confirm 
the efficacy and specificity of the socs4a ATG MO, coupled in vitro transcription-
translation of Socs4a was performed in the presence of the ATG MO or standard 
control MO (Ctl MO). This generated a band of the appropriate size for Socs4a 
(44 kD) when incubated with the Ctl MO, which was substantially abrogated in 
the presence of the Socs4a ATG MO (Fig 4.3B).  
MOs were delivered by microinjection into 1-8 cell stage embryos, which were 
then monitored by light microscopy at key developmental time-points for 
identification of phenotypic perturbations. The standard control MO (Ctl) was 
used to control against potential injection or vehicle induced phenotypes. 
Concentrations of MOs injected were optimized to a delivery dose that allowed 
for maximum phenotypic changes without inducing non-specific side effects. 
Embryos injected with the socs4a ATG MO first displayed phenotypic 
abnormalities during epiboly. In affected embryos, epiboly was marginally 
delayed and in a small subset of these morphants, epiboly did not reach 
completion, but rather stalled at approximately 90%. As development continued, 
embryos demonstrated a ventral tail curl from 24 hpf (Fig 4.3D-E, G-H) 
associated with perturbed development of the notochord, a rod-shaped structure 
essential for providing support and defining the primitive anterior-posterior (A-P) 
axis. The socs4a UTR MO also produced ventral tail curl (36%), although the 
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penetrance of this MO was not as great as that seen with the ATG MO (82.4%). 
Embryos treated with Std Ctl MO did not display any phenotypes (Fig 4.3C, F).  
To confirm the specificity of the ventral curl phenotype, the Socs4a UTR MO was 
co-injected on three separate occasions with synthetic capped mRNA encoding 
Socs4a but lacking the morpholino target sequence. This provided a mild rescue 
of the phenotypic defects produced, with 36% affected in those injected with UTR 
MO and 27% affected in those injected with UTR MO/RNA (Fig 4.3H, F, I). In 
addition, no embryos injected with UTR MO/RNA displayed the severe curling 
notochord phenotype compared to 7% in embryos injected with UTR MO alone. 
These results confirmed the specificity of phenotypes induced by the Socs4a 
UTR MO.  
In order to elucidate potential mechanisms underlying the ventral tail curl 
observed in Socs4a morphants, the notochord, which provides structural support 
during the development of embryos, and its associated structures were closely 
examined. Light microscopy revealed the notochord to be undulating in Socs4a 
morphant embryos, a phenotype which varied in severity. Close examination of 
the large vacuolated epithelial cells that fill the notochord, revealed no obvious 
morphological abnormalities, although cells appeared to be slightly compressed 
when compared to control embryos (Fig 4.3J-K).  
The floor plate, the ventral most component of the neural tube runs parallel with 
the notochord and abnormalities or absence of the floor plate has been 
associated with notochord curvature in zebrafish [334]. The hypochord, located 
ventral to the notochord plays a role in positioning the dorsal aorta [335]. 
However, both the floor plate and the hypochord were present in Socs4a 
morphants (Fig4.3 J-K). Measurement of morphant embryos at 4 dpf revealed 
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that, those displaying notochord phenotypes were significantly shorter along the 
A-P axis than age-matched control embryos, including at 48 hpf (Fig 4.3L).  
Light microscopic examination of the somites at all later time-points revealed that 
somite boundaries in socs4a ATG morphants were often not linear, but rather 
were curved, a potential consequence of inadequate structural support from the 
notochord (Fig 4.3M-N). Muscles fibers of the somites were examined at 72 hpf 
using fluorescently labeled phalloidin to highlight F-actin. This confirmed results 
seen by light microscopy, with individual muscle fibers structurally normal, but 
with a disturbed distribution as a result of overall ventral curvature (Fig 4.3O-P). 
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Figure 4.3 Phenotypic consequences of Socs4a knockdown 
Targeting of socs4a by morpholinos (A), showing mRNA schematic with 
sequences targeted by UTR MO and ATG MO indicated. Confirmation of 
morpholino efficacy by in vitro transcription and translation of socs4a in the 
presence of standard control (Std Ctl MO) or Socs4a ATG MO (1 mM) with 
asterisk indicating the position of the Socs4a protein at ~44 kDa (B). Analysis of 
embryos injected with Ctl MO (C, F, J, M, O), Socs4a ATG MO (D, E), Socs4a 
UTR MO (G, K, N, P) or both Socs4a UTR and in vitro transcribed socs4a mRNA 
(UTR/RNA) (H), by either light microscopy (C-H, J-K, M-N) or phalloidin staining 
of muscle fibers (O-P). All embryos are positioned with their anterior to the left 
and images are lateral view. Quantification of ventral curl phenotype in Ctl, ATG 
MO and UTR MO treated embryos (I) showing the extent of notochord disruption. 
Dot graph displaying embryos length (anterior-posterior) of Ctl and ATG MO 
embryos at 4 dpf with mean shown in black and standard error of mean in red 
(L). Statistical significance (p<0.05) between data sets as determined by t-test is 
indicated by a red asterisk. 
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Molecular analysis of Socs4a knockdown 
To more closely examine notochord and floor plate integrity, morphants were 
subjected to WISH with sonic hedgehog (shh), a marker of the developing 
notochord and floor plate [336]. This revealed severe undulations of the 
notochord at 24 hpf (Fig 4.4B-C, E), compared to controls (Fig 4.4A, D, F) and in 
a very small number of embryos, revealed a split posterior notochord (Fig 4.4C), 
although floor plates were present. Morphants were also examined for expression 
of ihhb, present in the chordamesoderm before its differentiation into notochord 
and prior to inflation of the vacuoles. This was expressed at normal levels 
compared to controls, albeit in an undulating location (Fig 4.4F-G). Staining with 
shh at 9 somites revealed the undulations and split notochords were already 
present at this early time-point (Fig 4.4H-J). 
To further Investigate the phenotype observed, the processes that lead to the 
mature notochord formation, convergence and extension of the cells of the dorsal 
midline (the presumptive cells of the notochord) were carefully examined. The no 
tail (ntl) gene is expressed in the shield and presumptive notochord cells, and is 
essential for the development of the notochord and the convergence process 
[337]. Expression levels of ntl in the germ ring and shield of Socs4a morphants 
were relatively unaltered, but the distribution of ntl+ cells highlighted a 
perturbation of convergence and extension when compared to control embryos 
at the equivalent time-points. Indeed, in a number of morphant embryos, ntl+ cells 
did not completely converge at the midline and did not fully extend from the 
vegetal pole together towards the animal pole (Fig 4.4K-M). To confirm this 
potential convergence and extension defect, expression of floating head (flt) (Fig 
4.4N-P), a gene which marks cells fated to become notochord [334], and snail1a 
(sna1) (Fig 4.4Q-S), a marker for involuting cells of the germ ring adjacent to the 
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dorsal midline [338], was examined. In both cases,  incomplete convergence of 
the marked cells was revealed.  
To determine whether this phenotype also affected tissues surrounding the 
notochord, myogenic differentiation 1 (myoD) was used to stain paraxial 
mesoderm, which flanks the developing notochord and neural tube and gives rise 
to somites and ultimately muscle [339]. Expression of myoD in the paraxial 
mesoderm of Socs4a ATG morphants at 9 somites was undulated, with 
expression in the developing somites reduced (Fig 4.4T-U). The distance 
between the paired paraxial mesoderm tissues was found to be significantly 
greater in morphants at 9 somites (Fig 4.4T-U), with the distance from anterior to 
posterior measured across the yolk, also significantly longer (Fig 4.4U-W). These 
data suggest that at 9 somites, Socs4a morphants were significantly shorter and 
wider than control embryos. 
Notochord signaling also plays a role in zebrafish pancreas patterning, with areas 
of shh signaling associated with an absence of expression of pancreatic markers 
[340]. Therefore expression of insulin (ins), a marker of the endocrine pancreas-
specific β-cells was examined. At 30 hpf, ectopic ins expression was noted in 
Socs4a morphants, with 43.8% of Socs4a ATG morphants displaying at least 2 
separate populations of ins expressing cells (Fig 4.4Z, a). 
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Figure 4.4 Effect of Socs4a knockdown on convergence and extension  
Embryos injected with either Ctl MO (A, D, F, H, K, N, Q, T, W, Z), UTR MO (B-
C, E, G, I-J, L-M, O-P, R-S, a) or ATG MO (U, X) were subjected to WISH at 24 
hpf (A-G), 10 hpf (H-J), 80% epiboly (K-S), 9 somites (T-U, W-X) and 30 hpf (Z, 
a) for shh (A-E, H-J), ihhb (F-G), ntl (K-M), flh (N-P), sna1 (Q-S), myoD (T-U, W-
X) and ins (Z, a). Both mild (B, I, L, O, R) and severe (C, J, M, P, S) phenotypes 
are shown. Graphical representation at 9 somites of distance between parallel 
paraxial mesoderm structures (V) and distance across yolk from anterior to 
posterior (Y). Statistical significance (p<0.05) as determined by t-test is indicated 
by a red asterisk. 
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Effect of Socs4a knockdown on the sensory system 
Expression of socs4a was identified in several cranial nerves, including cranial 
ganglia and the presumptive dorsal root ganglia, which contain cell bodies of 
afferent sensory nerves from the anterior and trunk, respectively. Expression 
analysis of the sensory motor neuron specific marker isl1 revealed substantially 
reduced expression in the sensory motor neurons of the hindbrain and anterior 
portion of the trunk at both 22 and 26 hpf when compared to controls (Fig 4.5A-
F). Given this observation, the mechanosensory response in Socs4a morphants 
was investigated. Embryos were subjected to a light touch with a fine stimulus 
just posterior to their otic vesicle to measure touch sensitivity and response [341]. 
Embryos were then categorized according to them time taken to respond, as 
indicated by movement away from the stimulus: either immediate, delayed or no 
response. Both Socs4a ATG (n=62) and UTR (n=80) morphants displayed an 
immediate response to touch in 50-52% of embryos, a delayed response in 16-
21% and no response in 28-32%, whereas 93% of Std Ctl embryos (n=109) 
displayed an immediate response (Fig 4.5G). This suggests a defective touch 
response in morphant embryos.  
Socs4a was also found to be expressed in the anterior and posterior lateral line 
ganglia, which innervate the neuromast structures of the lateral line, responsible 
for detection of water movement. MitoTracker dye was used to visualize the 
mitochondrial rich neuromasts, allowing examination of number, distribution and 
gross morphology. Neuromasts numbers in Socs4a morphants did not vary from 
numbers seen in Ctl embryos and displayed normal morphology (Fig 4.5H-J). 
The function of the lateral line neuromasts was tested by analysis of vibration 
detection and response at 3 dpf, when the lateral line mechanosensory system 
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is fully functional. No difference in response to water vibration was observed with 
ATG morphants when compared to Ctl (data not shown).  
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Figure 4.5 Mechanosensory analysis in Socs4a knockdown embryos 
Embryos were injected with Ctl MO (A, D, H), Socs4a ATG MO (B, E, I) or Socs4a 
UTR MO (C, F, J). WISH staining with isl1 probe was used to examine presence 
or absence of sensory neurons at 22 hpf (A-C) or 26 hpf (D-F). Response time to 
facial touch quantified at 24 hpf (G). Mitotracker red (mit) staining at 3 dpf to 
visualize lateral line neuromasts (H-J). Statistical significance (p<0.05) is 
indicated by a red asterisk. 
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4.5  Discussion 
SOCS4 remains the least well-characterized member of the SOCS family. 
Utilizing the zebrafish as a powerful alternative developmental model, this 
Chapter aimed to elucidate the embryonic expression profile and in vivo function 
of the zebrafish Socs4 paralogue, socs4a. 
The socs4a gene was investigated using 5’RACE, which identified the 
transcriptional start site and confirmed the identity of the likely start codon utilized 
during embryogenesis, facilitating the design of appropriate translation blocking 
anti-sense morpholinos. Analysis of the socs4a promoter revealed conservation 
of several putative neuronal and hematopoietic transcription factor binding sites 
between mouse SOCS4 and zebrafish socs4a, alluding to possible conserved 
expression during neurogenesis and hematopoiesis. However, analysis of the 
3’UTR revealed no conservation of the let-7 microRNA binding site found in 
mammalian SOCS4 genes in zebrafish socs4a, indicating that this mode of 
regulation is not conserved for socs4a.  
The phylogenic analysis presented in Chapter 3 revealed that the zebrafish socs4 
paralogues have diverged, with zebrafish Socs4a  protein more divergent from 
human Socs4 than zebrafish Socs4b. Analysis of other gene paralogues have 
shown that such genes may retain overlapping function to their mammalian 
orthologues, or may have divided the functional roles of the original orthologue 
or one or both of the genes may have taken on a novel function. Since socs4a is 
more divergent of the two socs4 paralogues, including loss of a miRNA-mediated 
regulatory element, it is perhaps more likely to have taken on a teleost specific 
functional role. 
Mammalian SOCS4 has been shown to be expressed in adult tissues including 
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the olfactory bulb, thymus and intestine 
(http://biogps.org/#goto=genereport&id=122809) [239], but the embryonic 
expression pattern of mammalian SOCS4 is yet to be described. RT-PCR 
analysis revealed zebrafish socs4a to be expressed throughout embryonic 
development, with the highest transcript levels identified at 31 hpf. WISH analysis 
identified a dynamic and complex spatio-temporal expression pattern during 
embryogenesis. Transcripts were observed at 1 cell, confirming maternal 
derivation, as zygotic expression begins around 3 hpf [314, 342, 343]. Broad 
expression was seen at the shield stage, around the onset of zygotic expression 
indicating that socs4a could function during gastrulation or epiboly. At 17 hpf, 
socs4a expression was restricted to developing cranial ganglia and peripheral 
neurons. By 24 hpf expression had expanded to include several more cranial 
ganglia and neurons associated with touch sensation, and later expression was 
restricted to the anterior and posterior lateral line ganglia, structures associated 
with the innervation of the neuromasts in the lateral line. The largely neuronal 
embryonic expression pattern was consistent with RT-PCR analysis of adult 
zebrafish tissue, with highest socs4a expression seen in the brain. With the 
exception of the olfactory bulb, mammalian Socs4 expression has not been 
described in neuronal tissues, adding to the likelihood that socs4a has a 
divergent function. 
In vitro mammalian SOCS4 has been shown to bind with strong affinity to the 
same phosphotyrosine on the EGF receptor as STAT3, thereby inhibiting STAT3 
activation [26]. This Chapter identified several potential STAT3 binding sites in 
the socs4a promoter. Importantly, expression of zebrafish stat3 overlaps with that 
of socs4a, including at the onset of epiboly and again towards the end of 
gastrulation [344, 345]. In addition, zebrafish stat3 has been shown to be 
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expressed in a variety of sensory neural structures including the anterior and 
posterior lateral line ganglia, trigeminal ganglia and statoacustic at 24 hpf. This 
overlap with locations of socs4a expression suggests that the STAT3 sites in the 
socs4a promoter are likely functional. This collectively suggests that Socs4a 
could function as a negative feedback regulator of STAT3, similar to CISH and 
STAT5 [71], although this remains to be validated. Interestingly, zebrafish stat3 
is thought to have a role in the convergence and extension process [344]. 
To investigate Socs4a function, a morpholino-mediated knockdown strategy was 
employed. This induced phenotypes as early as the shield stage. Analysis with 
the markers flh and ntl, genes essential for convergence/extension and notochord 
development, indicated reduced convergence of cells medially and reduced 
extension of cells towards the animal pole. This was confirmed with sna1, a 
marker for cells located outside the shield, as well as a general disorganization 
of cells at these sites. Correct convergence extension is essential for the normal 
development of the embryonic notochord. Analysis with shh revealed that the 
notochord was disrupted from its normal rod-like appearance, potentially causal 
to morphants being significantly shorter and curlier than control embryos by 4 dpf. 
In some rare cases, a “split” notochord phenotype was observed, likely due to the 
incomplete convergence of cells fated to develop the notochord. However, 
analysis using both light microscopy and WISH analysis with shh and ihhb 
revealed the notochord, floor plate and hypochord were all present. This data, 
taken together with the convergence extension defects noted, suggest that it is 
the essential process of convergence extension that leads to a failure of the 
notochord to converge medially and elongate fully, rather than an intrinsic 
notochord defect per se.  
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The notochord provides structural support as well as secreting signaling 
molecules influencing surrounding tissues. Staining with myoD at 9 somites 
revealed the paraxial mesoderm and developing somites, which lie adjacent to 
the notochord, also had an undulating pattern in Socs4a morphants, as well as a 
reduction in myoD expression. Light microscopy and phalloidin staining of muscle 
fibers revealed undulating and curved somite boundaries in morphants at 4 dpf, 
while also revealing individual muscle fibers were less extended horizontally than 
those seen in control embryos, concominant with a decrease in overall body 
length. Perturbations to somite and muscle development are likely an indirect 
consequence of abnormal convergence extension and/or incomplete notochord 
elongation. 
Signaling by shh from the notochord also plays a role in expression of ins in the 
β-cells of the endocrine pancreas. In contrast to the single population of ins+ 
cells, located medially, a large portion of Socs4a morphants had multiple distinct 
ins+ cell populations, suggesting that the abnormal notochord may indirectly 
affect patterning. Alternatively, convergence of the two endocrine precursor 
populations medially at 16 hpf, may have been incomplete in morphants as part 
of the convergent extension defect, resulting in additional ins+ cell populations. 
Analysis with the isl1 marker, expressed in many cranial ganglia and sensory 
neurons, revealed a significant reduction of isl1+ cells in the hindbrain and 
anterior trunk at 22 hpf. It is hypothesized that these cells are likely presumptive 
dorsal root ganglia or Rohon Beard neurons, both of which are involved in 
mediating mechanosensory sensation. Reduced numbers of isl1+ cells was 
confirmed over several time-points from 18-26 hpf, which suggests that these 
sensory cells failed to develop in Socs4a morphants rather than simply being 
delayed in development. Socs4a morphants were also found to be less 
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responsive to touch, with ~20% displaying a delayed response and ~30% 
exhibiting no response in both ATG and UTR morphants compared to ~5% and 
~3% respectively in control embryos. It is yet to be confirmed whether the 
decrease in isl1 expression or reduction in size/function of these sensory neurons 
is directly linked to the touch response defect identified in Socs4a morphants. 
The mechanism behind this loss of isl1 expression is also yet to be fully 
investigated. 
Finally, the strong expression of socs4a in the anterior and posterior lateral line 
ganglia, were examined further. Neuromasts of the lateral line, the sensory 
organs responsible for detection of water movement, are innervated by the lateral 
line ganglia. Close examination of neuromasts by Mitotraker Red staining did not 
reveal any structural abnormalities to the embryonic neuromasts in either the 
ATG or UTR morphants, and there was no detectable difference in water vibration 
response between Socs4a morphants and controls. 
Collectively, Chapter 4 has revealed a dynamic expression profile of socs4a 
during embryogenesis, initially ubiquitously expressed but becoming restricted to 
sensory ganglia as development progressed, with expression in adult zebrafish 
brains. Knockdown of zebrafish Socs4a revealed several phenotypes that were 
consistent with the socs4a expression profile, with perturbation of the 
convergence extension process and subsequent undulating notochord, along 
with a delayed response to touch stimuli. While it was outside the scope of this 
Chapter to investigate regulation of the socs4a gene, the presence of STAT3 
sites in the socs4a promoter, the overlapping expression of stat3 with socs4a and 
ablation of both genes affecting similar processes, suggests that functional 
interaction with STAT3 may play a key role in the biology of Socs4a.  
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Chapter 5: 
Characterization of 
zebrafish socs4b 
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5.1 Introduction 
Knowledge regarding the function of mammalian SOCS4 is limited, with in vitro 
studies demonstrating a regulatory role for SOCS4 in EGFR signaling [6, 225]. 
The work described in Chapter 3 revealed the presence of two zebrafish SOCS4 
paralogues, socs4a and socs4b. This Chapter aimed to broadly characterize 
socs4b, including analysis of the socs4b gene locus, examination of the socs4b 
spatio-temporal expression pattern and the production of a germline socs4b 
mutant zebrafish line using ZFN technology to assess the role of socs4b during 
embryogenesis. 
5.2 Analysis of the socs4b gene locus 
Promoter analysis  
To understand the regulation of socs4b, potential transcription factor binding sites 
in the three thousand base pairs preceding the transcription start site of both 
mouse Socs4 and zebrafish socs4b were analyzed and compared using TESS. 
As with socs4a, sites for a range of general transcription factors were found, 
along with sites for a variety of neuronal and hematopoietic factors (Fig 5.1). This 
suggests conservation in function of the SOCS4 genes between zebrafish and 
mammals, and alludes to possible roles in both neurogenesis and hematopoiesis, 
as was seen in the socs4a analysis. In addition, the presence of STAT binding 
sites was also examined as many SOCS genes are known to be regulated by 
STATs as part of the JAK-STAT-SOCS pathway. This analysis identified the 
presence of 6 potential STAT3 binding sites and a further 43 generic STAT sites 
in the region upstream of the socs4b 5’UTR region.  
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microRNA analysis  
Human SOCS4 expression has been shown to be regulated by members of the let-
7 family of microRNAs, including miR-98, via a partially complementary sequence in 
the 3’ UTR [62]. Therefore the 3’ UTR of mouse Socs4 and zebrafish socs4b were 
analyzed for potential binding sites for species-specific microRNAs of the let-7 family. 
As described in Chapter 4, a predicted binding site for mmulet-7e, mmulet-7g, 
mmulet-7b, mmulet-7d, mmulet-7a, mmulet-7c, mmulet-7f and mmulet-7i was found 
in the 3’UTR of mouse Socs4, similar to that seen in the human sequence. A single 
binding site in the zebrafish socs4b 3’ UTR was also predicted to interact with for 
drelet-7b, drelet-7c and drelet-7d (Fig 5.1). 
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Figure 5.1 Characterization of the socs4b gene locus  
The mouse Socs4 (A) and zebrafish socs4b (B) loci were analyzed for conserved 
transcription factor and microRNA binding sites using online prediction tools. The 
position and frequency of potential sites for neuronal, general and hematopoietic 
transcription factors in the promoter regions are represented by the numbers 
inside the shapes. The position and details of potential let-7 binding sites in the 
3’UTR region are shown, with corresponding free energy associated with 
microRNA binding (ΔΔG). 
  
 143 
5.3 Expression analysis of zebrafish socs4b  
To gain insight into potential in vivo roles of socs4b, embryonic and adult 
expression of the gene was analyzed. To characterize temporal embryonic 
expression of socs4b, semi-quantitative RT-PCR was employed as described in 
Chapter 4. This analysis was performed with socs4b specific primers designed to 
the first half of the coding region, covering the N-terminal domain, the most 
diverse domain amongst SOCS members, and part of the SH2 domain. Products 
of the appropriate size were visualized on agarose gels with representative 
products sequenced to confirm their identity. This revealed socs4b expression at 
all time-points tested during embryogenesis. Expression levels of the house 
keeping gene β-actin were consistent across all time-points, while samples 
containing reverse-transcriptase negative templates yielded no products, ruling 
out potential gDNA contamination (Fig 5.2A). Transcripts of socs4b were evident 
at the 1 cell stage, indicating maternal derivation, with levels decreasing slightly 
at 8 hpf before increasing again at 12 hpf due to zygotic expression. Expression 
levels plateaued at this point, remaining consistent until the end point of analysis 
at 6 dpf. In adult zebrafish, RT-PCR analysis of multiple tissues revealed broad 
expression of socs4b, with highest levels in the heart, gills and spleen, moderate 
levels in the liver, eggs, kidney and brain, and lowest levels in skeletal muscle 
(Fig 5.2B). 
With embryonic expression of zebrafish socs4b confirmed, whole-mount in situ 
hybridization was employed to determine the spatio-temporal expression pattern 
of the gene. An anti-sense RNA probe was generated against the full-length 
socs4b coding region and labeled with digoxigenin. WISH was performed on fixed 
WT embryos at several time-points across embryogenesis, with a full-length 
sense socs4b probe used as a control for non-specific staining. Broad anterior 
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expression became evident by WISH at 48 hpf (data not shown) and by 3 dpf 
expression had became concentrated third and fourth ventricle boundary as well 
as the retina (Fig 5.2C-E), with expression remaining at 5 dpf (Fig 5.2F-H) and 7 
dpf (data not shown).  
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Figure 5.2 Spatio-temporal expression profile of socs4b  
RT-PCR using total RNA extracted from embryos at the indicated times post 
fertilization (A, upper panel) or from adults tissues (B, upper panel). Levels of 
socs4b were quantified using densitometry and standardized to the control gene 
(β-actin) relative to expression at 1 cell for embryos (A, lower panel), or gills for 
adults (B, lower panel). Whole-mount in situ hybridization analysis of socs4b on 
embryos at 3 dpf (C-E) and 5 dpf (F-H) using either sense (Ctl) or anti-sense 
(socs4b) probes. Asterisk indicates ventricle boundary and arrowheads indicate 
retina. 
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5.4 Targeted knockout of zebrafish socs4b  
Preliminary investigations of socs4b function in vivo using a translational blocking 
MO produced phenotypes reminiscent of documented off-target effects 
commonly produced by MOs [346]. Therefore, an alternative approach was 
required to investigate the in vivo role of Socs4b. Zinc Finger Nuclease mediated 
mutagenesis was utilized to produce a socs4b mutant for further analysis. 
A pair of ZFNs targeting an area 6 bp downstream of the start codon were 
designed and constructed by a commercial supplier (Fig 5.3).  In vitro transcribed 
RNA encoding each ZFN was injected into single cell embryos. To confirm the 
efficiency of ZFN targeting, a sample of injected embryos were sacrificed for 
gDNA extraction and PCR, followed by analysis with Cel-I nuclease to identify 
embryos with potential alterations at the target site. Embryos injected with 400 
pg of socs4b ZFN showed a 3.3% mutation rate at the target site using this 
method (data not shown). Therefore, embryos injected at this dosage were raised 
to adulthood and subsequently mated with WT fish once they had reached sexual 
maturity, and offspring screened for germ line socs4b mutations via the PCR/Cel-
I method. This process identified a number of potential mutants, with sequence 
analysis confirming two independent mutants from a single founding male 
zebrafish. The first mutation was a 3 bp deletion after the start codon of the 
socs4b gene and the second was an 18 bp deletion that included the socs4b start 
codon (Fig 5.3B). While both represent in-frame deletions, the 18 bp deletion 
termed socs4bΔ18 included the start codon, with the next available in-frame 
methionine 131 amino acids downstream of the deletion site and approximately 
half way into the NTCR4-5 domain, if used at all.  
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Due to the absence of a commercially available antibody against zebrafish 
Socs4b, analysis of the encoded protein was not possible. To analyze potential 
protein production, expression plasmids (pBK-CMV) containing either the WT 
socs4b or socs4bΔ18 sequence were produced and used in a TNT Quick 
Coupled Transcription/Translation System reaction. The WT socs4b produced a 
protein product at the expected size of 54.7 kDa while the socs4bΔ18 template 
produced no product at 54.7 kDa, but instead produced a small amount of protein 
product at approximately 40-45 kDa, close to the predicted size for a protein 
generated from the second in-frame methionine, suggesting this methionine is 
poorly utilized. To confirm mRNA expressed in socs4bΔ18 fish contained the 18 
bp deletion, primers sets were designed to regions encoding the N-terminal and 
the C-terminal of socs4b and used in RT-PCR analysis (Fig 5.3D). A shorter 
product was seen using the N-terminal primers with socs4bΔ18 compared to WT 
sibling template, with but no difference in product size was noted when comparing 
C-terminal primer products.  
This 18 bp deletion allele of socs4b was backcrossed for 3 generations as 
confirmed by analysis of gDNA from fin clips (Fig 5.3E). Heterozygotes were then 
in-crossed to produce a homozygote line. Inheritance of the 18 bp deletion allele 
was tracked in offspring and was found to follow the classic Mendelian 
inheritance pattern. The socs4bΔ18 offspring were subsequent analyzed 
phenotypically in comparison to a WT line derived from littermates. Embryos were 
carefully assessed by light microscopy from 1 cell to 7 dpf, but no developmental 
abnormalities were observed (Fig 5.3F-I). Histology was also used to further 
investigate morphology of sectioned 5 dpf embryos, but again no abnormalities 
were detected (data not shown). As SOCS4 and SOCS5 are closely related and 
are thought to have some areas of overlapping function, transcript levels of all 
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socs4 and socs5 paralogues were examined by quantitative RT-PCR in 
socs4bΔ18 embryos at 24 hpf, which revealed small, but non significant, changes 
in transcript levels of all four zebrafish socs4 and socs5 genes (Fig 5.3J). 
To further investigate phenotypic consequences in the socs4bΔ18 line, WISH 
analysis was performed using markers for key cell populations during 
development. These were selected based on information from promoter analysis, 
roles of the socs4a paralogue, and roles of other SOCS family members. Genes 
included islet 1 (isl), marking CNS anatomy at 24 hpf, including sensory ganglia, 
sonic hedgehog (shh), marking the developing notochord at 24 hpf, insulin (ins), 
marking the β cells of the developing endocrine pancreas at 30 hpf, lysozyme 
(lyz), marking myeloid at 48 hpf and recombination activating gene 1 (rag1) 
marking T lymphocytes at 4 dpf. In addition, O-dianisidine staining was used to 
detect hemoglobin and Mitotracker red was used to examine presence and 
morphology of lateral line neuromasts. These analyses revealed no abnormal 
distribution of marked cells or alterations to expression levels in socs4bΔ18 
embryos when compared to WT controls (Fig 5.4A-K). in addition, qRT-PCR was 
performed on 7 dpf embryos with lyz and rag1 primers. Analysis did not reveal 
any statistically significant transcript changes in socs4bΔ18 embryos (Fig 5.4L). 
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Figure 5.3 Zinc-finger nuclease mediated targeting of zebrafish socs4b and 
phenotypic analysis of mutants 
Sequence of zebrafish socs4b wild type (A) and socs4bΔ18 (B), including 
corresponding chromatogram, with nucleotides numbered relative to mRNA and 
translation shown below, with the start methionine indicated by a red box and the 
sequences targeted by the ZFN pair indicated. Deleted nucleotides in socs4bΔ18 
are indicated by a broken line box showing the alternate amino acid sequence, 
with the next in-frame methionine indicated by a pink box. In vitro 
transcription/translation analysis of sequences encoding socs4b WT and 
socs4bΔ18 along with no template control (NTC) (C). Red asterisk indicates full-
length socs4b protein product and blue asterisk indicates truncated protein 
product. RT-PCR on RNA from pooled WT (+/+) and socs4bΔ18 (Δ/Δ) siblings at 
24 hpf and 7 dpf (D). Primers were specific to the regions encoding the socs4b 
N-terminus (N-term) and C-terminus (C-term) as shown along with those to β-
actin and control, with RT negative controls (-) shown for all time points (D). The 
shorter transcripts in Δ/Δ embryos with N-terminal primers are indicated with red 
arrows. PCR from gDNA from offspring of +/Δ and +/Δ intercross, showing +/+, 
+/Δ and Δ/Δ progeny (E). Light microscopy images of WT (+/+) (F, H) and 
socs4bΔ18 sibling (Δ/Δ ) (G, I) embryos at 2 dpf (F,G) and 3 dpf (H, I). Lateral 
view of embryos, with anterior to the left. Quantitative RT-PCR performed on 
mRNA extracted from +/+ and Δ/Δ embryos for socs4a, socs4b, socs5a and 
socs5b, with error bars indicating the standard error of the mean. Statistical 
significance (p<0.05) between data sets as determined by t-test is indicated by a 
red asterisk. 
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Figure 5.4 Molecular characterization of socs4bΔ18 mutants  
WISH analysis of WT (+/+) (A, D, G), socs4bΔ18 embryos (Δ/Δ) (B, E, H) and 
offspring of heterozygote in-cross (mixed) that contain a mix of +/+, +/Δ and Δ/Δ 
embryos (C, F, I), with ins (A, B), shh (C), isl (D, E), lyz (G, H) and rag1 (I) or 
staining with O-dianisidine (O-di) (F) and Mitotracker red (mito) (H, J), including 
a close up of neuromasts. Quantitative RT-PCR on mRNA extracted from +/+ and 
Δ/Δ embryos for relative expression of lyz and rag1 (L). Error bars indicate the 
standard error of the mean. Statistical significance (p<0.05) between data sets 
as determined by t-test is indicated by a red asterisk. 
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5.5 Regulation of EGFR signaling by zebrafish Socs4b 
Since SOCS4 has been previously implicated in EGFR signaling [26], potential 
interactions for Socs4b in EGFR signaling were investigated. Sequences 
encoding 5’FLAG tagged full-length (FL) Socs4b were cloned into the expression 
vector pBK-CMV, along with those encoding a 5’FLAG tagged Socs4b sequence 
lacking its SOCS box. These plasmids, along with the empty pBK-CMV vector, 
were transfected into human embryonic kidney 293T cells (HEK293T). At 48 post 
transfection, cells were stimulated with 20 ug EGF for 15 min, 45 min, 2 h or left 
unstimulated. Proteins were isolated from cell samples and analyzed via Western 
blotting (Fig 5.5A). To assess EGF signaling, phosphorylation of EGFR (pEGFR) 
and ERK (pERK), which lies downstream of EGFR, was assessed relative to total 
ERK (tERK) and GAPDH loading controls. This revealed an initial increase in 
both pEGFR and pERK in empty vector samples at 15 min post stimulation, which 
decreased slightly by 2 h post stimulation. Cells transfected with WT Socs4b 
showed enhanced levels of pEGFR at 15 min, which was similar to the empty 
vector control by 2 h, while pERK levels were reduced at later time points. SOCS 
box truncated Socs4b samples however, showed a similar pEGFR levels at 15 
min but these were reduced at 2 h post stimulation when compared to both empty 
vector and FL Socs4b. In contrast, pERK levels were lower initially and then 
increased, being highest at 2 h post stimulation. Anti-FLAG was used to confirm 
the expression of the two Socs4b constructs, with products at the expected sizes 
of 54.7 kDa (FL) and 44.8 kDa (ΔSOCS box). Interestingly, levels of WT Socs4b 
decreased over the time course, while those of the ΔSOCS box mutant remained 
constant.  
To confirm an interaction with the EGFR pathway in vivo, quantitative RT-PCR 
was used to measure expression levels of early growth response protein 1 (egr1), 
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a transcription factor whose expression is known to be induced by EGF signaling 
through the ERK – ELK1 signaling pathway in mutant embryos [347]. Quantitative 
RT-PCR revealed a statistically significant (t-test) 5.12-fold increase in egr1 
levels in socs4bΔ18 embryos at 26 hpf and a 3.69-fold increase at 7 dpf (Fig 
5.5B). 
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Figure 5.5 Analysis of potential interaction of zebrafish Socs4b with EGFR 
pathway  
HEK293T cells were transfected with empty vector control, or plasmids encoding 
Socs4b full-length or Socs4b ΔSOCS box and 48 hours later stimulated with EGF 
for the time indicated. Protein was extracted and subjected to Western blots with 
antibodies against Flag to confirm plasmid expression, pEGFR, pERK, tERK and 
GAPDH as a loading control (A). All Western immunoblotting was replicated at 
least twice on independent protein samples. Quantitative RT-PCR on mRNA 
extracted from +/+ and Δ/Δ embryos for relative expression of egr1 at 24 hpf and 
7 dpf, statistical significance between +/+ and Δ/Δ samples is indicated by a red 
asterisk (B).  
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5.6 Discussion 
This Chapter addressed the paucity of information on SOCS4 by using zebrafish 
as a developmental model to investigate the in vivo function of the zebrafish 
SOCS4 paralogue, socs4b. This Chapter involved the application of the emerging 
genome editing technology to create a socs4b mutant for functional analysis. In 
parallel, in vitro properties of zebrafish socs4b were also investigated, providing 
some mechanistic insights.  
Promoter analysis of the zebrafish socs4b gene revealed conservation of putative 
neuronal and hematopoietic transcription factor binding sites with mouse Socs4, 
consistent with what was seen in the socs4a promoter analysis. In contrast, a let-
7 microRNA binding site identified in mouse Socs4 3’UTR was conserved in the 
zebrafish socs4b 3’UTR but not that of socs4a. This adds some extra weight to 
the suggestion that socs4b is more closely conserved with SOCS4 than its 
paralogue, socs4a.  
Mammalian Socs4 is expressed in the adult olfactory bulb, thymus and intestine. 
RT-PCR analysis of adult zebrafish tissue showed broad expression of socs4b, 
with relatively consistent expression levels across most of the tissues analyzed, 
with highest transcript levels seen in the heart, followed by the gills and spleen. 
The embryonic expression pattern of socs4 is yet to be described. RT-PCR 
revealed zebrafish socs4b was maternally derived and expressed relatively 
consistently throughout embryogenesis. WISH analysis demonstrated broad 
anterior expression to 3 dpf. However, at 3 dpf, neuronal expression narrowed 
and became evident in cells lining the third and fourth ventricles, which continued 
to 5 dpf. By this time-point, expression was also evident in multiple cell layers of 
the retina of the developing eye.  
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Interestingly, as was the case with socs4a, some locations of socs4b mRNA 
expression overlapped with sites of stat3 expression. In particular, zebrafish stat3 
has been shown to be expressed in the retina and cells lining the ventricles of the 
brain [345], although expression of stat3 at this location was more extensive than 
that of socs4b. These overlapping sites of expression suggest these genes may 
interact in the same signaling pathways, although much additional analysis would 
be required to fully investigate this relationship.  
To investigate the in vivo function of socs4b, genome-editing technology was 
employed. Use of a commercially generated zinc finger nuclease resulted in the 
production of several mutants, including an in-frame 18 bp deletion of socs4b, 
termed socs4bΔ18, which removed the socs4b start codon. Commercial 
antibodies against mammalian SOCS4 and custom-made antibodies targeting 
both the N-terminal (prior to the second in frame methionine) and the C-terminal 
of zebrafish Socs4b were trialed (data not shown). Unfortunately, neither 
approach resulted in detection of Socs4b protein. Therefore, as an alternative 
approach to understand the consequences of the 18 bp deletion, an in vitro 
transcription/translation was utilized. This in vitro assay demonstrated production 
of full-length Socs4b protein from the WT sequence and confirmed the absence 
of full-length Socs4b production of protein from the socs4bΔ18 allele. Reduced 
amounts of a truncated Socs4b was observed, consistent with weak utilization of 
the next in-frame ATG, resulting in a protein missing the N-terminal 130 amino 
acids, including NTCR4/5 sequences. RT-PCR was also engaged to ensure this 
mutation was present in transcribed mRNA, with no alternative transcripts by-
passing the mutation observed. This suggests that the socs4bΔ18 allele is likely 
to be hypomorphic rather than a complete knockout. However, only successful 
production of customized Socs4b antibodies will definitively confirm Socs4b 
 160 
knockout or knockdown at the protein level. 
Generation of the socs4bΔ18 allele allowed the analysis of potential in vivo 
function. External monitoring of embryos by light microscopy revealed no overt 
abnormalities during development, with WISH markers for neurons, endocrine 
pancreas, notochord and blood cells revealing no obvious changes. Quantitative 
RT-PCR was employed to confirm results seen by WISH and examine genes that 
could not be visualized by WISH. This lack of developmental phenotype is 
consistent with the recently described Socs4 knockout mouse in which no 
developmental phenotype was described [242]. Compensation/redunancy may 
help explain this absence of a phenotype.  
Published data regarding SOCS4 has suggested that it plays a role in the 
regulation of EGFR signaling, where it binds with high affinity to the same EGFR 
phosphotyrosine site as STAT3, a known downstream signaling molecule. This 
knowledge prompted in vitro investigation of the effects of Socs4b on EGFR 
signaling cscade using HEK293T cells. Stimulation with EGF resulted in 
enhanced levels of pEGFR in cells transfected with FL Socs4b and reduced 
levels in those transfected with a truncated Socs4b in which the SOCS box 
domain was deleted. Levels of pERK, however, were decreased in samples 
transfected with FL Socs4b, but increased in samples transfected with the 
Socs4b SOCS box truncation. This suggests that Socs4b can negatively regulate 
signaling downstream of EGFR in vitro. This was validated by qPCR on 
socs4bΔ18 embryos where enhanced levels of egr1, a downstream target of 
EGFR signaling, was observed at both 24 hpf and 7 dpf compared to controls. 
How this relates to the alterations to EGFR phosphorylation remains to be 
determined, but it could reflect differential compartmentalization of the receptor.  
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Chapter 6: 
Characterization of 
zebrafish socs5a 
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6.1 Introduction 
SOCS5 is also yet to be fully characterized. Investigations to date have revealed 
mammalian SOCS5 to be expressed in a variety of tissues including the heart, 
brain, retina, lung, colon, bladder, testis and skeletal muscle as well as the 
placenta [20, 240, 246, 247]. Data surrounding the functional roles of SOCS5 in 
vivo remain limited. As with SOCS4, SOCS5 expression was induced by EGF 
signaling [240] and was able to regulate both RTK and cytokine receptor signaling 
in vitro. In these studies, SOCS5 has been shown to negatively regulate EGFR 
signaling [21, 240], and to a lesser extent IL-6R, LIFR [36] and IL-4R signaling 
[43]. SOCS5 is thought to regulate cellular signaling by initiating the proteasomal 
degradation of its target proteins, as seen in its regulation of EGFR, where both 
its SH2 domain and SOCS box were required for initiation of degradation [21, 
240]. SOCS5 Tg mice showed a significant reduction in Th2 development, 
thought to be facilitated by the ability of SOCS5 to inhibit IL-4R-mediated STAT6 
activation that normally stimulates differentiation of naïve T cells toward a Th2 
fate [43]. Despite data supporting a role for SOCS5 in T cell differentiation, Socs5 
KO mice showed no abnormalities in Th1/Th2 differentiation, indicating possible 
redundancy in its lymphoid role in mice [248]. SOCS5 has also been implicated 
in a variety of inflammatory disease states.  
The results of Chapter 3 confirmed the presence of two zebrafish SOCS5 
paralogues, socs5a and socs5b. This Chapter aimed to broadly characterize one 
of the zebrafish SOCS5 paralogues, socs5a. Characterization included 
elucidation of the socs5a spatio-temporal expression pattern during 
embryogenesis and in adult organs. In addition, this Chapter aimed to investigate 
the developmental roles of socs5a using an already established socs5a knockout 
zebrafish line.  
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6.2 Expression analysis of zebrafish socs5a  
To characterize the temporal expression of zebrafish socs5a during 
embryogenesis, semi-quantitative RT-PCR was employed. Specific primers 
designed to sequences encoding the N-terminal domain of socs5a and primers 
specific for the house keeping gene β-actin (Fig 6.1A). Products of the 
appropriate size were visualized on agarose gels, with representative products 
sequenced to confirm their identity. Expression levels of the house keeping gene 
β-actin were consistent across all time-points. Samples containing reverse-
transcriptase negative samples yielded no products, ruling out gDNA 
contamination. Transcripts of socs5a were evident at the 1 cell stage, indicating 
maternal derivation, with levels consistent at 8 hpf. Transcript levels increased 
gradually via zygotic expression, peaking at 31 hpf then decreasing until 5 dpf, 
when there was a small increase before decreasing again at 6 dpf, the end point 
of testing.  
Expression of socs5a was examined in adult zebrafish organs by RT-PCR. 
Highest levels of socs5a expression were present in the heart and brain, with 
moderate expression levels in the kidney, muscle, spleen, gills and gall bladder 
(Fig 6.1B).  
With the embryonic expression of zebrafish socs5a confirmed, WISH was 
employed to determine its spatio-temporal expression pattern during 
embryogenesis. An anti-sense-RNA probe was generated against the full-length 
socs5a coding region, with WISH performed on staged WT embryos at several 
time-points spanning development. Weak, ubiquitous expression was seen at 
early time points (Fig 6.1C and data not shown). However, from 18 hpf, 
expression of socs5a became restricted and was identified bilaterally in a broad 
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region surrounding the developing midbrain and hindbrain (data not shown), by 
24 hpf, this bilateral expression had expanded anteriorly and was present in the 
area posterior to the developing eye, and on the dorsal surface of the trunk, 
extending approximately 80% of the length of the trunk, consistent with neural 
crest cells (Fig 6.1). At 48 hpf expression became restricted instead to the inner 
nuclear layer (INL) and ganglion cell layer (GCL) of both eyes. Expression in 
these layers was also evident at 72 hpf, 4 dpf and 5 dpf (Fig 6.1J and data not 
shown) but was not evident in embryos exposed to the socs5a sense probe at 
matching time points. At 5 dpf expression of socs5a was also evident in the 
olfactory bulbs (Fig 6.1K), organs involved in detecting smell. 
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Figure 6.1 Expression profile of socs5a during zebrafish development and 
in adult organs. 
RT-PCR from total RNA extracted from embryos at the indicated times post 
fertilization (A, upper panel), or from adult organs (B, upper panel). Levels of 
socs5a quantified using densitometry and standardized to expression of the 
control β-actin gene at 1 cell for embryonic expression (A, lower panel) and 
relative to expression in the liver for adult expression (B, lower panel). Whole-
mount in situ hybridization analysis of embryos at 10 hpf (C), 24 hpf (D-I) and 5 
dpf (J-K) using either a socs5a anti-sense (socs5a) mRNA probe or sense 
(control) probe. Embryos are positioned with their anterior to the left and are 
either dorsal (G, I, J-K) or lateral (D-F, H) view. Staining in presumptive neural 
crest (NC) cells at 24 hpf and olfactory bulbs (OB), inner nuclear layer (INL) and 
ganglion cell layer (GCL) in the eye at 5 dpf is indicated.  
  
 167 
6.3 Effect of zebrafish socs5a knockout on embryogenesis 
To investigate potential in vivo roles of zebrafish socs5a, a knockout line 
identified in the Solnica-Krezel lab of Washington University, was examined. This 
mutant line (socs5avu383) was generated by TILLING on a AB* background  and 
possessed a point mutation that introduced a stop codon after amino acid 33, 
producing a protein devoid of the NTCR4-5, SH2 domain and SOCS box. 
Sequence analysis of RT-PCR products confirmed the introduced stop codon 
was incorporated into the socs5a transcript (Fig 6.2A). 
Both socs5a+/+ and socs5a-/- embryos were carefully assessed from the 1 cell 
stage through to 7 dpf for signs of overt abnormalities, with specific attention paid 
to those structures and functions derived from the neural crest cells, including 
melanocytes, craniofacial cartilage and smooth muscle; however no phenotypes 
were identified (Fig 6.2B-E). The anatomy of socs5a-/- embryos was further 
investigated through histology at 7 dpf, with close examination of the layers of the 
retina and olfactory organs, both sites of socs5a expression. This failed reveal 
any abnormalities in either of these structures (Fig 6.2F-I).  
To investigate other potential developmental phenotypes, WISH analysis was 
performed using markers specific for key cell populations during development. 
This confirmed normal development of notochord using sonic hedgehog (shh) at 
24 hpf (data not shown), normal left/right patterning as indicated by positioning 
of the exocrine pancreas, marked by trypsin (try) at 4 dpf (data not shown), and 
normal heart looping using myosin light polypeptide 7, regulatory (myl7), a marker 
for the atrium of the heart at 48 hpf (Fig 6.2J-K). Neural crest cells were examined 
using microphthalmia-associated transcription factor (mitfa), with no 
abnormalities identified (Fig 6.2L-M). The endocrine pancreas was also examined 
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by WISH, using markers for β cells, preproinsulin (ins) (Fig 6.2N-P) and α cells, 
glucagon-a (gcga) (data not shown) at 72 hpf with no distinguishable differences 
detected when comparing socs5a+/+ and socs5a-/- embryos.  
In addition, qRT-PCR was used to examine ins and gcga transcript levels, 
confirming no statistically significant difference in transcript levels between 
socs5a-/- and socs5a +/+ embryos at 72 hpf (Fig 6.2P) confirming the WISH 
result. Levels of the zebrafish Socs5 paralogue, socs5b, were also examined at 
72 hpf and found to be unaffected socs5a-/- and +/+ embryos.  In contrast, levels 
of egr1, a downstream signaling molecule of EGFR, showed a statistically 
significant reduction in socs5a-/- embryos when compared to socs5a+/+ embryos 
at 4 dpf.  
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Figure 6.2 Targeted knockout of zebrafish socs5a and its phenotypic 
consequences 
Chromatograms, encoded amino acid sequence and nucleotide sequence of 
socs5a+/+ and socs5a-/- zebrafish, with point mutation (red box) and 
corresponding amino acid, change from glutamine (Q) to a stop codon (*) 
indicated (A). Light microscopy of live socs5a+/+ (B, D) and socs5a-/- (C, E) at 
48 hpf (B-C) and 4 dpf (D-E) and histology of the eye (F, H) and olfactory vesicle 
(G, H), including cilia (arrowhead). WISH analysis using myl7 marking the atrium 
(J-K), mitfa marking neural crest cells (L-M) and ins marking endocrine β-cells 
(N-O). Quantitative PCR analysis of egr1 at 4 dpf, ins, gcga and socs5b at 72 hpf 
in socs5a-/- embryos compared to socs5b+/+ (-ΔΔct values presented) (P). 
Statistical significance is indicated by a red asterisk. 
Embryos are lateral view (B-E, L-M), ventral view (J-K), dorsal view (N-O) or 
sections (F-I). All embryos are positioned with anterior to the left.  
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As SOCS5 has been implicated in T cell development, a raft of hematopoietic 
markers were also examined in the socs5a-/- line. Staining with O-dianisidine was 
used to detect hemoglobin levels and red blood cell distribution revealed no 
abnormalities in the socs5a-/- embryos (Fig 6.3A-B). Granulocyte quantity and 
distribution, was assessed using lysozyme (lyz) at 48 hpf, with no abnormalities 
detected (Fig 6.3C-D). In contrast, differences in expression levels were 
observed for rag1, a marker of T lymphocytes, with expression reduced in 
socs5a-/- embryos compared to socs5a+/+ embryos at 7 dpf by WISH (Fig 6.3E-
F). 
Expression levels of rag1 were quantified by qRT-PCR. Interestingly, at 5 dpf, 
there was no difference in expression between in socs5a-/- and socs5a+/+ 
embryos, but by 6 dpf a statistically significant 1.84-fold reduction in rag1 
expression levels was seen in socs5a-/- embryos, which became 2.5 fold by 7 
dpf (Fig 6.2G). To further explore the reduction in T lymphocytes, several other 
markers were examined, with both lymphocyte cell kinase (lck) and T cell receptor 
alpha constant (trac) also decreased in socs5a-/- embryos by 1.42 and 1.43-fold 
on average, respectively. No difference was identified between socs5a+/+ and 
socs5a-/- embryos for the granulocyte specific marker lyz (Fig 6.2G) or the 
thymus specific forkhead box N1 (foxn1) (data not shown). 
Finally, in order to do a basic assessment of hematopoiesis in adult fish, 
peripheral blood smears were examined from socs5a+/+ and socs5a-/- zebrafish. 
No differences in morphology were observed (Fig 6.3H-I). In addition, manual 
differential counting revealed equivalent percentages of each cell population 
when comparing socs5a-/- and socs5a+/+ (Fig 6.3J). Smears taken from spleens 
from both socs5a+/+ and socs5a-/- were also indistinguishable (data not shown). 
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Figure 6.3 Knockout of zebrafish socs5a perturbs embryonic T cell 
development 
Both socs5a+/+ (A, C, E) and socs5a-/- (B, D, F) embryos were subjected to O-
dianisidine (O-dia) staining marking hemoglobin at 52 hpf (A, B), WISH staining 
with lyz, marking granulocytes at 48 hpf (C-D), rag1, marking mature T cells at 7 
dpf (E-F). Embryos are lateral view (C-F) or ventral view (A-B). All embryos are 
positioned with anterior to the left. 
Quantitative PCR analysis of socs5a-/- compared to socs5a+/+ embryos with 
hematopoietic markers rag1 at 5, 6 and 7 dpf and lck, trac and lyz at 7 dpf (G). 
Statistical significance is indicated by a red asterisk.  
Peripheral blood smears highlighting cell morphology in socs5a+/+ (H) and 
socs5a-/- (I). Manual blood cell differentiation of socs5a+/+ and socs5a-/- (n=5 
embryos with n=500 cells (J).   
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6.4 Discussion 
The in vivo roles of SOCS5 are still not fully characterized. This Chapter has used 
the zebrafish as an alternative model to elucidate the embryonic and adult 
expression pattern of the zebrafish SOCS5 orthologue, socs5a. It has also 
provided the first definitive insight into an in vivo role for socs5a by examining a 
knockout allele of the gene.  
Mammalian Socs5 was expressed in adult tissues of the heart, brain, retina, lung, 
colon, bladder, testis and skeletal muscle as well as the placenta [20, 240, 246, 
247], with embryonic expression yet to be described. RT-PCR analysis showed 
zebrafish socs5a to be expressed throughout zebrafish embryogenesis. 
Expression was evident at 1 cell, confirming maternal derivation; with levels 
steadily increasing as zygotic expression began, peaking at 31 hpf, with 
expression maintained at least to 6 dpf. WISH analysis demonstrated relatively 
low but ubiquitous expression levels during early development. By 24 hpf, 
bilateral socs5a expression could be identified in both the anterior and posterior 
of the embryo consistent with the position of neural crest cells at this time point. 
Neural crest cells, originating from the ectoderm flanking each side of the 
embryonic neural plate, are multipotent and migrate, eventually giving rise to a 
diverse range of structures including melanocytes, craniofacial cartilage and 
bone as well as smooth muscle and enteric neurons [320]. In addition, neural 
crest cells give rise to most of the cranial and spinal sensory ganglion cells [320]. 
By 48 hpf, expression was evident in the inner nuclear layer and ganglion cell 
layer of the zebrafish retina, which remained at all later time points tested. At 5 
dpf, socs5a expression was evident in the olfactory bulbs, the organs responsible 
for sense of smell. RT-PCR analysis of adult zebrafish tissue again showed broad 
expression of socs5a across the tissues analyzed, being highest in the heart and 
 175 
brain, and the lowest in the liver. Both embryonic and adult expression of socs5a 
was largely consistent with published mammalian expression, except for the 
olfactory bulb, which had not been previously reported, although SOCS4 is highly 
expressed in this organ.  
Analysis of the role of socs5a in embryogenesis was achieved in collaboration 
with the Selonica-Kretzel laboratory at Washington University, who produced an 
ENU mutagenesis-induced socs5a null mutant line carrying a non-sense 
mutation that would produce a protein truncated at residue 33. Socs5a-/- 
embryos were closely monitored from one cell onwards, but no abnormalities 
were detected at any stage of embryogenesis by light microscopy, qPCR and 
WISH for several key genes as well as other staining methods examining neural 
crest, carcinogenesis, pancreatic development, hematopoiesis and immunity. 
This is consistent with the absence of a phenotype reported in Socs5-/- mice 
[248]. Interestingly, egr1, a transcription factor downstream of EGFR did show a 
mild but statistically significant reduction in transcript levels in socs5a-/- embryos 
at 4 dpf, warranting further investigation of this pathway in the socs5a-/- line.  
Examination of hematopoietic cells revealed no apparent effect on myeloid or 
erythroid lineages, but lymphoid cells were affected. The production of T 
lymphocytes begins around 3 dpf [298] and rapidly expands from this point 
onwards. Initial levels of rag1+ T cells were normal in socs5a-/- embryos, but 
around 6-7 dpf, the number of cells was reduced relative to WT embryos. Other 
T cells markers (lck and trac) were also reduced at 7 dpf, by approximately 1.5-
fold approaching statistical significance. This suggests that loss of socs5a affects 
T cell numbers, rather than specification or differentiation per se. In addition, the 
socs5a-/- line showed no obvious decrease in mortality or increased incidence of 
disease when compared to socs5a+/+ fish. However comprehensive examination 
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and monitoring of adult socs5a-/- is required to confirm this.  
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Chapter 7:     
Perspective and further 
directions 
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7.1 Introduction 
The research presented in this Thesis has contributed to the understanding of 
SOCS family evolution generally, and the biology of SOCS4 and SOCS5 more 
specifically. Chapter 3 has provided insights into the evolutionary history of SOCS 
genes, and importantly identified the zebrafish SOCS4 and SOCS5 paralogues, 
which facilitated subsequent functional studies. Chapters 4, 5 and 6 have 
generated new understanding of the in vivo roles of the zebrafish SOCS4 
paralogues, socs4a and socs4b, and one of the zebrafish SOCS5 paralogues, 
socs5a, along with some mechanistic details. This has revealed both conserved 
and novel functions for these zebrafish genes when compared to their 
mammalian counterparts.  
 
7.2 Evolutionary perspective 
The first aim of this Thesis was to identify and characterize the repertoire of 
SOCS proteins in various key species, including arthropod, chordate and 
vertebrate species. This required exhaustive data-mining of multiple genomic 
databases, and additional bioinformatics analysis. From these data, a model of 
the evolution of the SOCS genes was formulated, which has shed light on the 
origins of the zebrafish SOCS orthologues, and importantly identified two 
zebrafish paralogues for each SOCS4 and SOCS5. This directly questioned the 
previous designation of the socs9 gene in zebrafish [325]. Data produced in this 
Thesis strongly suggested that this gene is actually a SOCS4 paralogue that may 
have emerged prior to the last common ancestor of the teleost and mammals. 
Additional bioinformatic data are required for the exact origin of this gene to be 
determined, although it is clearly part of the SOCS4/5 sub-family. Chapter 3 also 
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identified WGD events to be drivers of the expansion of the SOCS family, fitting 
well with similar role for WGD in the expansion of upstream CytoR/JAK/STAT 
pathway components in teleost fish. This is evidenced by the presence of 
paralogues for many of these, including GHR (ghr.a and ghr.b), PRLR (prlr.a and 
prlr.b), LIFR (lifr.a and lifr.b), CLF-1 (clf-1.a and clf-1.b), JAK2 (jak2a and jak2b), 
STAT1 (stat1a and stat1b) and STAT5 (stat5.1 and stat5.2) [24] [277].  
 
7.3 Analysis of in vivo expression profiles 
This Thesis has also provided new insights into the expression of SOCS4 and 
SOCS5 genes, especially during embryogenesis. Each of socs4a (Chapter 4), 
socs4b (Chapter 5), socs5a (Chapter 6) and socs5b (data not shown) were found 
to be expressed throughout the entirety of embryogenesis, with both maternally-
derived and zygotic expression evident. WISH analysis revealed a dynamic and 
complex expression pattern for socs4a, but a more limited and consistent pattern 
of expression for both socs4b and socs5a. Expression of socs4a was observed 
in a number of sensory ganglia at 24, 31 and 48 hpf, but this was reduced to just 
the lateral line ganglia from 3 dpf onwards. Specific socs4b expression did not 
become evident by WISH until 3 hpf, when it was observed in the retina and 
ventricle boundaries at 72 hpf. Expression of socs5a was evident in presumed 
neural crest cells at 24 hpf and in the olfactory bulbs and layers of the retina from 
3 dpf onwards with some potential overlap with socs4b in the retina. This provides 
the first detailed picture of SOCS4 and SOCS5 expression during 
embryogenesis. 
While the identity of socs4a and socs4b expressing cells during embryogenesis 
was clear, with some confirmed through dFISH, the exact identities of socs5a 
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expressing cells is yet to be confirmed. The methods of dFISH or dWISH, using 
appropriate markers such as microphthalmia-associated transcription factor a 
(mitfa) and crestin, would confirm neural crest cell expression. In addition, 
histological sectioning of socs5a WISH embryos would be useful for example, 
demarcating expression outside of the neural tube would be consistent with 
neural crest cells. 
SOCS4 has been described as being expressed in hematopoietic tissues and 
olfactory bulbs (http://biogps.org/#goto=genereport&id=122809) in mice and in 
the intestine and thymus in pigs [239, 242]. The adult expression profile of the 
zebrafish socs4 paralogues was broader than that seen in these mammalian 
studies, however, more detailed examination is required for a definitive 
comparison. The sites of expression for socs4 paralogues in both embryos and 
adults, correlated with the transcription factor binding sites found in their promoter 
regions, specifically neuronal and hematopoietic transcription factors. Adult 
expression of mammalian SOCS5 and zebrafish socs5a were more similar, with 
both expressed in the heart, brain and skeletal muscle.  
As hematopoietic transcription factor binding sites were identified in all zebrafish 
gene promoter regions, it would be wise to isolate the adult kidney and thymus 
to examine expression of all three genes in relevant populations, augmented by 
use of appropriate transgenic lines for flow cytometry analysis. As the socs5a 
promoter region also contains many sites for transcription factors associated with 
insulin regulation, it would also be pertinent to isolate the adult endocrine 
pancreas to look specifically at socs5a expression. This could be achieved throgh 
use of a fluorescent line such as ins:EGFP with FACS sorting used to isolate 
endocrine pancreas cells for RT-PCR analysis.  
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7.4 Role for Socs4a in convergence extension 
Mopholino mediated knockdown of Socs4a has provided new insights into its role 
during embryogenesis. Injected embryos commonly displayed shortened body 
length and undulating notochord, likely a result of a much earlier developmental 
defect, preventing the completion of convergence and extension during 
gastrulation. This led to shorter embryos with wavy or, in a small numbers of 
cases, split notochords. However, the signaling pathway(s) involved remains 
unknown. STAT3 is known to play an important role during convergence and 
extension in zebrafish [344]. Multiple STAT3 binding sites were identified in the 
socs4a promoter region and the reported sites of stat3 expression overlap with 
those of socs4a, including in the shield. In addition, SOCS4 has been implicated 
in regulation of STAT3 in mammalian systems. Therefore, this pathway is an 
obvious candidate for further investigation.  
As the zebrafish community moves away from the use of MO technology, use of 
a knockout mutant becomes essential for confirmation of any gene function 
identified. While the functional study of Socs4a used extensive controls (including 
p53 MO – data not shown) to confirm the specificity of the phenotypes described, 
a mutant socs4a line is essential to further confirm these results prior to 
publication. Genome targeting with TALENs and CRISPR, is currently the most 
effective method of zebrafish mutant production. Alternatively, the Welcome Trust 
Sanger Institute’s Zebrafish Mutation Project, which aims to create a knockout 
allele in every protein-coding gene in the zebrafish genome, has created two 
nonsense socs4a alleles, which could be assessed.  
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7.5 Role for Socs4a in mechanosensory response 
The Socs4a knockdown embryos also exhibited a reduced response to 
mechanical stimuli identified, which was consistent with the strong expression of 
socs4a in many different sensory ganglia. The touch response phenotype could 
be examined more closely, such as with video recording to allow for 
measurement of exact time from touch to response, although this would likely be 
compromised by the limited capacity of socs4a morphants to swim proficiently, 
due to their curly tail phenotype. Associated with the mechanosensory defect was 
a reduction in a population of mechanosensory cells in the hindbrain of 
morphants. It is yet to confirmed whether these cells are presumptive dorsal root 
ganglia or Rohon Beard neurons; however, both populations contribute to 
mechanosensory response and may be associated with the reduced touch 
response in Socs4a morphants.  
The functional interactions between STAT3 and Socs4a should be further 
explored. In vitro pull-down methods could be used to examine potential physical 
interactions to access if STAT3 was a target for socs4a. The potential of STAT3 
to regulate socs4a expression could be investigated by knockdown or over-
expression of stat3, the latter of which might replicate some of the phenotypes 
seen in socs4a knockout fish.  
 
7.6 Absence of a developmental role for Socs4b 
This study failed to elucidate an obvious role for Socs4b in development. While 
this consistent with the description of Socs4-/- mouse knockout, there remain a 
number of important validations for the zebrafish work. Firstly, the socs4bΔ18 line 
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needs to be definitevly characterized as to whether it expresses a truncated 
Socs4b protein or no Socs4b protein at all. This analysis could be performed via 
Western blot on protein lysates from socs4bΔ18 fish but first requires production 
and optimization of antibodies independently targeting the Socs4b N- and C-
termini. Secondly, genome editing technology, be it ZFN, CRISPR or TALENs, 
should be used to produce frame-shift or nonsense mutation Socs4b mutant lines 
to confirm the socs4bΔ18 results. Finally, it would be important to mirror the tests 
performed on the Socs4 knockout mouse, such as exposure to viral infection. 
  
7.7 Role for Socs4b in EGFR signaling 
Published data surrounding SOCS4 function suggests it to have a negative 
regulatory role in EGFR signaling. Western blot analysis revealed a role for 
Socs4b in EGF signaling in vitro, with the SOCS box confirmed as an essential 
domain for this regulation, although the results were complex. Unexpectedly, WT 
Socs4b showed increased levels of pEGFR while a SOCS-box deleted Socs4b 
led to reduced levels of pEGFR post EGF stimulation. However, analysis of the 
downstream ERK pathway showed pERK levels were decreased at later points 
in WT Socs4b samples, while in SOCS box deleted Socs4b samples levels of 
pERK were low initially but were significantly increased at later time-points. The 
mechanism for this is still unclear. However, one possibility is that WT Socs4b 
targets phosphorylated EGFR and/or ERK for ubiquitin-mediated degradation, 
with the loss of the SOCS box disrupting this process. This in vitro data promoted 
examination of EGF signaling in the socs4bΔ18 line. Levels of egr1, a gene 
downstream of EGFR and ERK signaling, were significantly greater in socs4bΔ18 
compared to control fish [347]. This suggests an in vivo role for Socs4b in EGFR 
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signaling, through the EGFR/ERK/EGR1 pathway supporting the in vitro data. It 
would be useful to confirm EGFR/ERK activation in the socs4bΔ18 line through 
Western blot analysis using antibodies cross-reactive with zebrafish signaling 
molecules, including the phosphorylated forms; a more intense analysis of 
EGFR-driven developmental pathways would also be warranted. As erg1 is 
important in zebrafish retina development [348], close examination of this 
structure in both socs4b knockout embryo and adult zebrafish would also be 
worthwhile.  
 
7.8 Role for zebrafish Socs5a in T cell proliferation 
The analysis of the in vivo function of Socs5a represents the first of its kind into 
either of the zebrafish SOCS5 paralogues. Consistent with the Socs5a-/- 
knockout mouse, the socs5a knockout zebrafish exhibited no overt phenotype 
during embryogenesis or adulthood. Examination by quantitative PCR however, 
revealed a modest reduction of rag1 expression in socs5a-/- embryos during late 
embryogenesis. However, normal expression of foxn1, a thymic epithelial cell 
marker was observed, as well as for markers of other hematopoietic cell lineages. 
Interestingly, socs5a-/- embryos survived into adulthood with no complications. A 
thorough investigation of the T cell phenotype, including examination of thymus 
morphology and functional analysis of T cell development is required during the 
larvae, juvenile and adult stages, with cell numbers and identity assessed through 
flow cytometry with transgenic lines such as rag1:GFP. Viral challenge of these 
fish would also seem warranted given the viral sensitivity of SOCS4-/- mice. 
As socs5 expression was noted in retinal layers which are essential for 
transmission and interpretation of light, examination of their structure and function 
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would be essential in the socs5a-/- fish. Both optokinetic (eye movements) and 
optomotor response could be tested in zebrafish embryos [349]. Analysis of 
olfactory bulb function should also be performed, as socs5a expression was 
noted in these structures at 5 dpf. This can be achieved by measurement of Ca2+ 
signals in afferents to olfactory glomeruli [350]. Neural crest derivatives could also 
be examined in more detail, including characterizing bone via Alician blue 
staining and smooth muscle using WISH markers such as alpha actin 2, an alpha 
actin isoform only expressed in smooth muscle. Examination of smooth muscle 
function would also include close analysis of the blood vessels and the aorta, 
lymphatic vessels, bladder, uterus, gastrointestinal tract and iris that utilize 
smooth muscle. Neural crest cells also give rise to sensory structures including 
peripheral neurons and most cranial and spinal ganglia. Touch and water 
vibration detection should therefore also be extended to adult socs5a-/- fish.  
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7.9 Conclusions 
This Thesis has revealed new insights into the evolution of the SOCS family 
including its least well-characterized members, SOCS4 and SOCS5. This 
bioinformatics data also underpinned the detailed functional analysis of three of 
the four zebrafish members of the SOCS4/5 sub-family. This demonstrated both 
similarities and differences with published mammalian data, including the 
identification of novel functions for Socs4a, the most divergent zebrafish 
paralogue. Zebrafish Socs4a plays an essential role during embryonic 
convergence and extension, as well as a subtler role in mechanosensory 
processing, which may be a result of a functional interaction with stat3 signaling. 
No clear developmental role was identified for Socs4b, although a combination 
of in vitro and in vivo approaches suggested Socs4b might regulate EGFR 
signaling. Zebrafish Socs5a was shown to contribute to T cell development, likely 
affecting proliferation, although the mechanism remains unclear.  
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